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THE PANCREAS AND ITS EXOCRINE AND ENDOCRINE FUNCTION 
 
The pancreas is a gland which is located behind the stomach. The head of the pancreas 
is lying immediately adjacent to the duodenum; the body, which forms the main bulk 
of the organ, ends in a tail that lies in contact with the spleen (Figure 1.1).1 The organ 
consists of an exocrine and endocrine part. 
 
 
FIGURE 1.1 The anatomy of the pancreas 
Source: http://www.britannica.com/EBchecked/topic/440971/pancreas (accessed on June 2010) 
 
 The exocrine part of the pancreas consists of acinar cells, which are grouped into 
lobules.1-3 Their main function is to secrete pancreatic juice containing digestive en-
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zymes. These enzymes, including trypsinogen, chymotrypsinogen, pancreatic lipase 
and pancreatic amylase, help in the further breakdown of the carbohydrates, protein, 
and fat in the chyme. These enzymes are released by the pancreas in response to the 
small intestine hormones secretin and cholecystokinin.1,2 Another component of the 
exocrine pancreas are ductal cells that form the epithelium lining of the highly 
branched ducts, which transport the digestive enzymes produced by the acinar cells 
into the duodenum.3,4 
 The endocrine part is made up of cell clusters called islets of Langerhans, which 
secrete hormones. These cell clusters account for only 1-2% of pancreatic tissue. There 
are five main types of islets cell. The beta-cells are the most common and are respon-
sible for insulin production. The other types include alpha, delta and F (or PP) cells, 
which secrete glucagon, somatostatin, and pancreatic polypeptide, respectively.2,3 
 
 
PANCREATIC CANCER 
 
Carcinogenesis 
Approximately 90% of the pancreatic neoplasms are adenocarcinomas.5 There is gen-
eral agreement that the pancreatic ductal epithelial cell gives rise to this type of pan-
creatic malignancy. However, animal studies indicated that transdifferentiation of 
other pancreatic cell types, such as acinar cells, might serve as an alternative route to 
pancreatic adenocarcinoma.4,6 
 Several molecular genetic alterations have been identified in adenocarcinomas of 
the pancreas. Over 90% of human pancreatic adenocarcinomas have a point mutation 
in the KRAS gene, whereas the p16/INK4A gene is inactivated in virtually all pancreatic 
adenocarcinomas. In addition, two other genes were frequently inactivated in pan-
creatic adenocarcinomas, that is, SMAD4/DPC4 (60%) and TP53 (50-80%).6-8 
 The improved understanding of the genetic alterations that characterize invasive 
pancreatic adenocarcinoma can be used to classify noninvasive precursor lesions in the 
pancreas. Researchers have characterized three premalignant lesions, including pan-
creatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasia 
(IPMN) and mucinous cystic neoplasia, from which pancreatic cancer appears to 
arise.6,7,9,10  
 PanINs show a spectrum of divergent morphological alternations relative to nor-
mal ducts and seem to represent progressive stages of neoplastic growth that may be 
precursors to pancreatic adenocarcinomas.6 The consecutive stages have been classi-
fied as normal duct, PanIN-1A or PanIN-1B, PanIN-2, PanIN-3, and adenocarcinoma. 
The PanINs usually involve the smaller pancreatic ducts (<5 mm in diameter).10 
 A growing number of studies have identified mutations in KRAS, TP53, SMAD4/ 
DC4, and p16/INK4A genes in PanIN lesions, which were shown to accumulate during 
progression through the various stages of PanIN lesions. This provides more evidence 
that PanINs might be precursors of pancreatic adenocarcinoma.6,8 
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IPMNs are larger than PanINs (usually >1 cm) and seem to arise in the larger pancreatic 
ducts.7,10 IPMNs may be a precursor to invasive adenocarcinoma of the pancreas and 
are growing in importance because more of these lesions are detected as the resolu-
tions of imaging improves.7 These lesions often harbor the same mutations as are 
found in invasive pancreatic adenocarcinomas, including KRAS, PT53 and p16/ INK4A, 
although at a lower frequency.7 
 
Classification 
Of the pancreatic adenocarcinomas, approximately two-thirds of pancreas tumors 
occur in the head of the organ with the remainder in the body or tail.11,12 At the mo-
ment, screening is not an option because it is unknown at what age screening should 
begin, in which high-risk groups, and whether any of our current methods are able to 
detect early pancreatic cancers.5 At diagnosis, most cases present with unresectable 
tumors (TNM-stage III [tumor extends beyond pancreas and have invaded major blood 
vessels] and stage IV [distant metastasis]). In the US, less than 10% of patients present 
with local disease at diagnosis, whereas 52% have distant metastases, mainly in the 
liver and peritoneal cavity.13 In the Netherlands, similar estimates have been found 
with only 7% of the patients presenting localized disease (stage IA [tumor ≤2 cm in 
greatest dimension] and stage IB [tumor >2 cm]; Figure 1.2) and 56% of the patients 
having distant metastasis (stage IV). 
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FIGURE 1.2 Distribution of patients by stage* at diagnosis with pancreatic cancer, the Netherlands,  
2003-2007 
Source: http://www.ikcnet.nl/page.php?id=11414 
*Staging system developed by the TNM committee of the UICC (International Union Against Cancer; 6th  
edition). 
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Besides exocrine pancreatic cancer there are also endocrine subtypes, such as Islet-cell 
tumors, sarcomas, and lymphomas; these are very uncommon tumors11 which are not 
further discussed here because these types probably have a different etiology. Many 
analyses of epidemiologic data do not distinguish between exocrine and endocrine 
neoplasms, most probably because of lack of data to obtain microscopic confirmation. 
But since pancreatic endocrine neoplasms are quite rare, their exclusion would proba-
bly not have altered the conclusions from studies in which they were included.  
 
Diagnosis and treatment 
Symptoms of pancreatic cancer  
Many patients present with very minor symptoms including abdominal pain, change in 
digestive problems and weight loss.1 Also jaundice is observed in more than 50% of the 
patients.12 Some patients (≤10%) present with new -onset diabetes.12 Especially in the 
elderly, pancreatitis may be a first signal of pancreatic neoplasia when there is no ob-
vious cause such as gallstones or alcohol abuse.12 Symptoms differ with location of the 
tumor: in patients with cancer of the head of the pancreas is jaundice (due to obstruc-
tion of the bile duct) a more common symptom, whereas in patients with tail and body 
tumors abdominal pain is a more common symptom.1,12 This abdominal pain is often 
dull in character and radiates through to the back. Other symptoms are more non-
specific such as anorexia and weight loss. Bile duct obstruction and jaundice may in-
frequently be a late phenomena.1 
 
Diagnosing techniques  
The most common imaging modalities for diagnosis and staging of pancreatic cancer 
include transcutaneous ultrasound (TCUS), computed tomography (CT) scan, magnetic 
resonance imaging (MRI), and most recently endoscopic ultrasound (EUS).15 Helical CT 
scan is the imaging procedure of choice for the initial evaluation.16 In patients where 
no visible mass is identifiable on CT, but in whom pancreatic cancer is suspected based 
on the symptoms, EUS could be of help detecting pancreatic tumors12,15 because this 
modality is superior to CT for detecting small tumors.12 
 Biopsies in patients with resectable pancreatic tumors can be taken during sur-
gery. For patients who are not suitable candidates for radical surgery, the most com-
mon approaches to obtain a tissue diagnosis are by CT-guided biopsy, by endoscopic 
retrograde cholangiopancreatography (ERCP) or by EUS with fine-needle aspiration 
(FNA).16 It has been shown that EUS-guided FNA is the most accurate diagnostic modal-
ity.15 Complications are rare but include tumor seeding, so obtaining tissue diagnosis 
using these types of diagnostic modalities should be reserved only for patients who 
will not undergo surgery.12 
 
Histological confirmation 
To date, pancreatic cancer continues to have among the lowest proportion of histolog-
ically verified cases of any major cancer.11 This is because the organ is inconveniently 
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located and because of the morbidity associated with biopsy. In Table 1.1, the average 
proportion of incident male cases are presented that has been verified histopathologi-
cally for various registries in various countries.17  
 
TABLE 1.1 Percentages of incident cancer of pancreas confirmed histopathologically, in men 
Area  Proportion of incident male cases  
confirmed histopatholgically (%) 
 Number of registries Mean Range 
Africa 5 35 16.7 - 59.1 
Japan 7 37 25.9 - 48.8 
United Kingdom 11 39 31.1 - 48.2 
Latin America 11 50 17.9 - 91.1 
Poland 3 51 39.5 - 59.6 
Canada 10 61 52.5 - 80.0 
Netherlands 2 63 50.4 - 74.6 
Scandinavia* 5 73 60.9 - 87.5 
United States† 42 77 68.3 - 85.4 
Source: Curado et al. (2007)17 
*Scandinavia: Denmark, Iceland, Finland, Norway, and Sweden. †Where percentages were provided by race, 
the data for “white” or “non-Hispanic white” was used. 
 
These figures vary throughout the world. This suggests that the accuracy of pancreatic 
cancer incidence estimates across countries/regions depends on enumeration of cases 
with and without histological examination.11 The enumeration of cases with diagnoses 
that are histologically unconfirmed are highly dependent on various factors, including 
proportion of cases ascertained through autopsy, accuracy of clinical records, motiva-
tion and training of the persons who code or screen the records for evidence of cancer 
diagnosis, and quality of diagnosis itself. This means that the enumeration of accurate 
diagnoses may be incomplete and variable throughout the world.18 This should be kept 
in mind, when interpreting differences in incidence and mortality rates described in 
the section below. Additionally, American data from SEER registries indicates that the 
proportion of cases with microscopic confirmation decreases with age at diagnosis.19 
 The group of cases not histologically verified is most probably comprised of a 
mixture of true pancreatic cancers and of other tumors arising in neighboring sites and 
infiltrating or metastasizing to the pancreas20 or can even include patients with chronic 
pancreatitis. 
 
Treatment 
Broadly, the treatment strategy can be divided into two different ways. The first is 
radical surgery for patients with early stage of disease, mainly stage I and partially 
stage II.12 Just few patients (15-20%) present with a locally resectable tumor.5,12 In 
these patients, the standard treatment option is radical pancreatic resection according 
to Whipple procedure (pancreatoduodenectomy, the most commonly performed re-
section procedure), distal pancreatectomy, or total pancreatectomy.12,16 The role of 
postoperative therapy with chemotherapy alone (e.g., 5-fluorouracil or gemcitabine) 
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or in combination with radiotherapy in patients with resected pancreatic cancer is 
controversial, showing some improved but still very poor survival (median survival is 
17-20 months in the groups not receiving adjuvant therapy after surgery and 20-22 
months in the treatment groups).12,16  
 When there are distant metastases or when the tumor has invaded any major 
vascular structures surrounding the tumor, the tumor is not resectable.5 In that case, 
the aim of treatment is the palliation of distressing symptoms related to this cancer, 
such as jaundice, pain, gastrointestinal symptoms etc.12 These patients may benefit 
from palliative bypass of biliary obstruction (head of pancreas) and/or palliative bypass 
of intestinal obstruction. In addition, treatment with chemotherapy alone or in combi-
nation with radiotherapy might palliate symptoms.12,16,21 
 Because there is no effective way to screen for this malignancy and survival is low 
due to late diagnosis and low number of resectable tumors, prevention could have a 
major impact on pancreatic cancer mortality. 
 
Burden of pancreatic cancer 
Pancreatic cancer is the 13th common cause of cancer in Europe and 10th in the United 
States and it is the 5th leading cause of death in Europe and 4th in the United States in 
the year 2006.13,22 Incidence and mortality rates are almost similar due to the rapid 
fatality rates of pancreatic cancer.  
 Figure 1.3 shows a map of the worldwide distribution of pancreatic cancer inci-
dence rates for 2008.23 
 
 
FIGURE 1.3 Worldwide distribution of the age standardized (world) incidence rates per 100,000 for pancrea-
tic cancer – 2008 
Source: http://globocan.iarc.fr.23 
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Men have an approximately 1.5 greater age-adjusted incidence rate than women.11,12 
Higher rates are observed in more developed countries (including the Netherlands, 
United States, and Japan) versus less developed countries (including all the regions of 
Africa, Asia [excluding Japan], and Latin America). Age-standardized incidence rates 
(world; ASR[W]) per 100,000 for 2008 in the United States, Japan, Europe, and the 
Netherlands are 7.0, 7.9, 6.4, and 5.4, respectively.23 For Africa, China, and India, inci-
dence rates for 2008 are 1.7, 2.8, and 1.0, respectively.23 In the United States, black 
Americans have higher incidence rates than white Americans (SEER, 9 registries; 1998-
2002) (ASR[W] per 100,000 are 10.9 versus 7.0 for males and 8.6 versus 5.7 for fe-
males, respectively).17 As described in the previous section, some of these differences 
in incidence rates reflect diagnostic capacity rather than differences in risk factors.18 
Therefore, the differences in incidence rates described above should be interpreted 
very cautiously. 
 In the United States, mortality rates for men increased steeply from the mid-
1930s to the mid-1950s, reached a peak in 1970 and then gradually declined (Figure 
1.4).24 
 
FIGURE 1.4 Trends in overall age-standardized (world) mortality rates (per 100,000) for pancreatic cancer in 
men and women in the United States and the Netherlands, 1955-2005 
Source: http://www.who.int/whosis/whosis/25 
 
For women, the rise of female mortality was slower but continuous from 1935 on-
wards,24 which leveled off in the 1990s (Figure 1.4). In the Netherlands, mortality rates 
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have increased between the late 1950s and the 1980s in men, followed by a decline 
until the late 1990s (Figure 1.4). Among women, mortality rates have increased until 
the 1990s followed by a leveling off until 2000 (Figure 1.4). In Europe as a whole, simi-
lar patterns have been observed as in the Netherlands,26 although mortality rates 
seem to have been more stable over time from the late 1990s.27 The decline or leveling 
off of pancreatic cancer mortality rates observed in the United States and Europe 
might partly be due to the decline in smoking, at least in men,28 which is an established 
risk factor for pancreatic cancer.29 For incidence rates, similar patterns have been ob-
served.23,27 
 Survival rates for pancreatic cancer are amongst the worst of all cancers with a 
median survival of about 3 months.11 Survival rates have almost not improved over 
time, with 5-year relative survival rates ranging from 3% in 1980s to 5% late 1990s- 
early 2000 in the United States, Europe and the Netherlands.14,30-32 Survival rates were 
similar in both men and women. Survival rates of pancreatic cancer differ between 
stages at diagnosis in the Netherlands (Table 1.2), ranging from a 30% survival rate in 
stage IA (tumor limited to pancreas, ≤2 cm in greatest dimension) to 1% in stage IV 
(distant metastasis). 
 
TABLE 1.2 Five-year relative survival rates among patients diagnosed with pancreatic cancer by stage at 
diagnosis, the Netherlands, 2003-2007 
TNM-stage* 5-year relative survival rate (%) 
IA 30 
IB 11 
IIA 10 
IIB 7 
III 2 
IV 1 
Unknown  8 
Source: http://www.ikcnet.nl/page.php?id=11414 
*Staging system developed by the TNM committee of the UICC (International Union Against Cancer; 6th 
edition). 
 
 
RISK FACTORS  
 
Demographic factors 
Age is one of the most important risk factors for pancreatic cancer. In the first three 
decades of life, this cancer is extremely uncommon. After the age of 30, rates increases 
steeply with age. The majority of cases occur between ages 65 and 79 years in the 
United States11 and between the ages 60 and 79 years in the Netherlands.14  
 As reported in the previous section, the incidence rates are approximately 1.5 
times higher among blacks than among whites in the United States, whereas incidence 
rates among blacks living in Africa appear to be low in comparison to those among 
African-Americans.11,33 Silverman et al.33 results suggested that the excess risk among 
Chapter 1 
 
16 
black Americans could potentially be explained by established risk factors, such as 
cigarette smoking and diabetes in men. The excess risk among black women could be 
explained by these two established risk factor plus less established risk factors, i.e., 
heavy alcohol drinking and elevated body mass index (BMI). A large cohort study was, 
however, unable to replicate these results and did not identify any individual or com-
binations of factors that explained the excess risk of pancreatic cancer in black Ameri-
cans.34 This might indicate that the excess pancreatic cancer risk in black Americans 
might be explained by other risk factors for pancreatic cancer, not yet determined, or 
by differences in genetic susceptibility.  
 
Lifestyle and environmental factors  
As already indicated above, cigarette smoking is one of the established risk factors for 
pancreatic cancer,29,35 with most studies indicating that current cigarette smokers have 
about a 2-fold increased pancreatic cancer risk compared with never smokers.35-39 
Regarding other types of smoking, pooled estimates for pipe smoking showed a non-
significantly increased pancreatic cancer risk of 39%, whereas for cigar smoking a sig-
nificantly increased risk of 53% was observed.35 Four case-control studies40-43 and four 
cohort studies44-47 have examined the relation between passive smoking and the risk of 
pancreatic cancer. Three of these studies observed a positive association with passive 
smoking in never smokers.41,44,47 
 One other established risk factor for pancreatic cancer is overweight/obesity.48,49 
One meta-analysis of prospective cohort studies investigating the association between 
BMI and pancreatic cancer risk, observed an increased pancreatic cancer risk of 1.12 
(95% CI: 1.06-1.17) per 5 kg/m2 increase in BMI.49 In addition to BMI – which is a 
measure of total body fat – the distribution of fat has been investigated in relation to 
pancreatic cancer risk by means of waist circumference or waist-to-hip circumference 
ratio (WHR), showing inconsistent results so far. Epidemiological studies observed 
either an increased pancreatic cancer risk with a higher waist circumference50-52 or 
WHR50,53 or no association with waist circumference53 or WHR.52,54 
 Results regarding physical activity and pancreatic cancer risk have been inconsis-
tent so far, observing both decreased risks55,56 and no association.50,57 Two meta-
analyses observed only for occupational physical activity a decreased pancreatic cancer 
risk – which were based on only a few prospective cohort studies (three and four stu-
dies, respectively) – and no association with leisure-time physical activity.58,59 
 Occupation and workplace exposures have extensively been examined in relation 
to pancreatic cancer.11 However, studies performed so far have found no consistently 
strong association with pancreatic cancer and data is insufficient to identify any specif-
ic exposure as likely to substantially increase the risk of pancreatic cancer.11 
 
Hormonal and reproductive factors 
Because pancreatic cancer is more common among men than women, and estrogen 
receptors are present in normal pancreatic tissue and in neoplastic pancreatic tissues, 
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it is plausible that hormonal and reproductive factors could play a role in pancreatic 
carcinogenesis.11,60 Data from epidemiologic studies, however, do not support an ef-
fect of hormonal and reproductive factors on pancreatic cancer risk.11,60,61 
 
Dietary factors 
So far, numerous epidemiological studies have investigated the relation between 
meat, eggs, different types of fat, fruit and vegetables and pancreatic cancer (summa-
rized in Ref. 48). These data have shown inconsistent results so far. In the second 
World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) 
expert report, it was concluded that there is limited evidence suggesting that red meat 
is a cause of pancreatic cancer in humans, whereas fruit might protect against pan-
creatic cancer.48 Data on processed meat, chicken, fish, eggs, dietary fat, specific fatty 
acids, vegetables and vitamin C were either of too low quality, too inconsistent, or the 
number of studies too few to allow conclusions to be reached. 
 Another factor that is investigated in relation to pancreatic cancer is the glycemic 
index (GI). This is a measure that can be used to quantify the postprandial glycemic 
effects of individual foods items.62 To estimate the total glycemic effect of the diet, the 
glycemic load (GL) is calculated by using both the overall GI of a diet as well as the 
actual amount of carbohydrates consumed in the diet.63 Studies investigating the in-
fluence of dietary GI and GL on pancreatic cancer have been limited so far. A meta-
analysis on cohort studies observed no associations between pancreatic cancer risk 
and high GI or GL.64  
 For alcohol intake, inconsistent findings were observed in cohort studies and the 
numerous case-control studies that have been conducted (findings are summarized in 
Ref. 48). Recently, the second WCRF/AICR expert report concluded that low-to-
moderate levels of alcohol consumption were unlikely to have an effect on pancreatic 
cancer risk, but it could not be excluded that heavy drinking might have an effect.48 
 Furthermore, animal studies showed that moderate energy restriction decreased 
pancreatic cancer risk.65,66 So far, no observational studies have investigated the rela-
tion between energy restriction and pancreatic cancer risk. 
 Early studies indicated that coffee consumption was positively associated with 
pancreatic cancer risk; however, the majority of studies conducted have failed to con-
firm such a risk.67,68 Both a Working Group of The International Agency for Research on 
Cancer (IARC) and the second WCRF/AICR expert report have concluded that there was 
little evidence to support a causal relation between coffee consumption and pancrea-
tic cancer risk.48,68 
 
Medical history 
The role of several medical conditions in the etiology of pancreatic cancer has been 
investigated. Diabetes mellitus has been examined most extensively and there is evi-
dence for a causal association between longstanding diabetes mellitus and pancreatic 
cancer risk;69,70 even when for reasons of reverse causality cases are excluded who are 
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diagnosed with diabetes mellitus less than 5 years prior to diagnosis of pancreatic 
cancer. In addition, patients with chronic pancreatitis have an increased risk of devel-
oping pancreatic cancer.11,71,72 Several studies have investigated the relation between 
pancreatic cancer risk and other medical conditions, such as gallstones,73,74 cholecys-
tectomy,11,73-75 peptic ulcer and peptic ulcer surgery,11,76 hypertension,11,77 and hepati-
tis,11,78 but results have been inconsistent.  
 Although animal and laboratory studies have shown that aspirin and other NSAIDs 
may inhibit pancreatic carcinogenesis, findings from observational epidemiologic stu-
dies of aspirin and NSAID use in relation to pancreatic cancer risk have been inconsis-
tent.11,79 Two meta-analyses recently conducted, have concluded that current epide-
miologic data does not indicate that use of aspirin or NSAIDs is associated with pan-
creatic cancer risk.79,80 
 
Family history and genetic predisposition to pancreatic cancer 
Up to 10% of pancreatic cancer patients report a family history of the disease. This 
familial clustering may be due to genetics, shared environment, or both.81-86 Further-
more, the first-degree relatives of pancreatic cancer cases are at an estimated 2- to 4-
fold higher risk,82,85 with the risk increasing up to as high as 57-fold if 3 or more rela-
tives are affected.86 A large twin study, including 44,788 pairs of twins listed in the 
Swedish, Danish, and Finnish twin registries, showed that heritable factors account for 
36% (95% confidence interval [CI]: 0-53%), whereas (non-shared) environmental fac-
tors account for 64% (95% CI: 47-86%) of the variation in occurrence of pancreatic 
cancer among twins.87 
 The observed familial clustering of pancreatic cancer may be explained by the 
presence of germline mutations in a major pancreatic cancer susceptibility gene, ana-
logues to the breast cancer susceptibility genes BRCA1 and BRCA2. Indeed, a complex 
segregation analysis, including 287 families of pancreatic cancer cases, produced evi-
dence supporting the role of a rare major gene (or multiple genes acting in a similar 
fashion) influencing risk of pancreatic cancer within families.84 To date, this major pan-
creatic cancer gene has not yet been identified. The results from a linkage study, based 
on a single multiplex familial pancreatic cancer kindred, pointed out the 4q32-34 re-
gion as a susceptibility locus for pancreatic cancer.88 This result could not be replicated 
in subsequent linkage studies, nor did these studies produce evidence for further pan-
creatic cancer susceptibility loci.89-91 
 Pancreatic cancer is associated with several genetic syndromes, where germline 
mutations in specific genes are involved.92 These include hereditary breast cancer 
(BRCA2), familial atypical multiple mole melanoma syndrome (CDKN2A), Peutz-Jeghers 
syndrome (STK11/LKB1), hereditary pancreatitis (PRSS1, SPINK1), and hereditary non-
polyposis colorectal cancer (mismatch repair genes, including hMSH2 and hMLH1). 
These syndromes, however, explain little of the observed familial aggregation of pan-
creatic cancer. 
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It is likely that relatively common genetic variants, with modest effects on pancreatic 
cancer risk, play an important role in both the familial and sporadic forms of the dis-
ease (i.e., without a clear-cut inheritance pattern), either individually or in interaction 
with environmental factors. Such variants typically display a relatively high frequency 
in the population, as opposed to the rare high-penetrance variants, and could there-
fore, potentially explain a substantial portion of pancreatic cancer risk. To date, associ-
ation studies employing a candidate gene approach have tested variants in genes in-
volved in carcinogen metabolism, DNA repair, inflammation, one-carbon metabolism, 
and mitochondria (reviewed by Milne et al.93). None of these variants have been con-
clusively established as risk factors, partly due to the lack of replications in indepen-
dent data sets and the inherent problems of the candidate gene approach. 
 The emergence of new high-throughput genotyping technologies, and consequent 
decrease in their cost, means that genome-wide association studies (GWAS) are be-
coming more feasible. Results for other complex diseases, including cancers from vari-
ous sites, suggest that GWAS may be more effective in identifying main effects of 
common low-penetrance genetic variants.94 So far, four GWAS have been per-
formed.95-98 The first GWAS consisted of a consortium (“Panscan1”) of 12 prospective 
cohort studies and a hospital-based case-control study, providing 1,896 cases and 
1,939 controls. Eight additional case-control studies (2,457 cases and 2,654 controls) 
were used for replication. This GWAS identified a single nucleotide polymorphism 
(SNP) in the first intron of the ABO blood group gene, conferring an odds ratio (OR) of 
1.20 (95% CI: 1.12-1.28).95 This finding is in line with earlier epidemiological evidence 
that individuals with blood group O may have a lower risk of pancreatic cancer com-
pared with groups A and B.99 The second GWAS, using a smaller population of 160 
cases and 172 controls, reported an association with a variant in the GGT1 gene (γ-
glutamyltransferase 1; OR = 1.66, 95% CI: 1.18-2.32).96 The third GWAS reported was a 
second scan of the Panscan-consortium, which identified multiple susceptibility loci, 
including 13q22.1 (KLF5 and KLF12, OR = 1.26, 95% CI: 1.18-1.35), 1q32.1 (NR5A2, OR = 
1.30, 95% CI: 1.19-1.41), and 5p15.33 (CLPTM1L-TERT, OR = 1.19, 95% CI: 1.11-1.27).98 
The most recent GWAS, using 991 cases and 5,209 controls from Japan, identified 
three pancreatic cancer susceptibility loci, including 6p25.3 (OR = 1.29, 95% CI: 1.17-
1.43), 12p11.21 (OR = 1.32, 95% CI: 1.19-1.47), and 7q36.2 (OR = 3.73, 95% CI: 2.24-
6.21).97 The results from these initial GWAS await additional replication and functional 
studies to elucidate the (genetic) etiology of pancreatic cancer. 
 
 
RATIONALE AND AIMS OF THIS THESIS 
 
Rationale  
Because the pancreas is intimately related to digestion and absorption, it is reasonable 
to place diet high among the possible causal factors for pancreatic cancer. However, 
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the specific dietary components and mechanisms involved in the etiology of pancreatic 
cancer remain unclear, primarily because of limited and inconsistent study findings. 
 One of the reasons that study findings have been inconsistent between case-
control studies and cohort studies might be because case-control studies are prone to 
more biases, including recall bias, compared with cohort studies. Recall bias could lead 
to risk estimates that are either exaggerated or underestimated because dietary intake 
is assessed in cases after diagnosis. Furthermore, patients in case-control studies tend 
to report current rather than past diet which can introduce bias because current diet 
might be influenced by prediagnostic symptoms of disease.100 Differential misclassifica-
tion of the exposure could also have occurred due to the need to use next-of-kin inter-
views in case-control studies because pancreatic cancer is rapidly fatal. Indeed, a study 
has shown that this resulted in misclassification of exposure and that this misclassifica-
tion varies according to the type of exposure and the relation of the proxy respondent 
to the subject.101 In addition, case-control studies of pancreatic cancer are highly sus-
ceptible to selection bias. Due to the high fatality rates, many cases are either not 
approached for studies because they die before they could be included in the study, or 
they are unable or unwilling to participate because of the severity of their disease. 
Excluding these patients might introduce selection bias because the included cases 
might differ from excluded cases regarding the aggressiveness of the disease or in 
other ways. Also, pancreatic cancer shows relatively low incidence rates, which has 
resulted in relatively low case numbers in most prospective studies. A large-scale co-
hort study with a substantial number of cases would be informative to overcome these 
biases and to make a substantial contribution to the epidemiological knowledge re-
garding the association between risk factors and pancreatic cancer risk. The prospec-
tive design avoids differential misclassification and the need to use next-of-kin respon-
dents. 
 
Design Netherlands Cohort Study  
The prospective Netherlands Cohort Study (NLCS) was initiated in September 1986 and 
included initially 58,279 men and 62,573 women aged 55-69 years from 204 Dutch 
municipalities with computerized population registries.102 A self-administered 11-page 
food frequency and lifestyle questionnaire, including detailed information on potential 
risk factors for pancreatic cancer, was completed at baseline in 1986. For increased 
efficiency in the processing of the questionnaire and follow-up, the case-cohort ap-
proach was used.103 Incident cases were derived from the entire cohort, whereas the 
person-years at risk were estimated from a random sample of 5,000 subjects (2,411 
men and 2,589 women). This subcohort was chosen immediately after baseline and 
followed up for vital status information. The entire cohort is being monitored for can-
cer occurrence by annual record linkage to the Netherlands Cancer Registry and the 
Netherlands Pathology Registry.104,105 Follow-up is still ongoing for the NLCS, which is 
why two different follow-up periods were used in this thesis. A schematic presentation 
of the design is given in Figure 1.5. For the first part of the thesis, a total of 13.3 years 
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of follow-up (baseline to December 1999) was used for the analysis, for which 408 
incident exocrine pancreatic cancer cases (ICD-O-3 code C25; excluding Islet-cell carci-
noma [ICD-O-3 code C25.4]) were available. Sixty-six percent of these cases were mi-
croscopically confirmed pancreatic cancer (n = 269), whereas microscopic confirmation 
was lacking for 34% (n = 139). Diagnosis of the latter group was made by the treating 
clinician and was based on clinical symptoms, physical examination, and imaging re-
sults.106 Data were abstracted and recorded by a trained tumor registrar. When data 
became available in 2008 for a period of 16.3 years (baseline to December 2002), the 
follow-up period was extended. This extended follow-up period was used for the ana-
lyses described in the last chapters of this thesis, for which 520 incident exocrine pan-
creatic cancer cases (62% microscopically confirmed) were available. 
 
  
 
FIGURE 1.5 Schematic presentation of Netherlands Cohort Study design 
Abbreviations: MCPC, microscopically verified pancreatic cancer; NLCS, Netherlands Cohort Study. 
 
 In a previous analysis of anthropometric measures and pancreatic cancer risk 
within the NLCS, a significantly positive association between BMI and pancreatic can-
cer risk was observed only among microscopically verified cases, whereas this associa-
tion was obscured when non-microscopically verified cases were included.107 Also, two 
other studies showed that diagnostic misclassification for pancreatic cancer biased risk 
estimates towards the null when they investigated the relation between pancreatic 
cancer risk and exposure to cigarette smoking or exposure to DDT.19,108 Therefore, next 
to the overall analyses including all pancreatic cancer cases, we restricted additional 
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analyses in this thesis to microscopically verified cases to create a group with a higher 
degree of diagnostic certainty of pancreatic cancer. 
Aims  
The overall aim of this thesis was to investigate associations between dietary and life-
style factors and pancreatic cancer risk. These factors were investigated within the 
context of the NLCS on diet and cancer. In Chapter 2, the following hypotheses were 
investigated: (i) Physical activity is inversely associated with pancreatic cancer risk and 
will be more protective in those who are overweight or obese; and (ii) energy restric-
tion in adolescence is associated with a reduced risk of pancreatic cancer. Additionally, 
several other dietary factors were investigated in relation to pancreatic cancer risk. 
The following factors were hypothesized risk factors: a high alcohol intake (described 
in Chapter 3) a diet high in GI and GL (Chapter 4), and a high meat and fat intake 
(Chapter 5). In Chapter 6, we investigated the hypothesis that a high intake of vegeta-
bles, fruits, carotenoids, and vitamin C and E is inversely associated with pancreatic 
cancer risk. Furthermore, we have investigated whether cigarette smoking and passive 
smoking exposure were positively associated and quitting cigarette smoking was in-
versely associated with pancreatic cancer risk (Chapter 7). Finally, the findings de-
scribed in this thesis are discussed, as well as implications for future research regarding 
risk factors for pancreatic cancer (Chapter 8). The association between anthropometry 
and pancreatic cancer risk has already been investigated within the NLCS, observing an 
association between BMI and gain in BMI from age 20 years and pancreatic cancer 
risk.107 These factors were therefore, not included in the current thesis. 
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ABSTRACT 
 
Background 
Previous studies suggested that higher physical activity levels and energy restriction 
might decrease pancreatic cancer risk. The insulin-like growth factor axis might play a 
mechanistic role in these associations. 
 
Objective 
We examined prospectively the associations between physical activity, energy restric-
tion, and pancreatic cancer risk. 
 
Methods 
The Netherlands Cohort Study consisted of 120,852 men and women who completed a 
baseline questionnaire in 1986. After 13.3 years of follow-up, 408 incident pancreatic 
cancer cases were available for analysis. Self-reported information on physical activity 
was collected. Three indicators were used as proxies for energy restriction: place of 
residence during the Hunger winter (1944-1945) and World War II years (1940-1944), 
and father’s employment status during the Economic Depression (1932-1940). 
 
Results 
For sports activity in the past, we observed a statistically significantly decreased pan-
creatic cancer risk (hazard rate ratio [HR] = 0.78, 95% confidence interval [CI]: 0.62-
0.98). Compared with individuals who resided in non-western area during the Hunger 
winter, residing in western rural area increased cancer risk with 37% (95% CI: 1.00-
1.86), whereas no association was observed for residing in a western city. Individuals 
who resided in a city in 1942 had a decreased risk (HR = 0.76, 95% CI: 0.59-0.98). Occu-
pational physical activity and exposure to energy restriction during the Economic De-
pression were not associated with pancreatic cancer risk. 
 
Conclusions 
Overall, our results suggest a modestly decreased pancreatic cancer risk for sports 
activity in the past, whereas findings with respect to proxies for energy restriction did 
not support our hypothesis that energy restriction may reduce pancreatic cancer risk. 
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INTRODUCTION 
 
Pancreatic cancer is the 5th leading cause of death in Europe and 4th in the United 
States,1,2 with a 5-year survival rate of 6% or less.2,3 So far, just few risk factors have 
been identified, including cigarette smoking, body mass index, and diabetes mellitus.4-7 
 Observational studies on pancreatic cancer suggest that high insulin concentra-
tions, glucose intolerance and insulin resistance may play a role in carcinogenesis, even 
without a diagnosis of diabetes mellitus.8,9 Furthermore, experimental studies show 
that insulin might act as a growth promoter and mitogen in the pancreas.10,11 Addition-
ally, excess insulin can downregulate insulin-like growth factor (IGF)-1 binding proteins 
resulting in more bioavailable IGF-1, which has been positively associated with cell 
proliferation in pancreatic cancer.9,12 Human intervention studies showed that pro-
longed exercise (e.g., marathon running) lowers IGF-1 levels.13 In addition, intervention 
studies showed that chronic exercise training reduces insulin resistance, even in the 
absence of weight loss.5,9,14 Experimental studies have shown that energy restriction 
reduces levels of circulating IGF-1 and insulin.5,9 Furthermore, energy restriction sup-
presses tumor development in experimental animals.5 In rat models, it was also shown 
that moderate energy restriction decreased pancreatic cancer risk.15,16 Therefore, we 
hypothesized that both physical activity and energy restriction may reduce pancreatic 
cancer risk. 
 So far, findings from epidemiological studies investigating physical activity in rela-
tion to pancreatic cancer risk have been inconsistent. Some cohort and case-control 
studies suggest that higher physical activity levels (both occupational and non-
occupational) might decrease risk, especially in overweight or obese persons.17-20 Oth-
er cohort studies, however, did not observe an association between physical activity 
and pancreatic cancer risk.21-24 To our knowledge, no observational study has investi-
gated the relation between energy restriction and pancreatic cancer risk. 
 In the current study, we investigated both non-occupational and occupational 
physical activity in relation to pancreatic cancer risk. We also investigated whether the 
association between physical activity and pancreatic cancer risk was modified by body 
mass index (BMI), and change in BMI. Finally, the Netherlands Cohort Study (NLCS) is 
comprised of individuals who grew up during the Hunger winter (winter of 1944-1945). 
This period offers the rare opportunity to study the effect of severe short-term energy 
restriction during adolescence on the risk of pancreatic cancer in later life. We also had 
information on two preceding periods of more moderate energy restriction: World 
War II (WW II; 1940-1944) and the Economic Depression (1932-1940). Although indi-
vidual food intake data is not available for these three time periods, proxy measures 
have been collected from cohort members that reflect their exposure to energy re-
striction; that is, place of residence during the Hunger winter and WW II, and employ-
ment status of the father during the Economic Depression. 
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SUBJECTS AND METHODS 
 
Study population and cancer follow-up  
The study design of the NLCS has been reported in detail elsewhere.25 Briefly, the NLCS 
was begun in September 1986 and included initially 58,279 men and 62,573 women 
aged 55-69 years from 204 Dutch municipalities with computerized population regi-
stries. A self-administered questionnaire on dietary habits and other risk factors for 
cancer was completed at baseline, including non-occupational physical activity at base-
line, history of sports participation and occupational history. Also included were ques-
tions about the residences of the cohort members during their entire life, including the 
residence in the war years and the winter of 1944-1945, and the fathers’ employment 
status during the Economic Depression. For increased efficiency in the processing of 
the questionnaire and follow-up, the case-cohort approach was used.26 Incident cases 
were derived from the entire cohort, whereas the person-years at risk were estimated 
from a random sample of 5,000 participants (2,411 men and 2,589 women). This sub-
cohort was chosen immediately after baseline and followed up for vital status informa-
tion. The entire cohort is being monitored for cancer occurrence by annual record 
linkage to the Netherlands Cancer Registry and the Netherlands Pathology Registry.27,28 
A total of 13.3 years of follow-up (baseline to December 1999) was used for the cur-
rent analysis. Only two subcohort member were lost to follow-up and completeness of 
cancer follow-up was estimated to be >96%.29 
 All prevalent cancer cases at baseline other than skin cancer were excluded, re-
sulting in a subcohort of 4,774 men and women. After 13.3 years of follow-up, 447 
incident pancreatic cancer cases (ICD-O-3 code C25) were identified. Of these cases, 
endocrine subtypes (ICD-O-3 code C25.4; n = 1) were excluded. Sixty-five percent of 
the 446 pancreatic cancer cases were microscopically confirmed pancreatic cancer 
(MCPC; n = 290), whereas confirmation was lacking for 35% (n = 156). Diagnosis of the 
latter group was made by the treating clinician and was based on clinical symptoms, 
physical examination and imaging results. Data were abstracted and recorded by a 
trained tumor registrar.30 The NLCS has been approved by the institutional review 
boards of the TNO Nutrition and Food Research Institute (Zeist, the Netherlands) and 
Maastricht University (Maastricht, the Netherlands). 
 
Exposure assessment  
Questionnaire data were key-entered and processed for all incident cases in the cohort 
and subcohort members in a standardized manner, blinded with respect to case or 
subcohort status. This was done to minimize observer bias in the coding and interpre-
tation of the data. Subcohort members and cases with incomplete or inconsistent 
dietary data were excluded from analyses. Additional details are given elsewhere.31 
This resulted in a final subcohort of 4,438 participants (2,191 men, 2,247 women) and 
408 exocrine pancreatic cancer cases (217 men, 191 women) available for analysis. 
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Physical activity  
Information on both non-occupational and occupational physical activity was assessed 
in the questionnaire. In this paper, we use the term “non-occupational physical activi-
ty” to cover both leisure-time physical activity and other physical activities outside of 
the job. Our calculations did not include household chores. 
 Non-occupational physical activity at baseline was calculated by adding the num-
ber of minutes spent per day on cycling or walking to work, shopping, and walking the 
dog, and the number of hours spent per week on gardening or odd jobs, recreational 
cycling or walking, and sports or exercise as reported previously.32 The minutes spent 
per day on these activities were categorized: <30, 30-<60, 60-<90, and ≥90 min/day. 
 Data on history of sports participation was also available; respondents were asked 
what type of sport they had conducted, the number of hours per week and the dura-
tion of this sport in years. In total, respondents could describe three sports. Participat-
ing in sports activity was first dichotomized to “never” or “ever” participating in 
sports.32 The total duration of sports activities in years was calculated by adding up the 
duration of all episodes of participation in each sport (accounting for the overlap be-
tween sports). Duration of sports participation was categorized as <15, 15-<30, and 
≥30 years of sports participation. The total numbers of hours per week that respon-
dents had participated in each sport were also added up. This variable was categorized 
as <2, 2-<4, and ≥4 hours/week of sports participation. The respondents who reported 
“never to have participated in sports” where assigned the value zero. 
 Respondents were asked for their lifetime occupational history, with regard to job 
title and duration. We used information about the longest job ever held as well as 
information about the last occupation as indicators for the lifetime physical activity at 
work. Two different measures of occupational physical activity have been used: (i) 
sitting time (hours/day) and (ii) energy expenditure (kJ/min).33 For sitting time respon-
dents were classified into three groups: >6, 2-6, and <2 working hours/day spent sit-
ting. Total energy expenditure was based on a rating system developed by Hettinger et 
al.34 Respondents were classified into three energy expenditure groups: <8, 8-12, and 
>12 kJ/min.33 Occupational physical activity was not calculated for women because 
most Dutch women of this generation had not held a job or had worked for only a 
short period of time, mostly in the distant past. 
 
Energy restriction  
Individual food intake data of the cohort members was not available for the three 
mentioned periods of energy restriction in the Netherlands; we therefore used proxy 
variables to describe exposure to energy restriction.35 With respect to the Economic 
Depression years (1932-1940), the occupation of the father was the best available 
proxy variable for moderate energy restriction. Several surveys showed that having an 
unemployed father indicated that the amount of calories available was less and the 
variation in the individual’s food pattern was limited compared with families with an 
employed father.35,36 The exposure variable for the Economic Depression years was 
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dichotomous: respondents whose father had a job and respondents whose father had 
no job during that period. 
 For the War period (1940-1944) and the Hunger winter (1944-1945), the city of 
residence during these periods was taken to approximate the exposure to energy re-
striction. During WW II, food rationing was introduced and caloric intake was reduced 
to about 1,700 calories a day during 1941-1943.37 Between 1943-1944, the nutritional 
status of the Dutch population deteriorated, especially for those living in the cities.35 
Place of residence 1942 (midpoint of war years) was used as a proxy for moderate 
energy restriction during the war. This exposure variable was dichotomous (living in a 
rural area in 1942 versus living in a city in 1942). 
 With respect to the Hunger winter, cohort members were specifically asked 
where they lived during the winter of 1944-1945. Living in a western city in 1944-1945 
was considered an indicator for severe energy restriction. Whereas the diet remained 
nutritionally balanced, individuals living in western urban areas experienced rationing 
of less than 700 kcal per day.38 
 
Statistical analysis  
Age-adjusted and multivariable-adjusted hazard rate ratios (HRs) and corresponding 
95% confidence intervals (95% CIs) were estimated using Cox proportional hazards 
models. The total person-years at risk estimated from the subcohort were used in the 
analyses.39 Standard errors were estimated by using a robust covariance matrix esti-
mator to account for increased variance due to sampling from the cohort.40 We tested 
the proportional hazards assumption by using the scaled Schoenfeld residuals.41 All 
analyses were conducted for both sexes combined and separately for men and wom-
en. 
 The following variables were considered as potential confounders: age, sex, smok-
ing, BMI at baseline, height, energy intake, alcohol intake, intake of vegetables and 
fruit, level of education, family history of pancreatic cancer, history of diabetes melli-
tus and hypertension. These potential confounding variables were added to the multi-
variable-adjusted model if they (i) were associated with the disease and with the expo-
sure of interest and (ii) changed the age- and sex-adjusted regression coefficients by at 
least 10% (using a backwards stepwise procedure). The following confounders were 
included in all multivariable-adjusted models: age at baseline (years), sex (included in 
all models except for occupational physical activity), smoking (current smoking: 
yes/no; number of cigarettes smoked per day; number of years of smoking), BMI at 
baseline (kg/m2), level of education (primary school or lower vocational school/inter-
mediate vocational school or high school/higher vocational school or college), energy 
intake (kcal/day), and intake of vegetables (g/day). The model for energy restriction 
additionally included non-occupational physical activity (total non-occupational physi-
cal activity at baseline, min/day; history of sports participation: never/ever) in the 
multivariable-adjusted model. To enable comparison, age- and sex-adjusted analyses 
were restricted to participants included in multivariable-adjusted analyses. Trends 
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were evaluated with the Wald test by assigning participants the median value for each 
level of the categorical exposure variable among the subcohort members and this 
variable was entered as a continuous term in the Cox regression model.  
 In the present study the overall analyses included all pancreatic cancer cases. We 
restricted additional analyses to MCPC cases to create a group with a higher degree of 
diagnostic certainty of pancreatic cancer, which was shown to be important in pre-
vious studies.42,43 In additional analyses, respondents who reported a history of di-
abetes at baseline (n = 184) were excluded. To evaluate whether early symptoms of 
pancreatic cancer before diagnosis could have influenced the results, early cases (diag-
nosed within 2 years after baseline) were excluded in additional analyses of physical 
activity. Michaud et al. showed that physical activity was inversely associated with 
pancreatic cancer risk among individuals with a BMI of ≥25 kg/m2, whereas no associa-
tion was observed for normal weight individuals.18 Therefore, interactions between 
physical activity (non-occupational physical activity at baseline and history of sports 
participation), and BMI at baseline (cutoff: 25 kg/m2) were investigated. Also, interac-
tions between physical activity and BMI at age 20 years (cutoff: 21 kg/m2) were inves-
tigated. Increases in body weight during adulthood – due to excess energy intake, 
physical inactivity, or both – depend mostly on accumulation of fat rather than lean 
tissue.5,44 Hence, change in weight may better reflect fatness than adult attained 
weight itself, which is more dependent of lean mass. Therefore, interactions of physi-
cal activity with change in BMI since age 20 years (≥6, 2-<6, and <2 kg/m2) were inves-
tigated as well. All analyses were performed using the STATA statistical software pack-
age (intercooled STATA, version 9). All p values were based on two-sided tests and 
considered statistically significant if <0.05. 
 
 
RESULTS 
 
In Table 2.1, baseline characteristics (stratified by sex) are presented. Most characte-
ristics did not differ between pancreatic cancer cases and subcohort members; how-
ever, there were more current smokers and more individuals with a history of diabetes 
mellitus among cases than among subcohort members, especially in men. 
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TABLE 2.1 Baseline characteristics of pancreatic cancer cases and subcohort members; Netherlands Cohort Study on 
diet and cancer, 1986-1999 
Characteristic Men  Women 
  All pancreatic 
cancer cases 
 
Subcohort 
 All pancreatic 
cancer cases 
 
Subcohort 
n 217 2,191  191 2,247 
Age, years, mean ± SD 62.2 ± 4.0 61.3 ± 4.2  62.5 ± 4.2 61.4 ± 4.3 
Current smokers (%) 47.5 35.7  28.3 21.0 
Years of smoking*, years, mean ± SD 35.9 ± 12.1 33.7 ± 11.8  29.5 ± 12.1 27.8 ± 12.5 
BMI at baseline, kg/m2, mean ± SD 25.3 ± 3.0 25.0 ± 2.6  25.6 ± 3.5 25.1 ± 3.6 
BMI at age 20 years, kg/m2, mean ± SD 21.8 ± 2.2 21.7 ± 2.4  21.4 ± 3.6 21.4 ± 2.8 
Change in BMI since age 20 years, kg/m2, 
mean ± SD 
 
3.6 ± 3.3 
 
3.3 ± 3.0 
  
4.2 ± 4.0 
 
3.7 ± 3.7 
History of diabetes mellitus (%) 8.8 3.4  5.2 3.6 
History of hypertension (%) 23.5 23.4  31.4 29.5 
Level of education (%)      
 Low 46.1 45.7  57.4 56.7 
 Medium  33.2 35.6  35.2 34.5 
 High 20.7 18.7  7.4 8.8 
Daily intake      
 Energy intake, kcal, mean ± SD 2159 ± 474 2166 ± 511  1693 ± 403 1686 ± 398 
 Total fat†, g, mean ± SD 93.1 ± 13.8 93.9 ± 14.3  74.0 ± 11.4 74.0 ± 10.3 
 Total carbohydrates†, g, mean ± SD 223.4 ± 37.6 226.7 ± 37.5  176.6 ± 27.1 178.8 ± 26.7 
 Alcohol, g, median (IQR) 11.0 (0-69.5) 9.7 (0-96.7)  2.6 (0-41.8) 1.6 (0-66.4) 
 Vegetable intake, g, mean ± SD 193.5 ± 90.6 191.6 ± 84.9  211.6 ± 82.7 195.5 ± 81.3 
 Fruit intake, g, mean ± SD 150.7 ± 120.2 154.0 ± 114.1  192.4 ± 107.2 196.4 ± 121.1 
Non-occupational physical activity      
Non-occupational physical activity at baseline     
Total non-occupational physical activity at 
baseline, min/day, median (IQR) 
 
60.0 (12.9-222.9) 
 
62.1 (0-402.9) 
  
51.4 (0-214.3) 
 
53.2 (0-402.9) 
History of sports participation (%)      
 Never 54.4 45.9  57.1 54.8 
 Ever 45.6 54.1  42.9 45.2 
 No. of hours of sport per week‡,  
median (IQR) 
 
5 (1-22) 
 
5 (1-36) 
  
3 (1-14) 
 
3 (0.5-42) 
 Duration of sports participation‡, 
years, median (IQR) 
 
15.5 (2-51) 
 
12 (1-61) 
  
12 (2-52) 
 
10 (1-61) 
Occupational physical activity§      
Longest held job      
Sitting time per day, hours/day (%)      
 >6 24.3 25.6  - - 
 2-6 40.8 44.5  - - 
 <2 34.9 29.9  - - 
Energy expenditure, kJ/min (%)      
 <8 58.2 57.9  - - 
 8-12 27.5 25.6  - - 
 ≥12 14.3 15.5  - - 
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TABLE  2.1 continued      
 Men  Women 
 All pancreatic 
cancer cases 
 
Subcohort 
 All pancreatic 
cancer cases 
 
Subcohort 
Energy restriction      
Hunger winter 1944-1945 (%)      
 Non-west 60.4 59.8  50.3 56.6 
 Western rural area 19.5 15.4  18.2 15.0 
 Western city 20.1 24.8  31.5 28.4 
War years 1940-1944 (%)      
 Rural area in 1942 53.5 49.5  52.3 46.8 
 City in 1942 46.5 50.5  47.7 53.2 
Economic Depression 1932-1940 (%)      
 Father had a job 89.2 89.3  88.8 88.5 
 Father had no job 10.8 10.7  11.2 11.5 
Abbreviations: BMI, body mass index; IQR, interquartile range; SD, standard deviation. 
*Never smokers excluded. †Energy-adjusted intake. ‡Participants who reported to have never engaged in sports 
activities excluded. §Women excluded since most women of this generation had not held a job or had worked for 
only a short period of time, mostly in the distant past. 
 
 In Table 2.2, HRs are presented for physical activity. After adjustment for age and 
sex, we observed no association for total non-occupational physical activity at base-
line. For respondents who reported ever to have participated in a sport, we observed a 
reduction in pancreatic cancer risk, which was of borderline significance. We observed 
a decreased pancreatic cancer risk for participants who reported to have participated 
in sports for 2-4 hours per week and for ≥4 hours per week compared with participants 
who have never participated in sports (Table 2.2), although the highest category was 
not statistically significant and also no clear dose-response relation was observed (p 
for trend = 0.09). For total duration of sports, we observed a statistically significantly 
reduced pancreatic cancer risk for participants who reported to have participated in 
sports <15 years, but no association was observed when participants participated in 
sports for 15 years or more (Table 2.2). No associations were observed between occu-
pational physical activity in men and pancreatic cancer risk (Table 2.2). 
 Most results were similar after including the confounders in the model (Table 
2.2). However, the decreased pancreatic cancer risk observed for respondents who 
reported ever to have participated in sports became statistically significant after in-
cluding the confounders (HR = 0.78, 95% CI: 0.62-0.98; Table 2.2). For participants who 
reported to have participated ≥4 hours in sports, the risk estimate became significant 
showing a significantly dose-response relation (HR = 0.74, 95% CI: 0.56-0.98, p for 
trend = 0.04; Table 2.2). After excluding the first 2 years of follow-up, the results were 
not substantially different (data not shown). 
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TABLE 2.2 Age-adjusted and multivariable-adjusted hazard rate ratios (HRs) and 95% CIs for pancreatic 
cancer according to physical activity (both non-occupational and occupational); Netherlands Cohort Study on 
diet and cancer, 1986-1999 
Exposure variable Person- 
years* 
All pancreatic cancer cases 
  Cases* HR (95% CI)† HR (95% CI)‡ 
Non-occupational physical activity    
Total non-occupational physical activity at baseline§ (min/day)  
 <30║ 9,358 67 1.00 1.00 
 30-<60 15,489 118 1.06 (0.78-1.45) 1.08 (0.79-1.49) 
 61-<90 10,593 89 1.20 (0.86-1.67) 1.22 (0.87-1.71) 
 ≥90 13,427 87 0.87 (0.63-1.22) 0.87 (0.62-1.22) 
 p for trend   0.31 0.25 
History of sports participation§    
 Never║ 24,506 198 1.00 1.00 
 Ever 24,869 164 0.81 (0.65-1.00) 0.78 (0.62-0.98) 
 No. of hours of sport per week (hours/week)   
 <2 3,592 30 1.11 (0.73-1.67) 1.17 (0.77-1.78) 
 2-<4 7,637 41 0.67 (0.47-0.95) 0.65 (0.45-0.92) 
 ≥4 12,521 84 0.79 (0.60-1.04) 0.74 (0.56-0.98) 
 p for trend   0.09 0.04 
 Duration of sports participation (years)   
 <15 14,214 80 0.70 (0.53-0.92) 0.68 (0.51-0.90) 
 15-<30 5,265 37 0.85 (0.58-1.22) 0.84 (0.57-1.23) 
 ≥30 3,712 35 1.11 (0.76-1.62) 1.06 (0.71-1.59) 
 p for trend   0.84 0.93 
Occupational physical activity¶    
Longest held job     
Sitting time per day (hours/day)    
 >6║  5,383 39 1.00 1.00 
 2-6 9,603 66 0.92 (0.61-1.40) 0.93 (0.61-1.43) 
 <2 5,678 57 1.36 (0.88-2.09) 1.43 (0.87-2.34) 
 p for trend   0.15 0.17 
Energy expenditure (kJ/min)    
 <8║ 12,439 96 1.00 1.00 
 8-12 5,270 44 1.07 (0.73-1.55) 1.01 (0.65-1.56) 
 >12 2,954 22 0.94 (0.58-1.53) 0.90 (0.53-1.53) 
 p for trend   0.94 0.76 
Last job     
Sitting time per day (hours/day)    
 >6║  5,698 46 1.00 1.00 
 2-6 10,132 70 0.85 (0.57-1.25) 0.85 (0.57-1.27) 
 <2 5,608 53 1.16 (0.76-1.75) 1.18 (0.72-1.91) 
 p for trend   0.49 0.57 
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TABLE 2.2 continued     
 Person- 
years* 
All pancreatic cancer cases 
Cases* HR (95% CI)† HR (95% CI)‡ 
Energy expenditure (kJ/min)    
 <8║ 13,343 103 1.00 1.00 
 8-12 5,067 41 1.04 (0.71-1.53) 1.01 (0.64-1.58) 
 >12 3,027 25 1.06 (0.67-1.68) 1.05 (0.63-1.77) 
 p for trend   0.77 0.86 
*Number of cases and person-years do not add up to the total number because of missing values for cova-
riables. †Adjusted for age (years). ‡Adjusted for age (years), smoking (current smoking: yes/no; number of 
cigarettes smoked per day; number of years of smoking), body mass index (kg/m2), level of education (pri-
mary school or lower vocational school/intermediate, vocational school or high school/higher vocational 
school or college), energy intake (kcal/day), and intake of vegetables (g/day). §Additionally adjusted for sex. 
║Reference category. ¶Women excluded from analyses since most women of this generation had not held a 
job or had worked for only a short period of time, mostly in the distant past. 
 
 For energy restriction (Table 2.3), we observed a borderline statistically signifi-
cantly increase in risk for individuals who resided in western rural area during the Hun-
ger winter in 1944-1945 compared with individuals who resided in non-west area, 
whereas no association was observed for individuals who resided in a western city 
during the Hunger winter. For the energy restriction during WW II and during the Eco-
nomic Depression, we observed no statistically significant associations, although living 
in a city in 1942 during WW II suggested a decreased risk. Adding confounders to the 
model did not materially change the results. However, the decreased pancreatic can-
cer risk observed for individuals living in a city in 1942, was of similar strength com-
pared with the age- and sex-adjusted effect estimate, but became statistically signifi-
cant after including the confounders (HR = 0.76, 95% CI: 0.59-0.98; Table 2.3). 
 Results did not differ between men and women (results not shown). The exclusion 
of participants without histological confirmed pancreatic cancer did not change most 
findings (results not shown), although the statistically significantly decreased pancrea-
tic cancer risk observed for respondents who reported ever to have engaged in sports 
became non-significant (HR = 0.77, 95% CI: 0.58-1.02). For participants who reported 
to have participated ≥4 hours in sports, the risk estimate attenuated and became non-
significant (HR = 0.81, 95% CI: 0.58-1.13), as did the dose-response relation (p for trend 
= 0.22). For energy restriction, the increased risk observed among individuals who 
resided in western rural area during the Hunger winter attenuated and became statis-
tically non-significant (HR = 1.19, 95% CI: 0.81-1.75). The risk estimate observed for 
individuals who lived in a city in 1942 during the war became non-significant (HR = 
0.77, 95% CI: 0.56-1.05), when we excluded participants without histological confirmed 
pancreatic cancer, possibly due to smaller numbers. 
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TABLE 2.3 Age-adjusted and multivariable-adjusted hazard rate ratios (HRs) and 95% CIs for pancreatic 
cancer according to energy restriction; Netherlands Cohort Study on diet and cancer, 1986-1999 
Exposure variable Person- 
years* 
All pancreatic cancer cases 
Cases* HR (95% CI)† HR (95% CI)‡ 
Hunger winter 1944-1945     
 Non-west§ 24,944 175 1.00 1.00 
 Western rural area 6,594 61 1.36 (1.00-1.85) 1.37 (1.00-1.86) 
 Western city 11,781 75 0.91 (0.69-1.21) 0.89 (0.67-1.18) 
War years 1940-1944     
 Rural area in 1942§ 17,334 150 1.00 1.00 
 City in 1942 19,015 133 0.80 (0.62-1.02) 0.76 (0.59-0.98) 
Economic Depression 1932-1940    
 Father had a job§ 41,692 302 1.00 1.00 
 Father had no job 5,175 37 0.97 (0.68-1.38) 0.91 (0.63-1.31) 
*Number of cases and person-years do not add up to the total number because of missing values for cova-
riables. †Adjusted for age years) and sex. ‡Adjusted for age (years), sex, smoking (current smoking: yes/no; 
number of cigarettes smoked per day; number of years of smoking), body mass index (kg/m2), level of edu-
cation (primary school or lower vocational school/intermediate, vocational school or high school/higher 
vocational school or college), total baseline leisure-time physical activity (min/day), history of sports partici-
pation (never/ever), energy intake (kcal/day), and intake of vegetables (g/day). §Reference category. 
 
 BMI at baseline, and change in BMI between age 20 years and baseline did not 
modify the association between pancreatic cancer risk and baseline non-occupational 
physical activity (results not shown). For history of sports participation, we observed a 
HR of 0.59 (95% CI: 0.42-0.82) for lean individuals at baseline (<25 kg/m2) who re-
ported ever to have participated in sports compared with overweight individuals who 
reported never to have participated in sports (Table 2.4). No association was observed 
among the overweight individuals at baseline (≥25 kg/m2) reporting ever to have parti-
cipated in sports. The interaction term on a multiplicative scale was, however, not 
statistically significant (p for interaction = 0.39). For change in BMI between age 20 
years and baseline, we observed a decreased pancreatic cancer risk for individuals who 
reported to have ever participated in sports and changed less than 6 kg/m2 in BMI. The 
interaction term was not statistically significant (p for interaction = 0.71). BMI at age 
20 years did not modify the association between pancreatic cancer risk and history of 
sports participation. Our findings remained the same when excluding respondents who 
reported a history of diabetes at baseline from the analyses (data not shown). 
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TABLE 2.4 Multivariable-adjusted hazard rate ratios (HRs) and 95% CIs for pancreatic cancer according to 
history of sports participation, stratified by body mass index (BMI) and change in BMI; Netherlands Cohort 
Study on diet and cancer, 1986-1999 
Interaction 
variable 
History of sports participation 
Never  Ever p for 
interaction Cases* HR (95% CI)†  Cases* HR (95% CI)† 
BMI at baseline (kg/m2)      
 ≥25 100 1.00‡  87 0.85 (0.62-1.16) 0.39 
 <25 98 0.84 (0.62-1.13)  77 0.59 (0.42-0.82)  
BMI at age 20 y (kg/m2)      
 ≥21 90 1.00‡  84 0.84 (0.60-1.16) 0.30 
 <21 79 1.20 (0.87-1.65)  57 0.78 (0.54-1.13)  
Change in BMI since age 20 years§ (kg/m2)     
 ≥6 42 1.00‡  33 0.85 (0.52-1.40) 0.71 
 2-<6 72 0.82 (0.54-1.23)  64 0.64 (0.42-0.98)  
 <2 22 0.86 (0.54-1.36)  44 0.57 (0.35-0.92)  
*Number of cases does not add up to the total number because of missing values for covariables. †The model 
included age (years), sex, smoking (current smoking status: yes/no; number of cigarettes smoked per day; 
number of years of smoking), intake of vegetables (g/day), energy intake (kcal/day), and level of education 
(primary school or lower vocational school/intermediate, vocational school or high school/higher vocational 
school or college). ‡Reference category. §Model additionally included body mass index at age 20 years 
(kg/m2). 
 
 
DISCUSSION 
 
Our results showed that participating in sports in the past modestly decreased pan-
creatic cancer risk compared with never participating, whereas no association was 
observed for non-occupational physical activity at baseline and occupational physical 
activity. Results in the literature regarding physical activity and pancreatic cancer risk 
have been inconsistent so far. Decreased risks have been observed for total physical 
activity (occupational and non-occupational combined)19,20 and non-occuaptional phys-
ical activity17,18 in two cohort studies and two case-control studies, whereas no associa-
tion was observed for total physical activity22 and non-occuaptional physical activi-
ty21,23,24 in other cohort studies. A meta-analysis observed for occupational physical 
activity a 25% statistically significantly decreased pancreatic cancer risk and no associa-
tion with leisure-time physical activity.45 However, the estimate regarding occupational 
physical activity was based only on three cohort studies. Because most subjects in the 
NLCS started to participate in sports before the age of 20 years (interquartile range: 
11-21 years), our findings seem to suggest that participating in sports during childhood 
or adolescence reduces pancreatic cancer risk, whereas being physically active (both at 
work and outside of work) when middle-aged is not associated with pancreatic cancer 
risk. So far, previous epidemiological studies have investigated the effect of physical 
activity on pancreatic cancer risk during adult life only and not during childhood or 
adolescence. Therefore, our results must be regarded with some caution and further 
studies are needed to replicate our findings. 
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We were unable to reproduce the finding of Michaud et al., who observed an inverse 
association between total non-occupational physical activity and pancreatic cancer risk 
among overweight individuals.18 It might be, however, that BMI at age 20 years was 
not the best measure to investigate this for sports history because most subjects 
started to participate in sports before the age of 20 years as already indicated above. 
Furthermore, only 7.6% of our population was overweight (≥25 kg/m2) at the age of 
20. It could also be that being physically active in the past resulted in less weight gain 
and hence a less high BMI at older age compared with individuals that were not physi-
cally active in the past, which might explain why we observed a statistically significant-
ly decreased pancreatic cancer risk only in lean individuals who reported to have ever 
participated in sports. 
 To our knowledge, we are the first epidemiological study that investigated the 
relation between energy restriction during adolescence and pancreatic cancer risk. We 
observed a modestly decreased pancreatic cancer risk for individuals who resided in a 
city during the war years compared with those who did not, which was meant to indi-
cate a period of more moderate energy restriction. Regarding the exposure to a short 
period of severe energy restriction during the Hunger winter, individuals living in west-
ern rural area had an increased pancreatic cancer risk compared with individuals living 
in non-western area, whereas living in a western city was not associated. No associa-
tion was observed for exposure to energy restriction during the Economic Depression. 
Previous work on the NLCS cohort has found an inverse association between severe 
energy restriction during adolescence and colorectal cancer risk in men,46 but no asso-
ciation has been observed for colorectal cancer in women and for breast cancer.35,46 
Ecological studies have indirectly associated breast and colorectal cancer risk with the 
1940-1945 wartime conditions in Norway, when caloric intake was substantially re-
duced.47,48 A drop in colorectal cancer incidence was observed among cohorts born 
during or shortly after the war years and a drop in breast cancer incidence was ob-
served among women who experienced puberty during the war.47,48 These findings 
have led to the conclusion that dietary factors early in life, including energy restriction, 
may have an impact on later breast or colorectal cancer risk. 
 A factor that could have influenced the results of our study is misclassification of 
exposure to energy restriction, because of the use of place of residence and father’s 
employment status as proxies for exposure to energy restriction. In a follow-up study 
in the NLCS, female subcohort members were asked whether they really had expe-
rienced hunger during the winter of 1944-1945. These results showed that 75% of the 
women living in a western city reported that they experienced hunger during the win-
ter of 1944-1945, of whom 35% experienced severe hunger. Of the women who re-
ported severe hunger during the Hunger winter, 80% lived in a Western city during this 
winter.35 The hypothesis that energy restriction might protect against pancreatic can-
cer risk is based entirely on experimental studies because no epidemiological studies 
have been conducted so far. However, the animals in these studies were fed from 
early age onwards an energy restricted diet only, after which they were sacrificed.15,16 
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In our population, on the other hand, exposure to energy restriction took place mostly 
during adolescence and the period of exposure was relatively short, whereas after the 
war food was abundant again. A study in postmenopausal women observed that ado-
lescence exposure to the Dutch Hunger winter in 1944-1945 was associated with in-
creased plasma levels of IGF-1 and IGF binding protein-3;49 factors which are asso-
ciated with an increased cancer risk.9 It was hypothesized that this could indicate a 
permanent overshoot in IGF-1 after the Hunger winter upon improvement of nutri-
tional status after the war.49 This could possibly explain our finding for living in western 
rural area during the Hunger winter. It does, however, not explain why we did not 
observe a similar increase in risk for living in a western city during the Hunger winter. 
When we restricted the analyses to microscopically verified cases, the increased pan-
creatic cancer risk observed for residing in rural area during the Hunger winter atte-
nuated and became non-significant. Furthermore, the period of the Hunger winter was 
relatively short (7 months of severe deprivation at less than 40% of normal energy 
intake)38 and was maybe too short to find a decreased effect on pancreatic cancer risk. 
We did observe a decreased risk for living in a city during the war years compared with 
those who did not, which was meant to indicate a period of more moderate energy 
restriction. However, a study by Trienekens suggested that only the composition of the 
daily food intake had changed during the war years and not the caloric intake.50 
 The IGF axis is responsive to both nutritional status and physical activity levels and 
may be involved as one of the underlying mechanisms through which energy restric-
tion and physical activity could affect cancer risk.9 Human intervention studies showed 
that a short bout of exercise increases IGF-1 levels, whereas regular exercise (“train-
ing”), leading to a negative energy balance, lowers IGF-1 levels.9 A few nested case-
control studies have investigated whether IGF-1 and IGFBP-3 levels were associated 
with pancreatic cancer risk in humans. These studies showed inconsistent results, ob-
serving no51,52 and positive53 associations with pancreatic cancer risk. Moreover, two of 
these studies were rather small, with case numbers <150.51,53 Further studies are 
needed to elucidate the role of the IGF axis on pancreatic carcinogenesis. 
 The possibility to further restrict the analyses to microscopically verified cases 
only, where misclassification by disease status would be less likely than among NMCPC 
cases,42 is one of the strengths of this study. Other strengths include the large sample 
size, and detailed information on potential risk factors of pancreatic cancer. Differen-
tial follow-up is unlikely to have made a material contribution to our findings, as com-
pleteness of follow-up was high.29 The prospective design avoided recall bias and the 
need to use next-of-kin respondents. 
 Overall, our results suggest a modestly decreased pancreatic cancer risk for sports 
activity in the past. Occupational physical activity and non-occupational physical activi-
ty at baseline were not associated with pancreatic cancer risk. The findings with re-
spect to proxies for energy restriction did not support our hypothesis. For exposure to 
energy restriction during the Hunger winter, an increased pancreatic cancer risk was 
observed for individuals living in western rural area, whereas living in a western city 
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was not associated. For exposure to energy restriction during the war years, a modest-
ly decreased pancreatic cancer risk was observed. 
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ABSTRACT 
 
To examine prospectively the relation between alcohol consumption and pancreatic 
cancer risk, the authors analyzed data from the Netherlands Cohort Study. Participants 
were 120,852 persons who completed a baseline questionnaire in 1986. After 13.3 
years of follow-up, 350 cases of pancreatic cancer (67% microscopically confirmed) 
were available for analysis. Compared with abstention, the highest category of alcohol 
consumption (≥30 g/day of ethanol) was positively associated with pancreatic cancer 
risk (for all cases: rate ratio = 1.57, 95% confidence interval: 1.03-2.39, p for trend = 
0.12; for microscopically confirmed cases: rate ratio = 1.54, 95% confidence interval: 
0.94-2.54, p for trend = 0.22). In a subgroup of stable alcohol users (no change during 
the 5 years before baseline), a similarly increased risk of pancreatic cancer was found. 
This increased risk was limited to the first 7 years of follow-up. No associations were 
observed between consumption of specific alcoholic beverages and risk of pancreatic 
cancer. The associations were not modified by folate intake or smoking. Overall, these 
findings suggest an increased pancreatic cancer risk for persons with a high ethanol 
intake (≥30 g/day). However, this increased risk was observed only during the first 7 
years of follow-up. 
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INTRODUCTION 
 
Pancreatic cancer is among the most fatal cancers worldwide, with a 5-year survival 
rate of 6% or less.1,2 Since there is no effective way to screen for this malignancy, pre-
vention could have a major impact on pancreatic cancer mortality. So far, cigarette 
smoking, diabetes mellitus, and body fatness have been identified as risk factors.3-5  
 There is evidence that chronic alcohol consumption may alter pancreatic func-
tion,6 which may predispose people to pancreatic cancer. Several mechanisms have 
been suggested. First, heavy alcohol consumption is a known risk factor for chronic 
pancreatitis,3,7 which has been linked to pancreatic cancer.8,9 In addition, evidence 
suggests that the metabolites generated during metabolism of alcohol (e.g., acetalde-
hyde) may be carcinogenic.3,10,11 Furthermore, the effects of alcohol may be mediated 
through the generation of free-radical oxygen species which can lead to DNA dam-
age.11  
 Eight cohort studies have found no association between alcohol consumption and 
pancreatic cancer risk.12-18 Seven cohort studies have found an increased risk,19-25 but 
results were statistically significant in only 2.22,25 Inconsistent findings have also been 
obtained in the numerous case-control studies that have been conducted.3 Recently, 
the second World Cancer Research Fund/American Institute for Cancer Research ex-
pert report concluded that low-to-moderate levels of alcohol consumption were un-
likely to have an effect on pancreatic cancer risk, but the possibility could not be ex-
cluded that heavy drinking might have an effect.3 
 Our aim in this study was to investigate the association between alcohol con-
sumption and the risk of pancreatic cancer in a large prospective cohort study in the 
Netherlands. Furthermore, we investigated whether the association between pancrea-
tic cancer risk and alcohol consumption was modified by smoking status or folate in-
take. 
 
 
MATERIALS AND METHODS 
 
Study population and cancer follow-up 
The design of the Netherlands Cohort Study has been reported in detail elsewhere.26 
Briefly, the study was begun in September 1986 and included initially 58,279 men and 
62,573 women aged 55-69 years from 204 Dutch municipalities with computerized 
population registries. A self-administered questionnaire on potential risk factors for 
cancer was completed at baseline. For increased efficiency in the processing of the 
questionnaire (which was very detailed and of which only the first page could be opti-
cally scanned) and follow-up, the case-cohort approach was used.27 Case subjects were 
derived from the entire cohort, whereas person-years at risk were estimated from a 
random sample of 5,000 subjects. This subcohort was chosen immediately after base-
line and was followed up for vital status information. The entire cohort is being moni-
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tored for cancer occurrence through annual record linkage with the Netherlands Can-
cer Registry and the Netherlands Pathology Registry.28 For the current analyses, follow-
up was restricted to the period from baseline to December 1999, a total of 13.3 years. 
Only two subcohort members were lost to follow-up, and completeness of follow-up 
was estimated to be greater than 96%.29 
 For cases and subcohort members, all persons with prevalent cancer (other than 
non-melanoma skin cancer) at baseline were excluded (n = 226). Of the 447 incident 
cases of pancreatic cancer, persons with endocrine subtypes (Islet-cell carcinoma; n = 
1) were excluded. Additionally, subjects with incomplete or inconsistent dietary data 
(336 subcohort members, 38 cases) and subjects with incomplete alcohol data (130 
subcohort members, 13 cases) were excluded from analyses. Details are given else-
where.30 Alcohol data were considered incomplete when all questions on the con-
sumption frequency of alcoholic beverages were left blank and two questions on alco-
hol consumption pattern did not indicate that the subject was an abstainer. These two 
questions concerned alcohol intake during the past week and 5 years previously. 
 The Netherlands Cohort Study protocol has been approved by the institutional 
review boards of the TNO Nutrition and Food Research Institute (Zeist, the Nether-
lands) and Maastricht University (Maastricht, the Netherlands). 
 
Questionnaire 
The dietary section of the baseline questionnaire was a 150-item semiquantitative 
food frequency questionnaire, which concentrated on habitual consumption during 
the year preceding the start of the study. Alcohol consumption was measured by   
assessing six items: beer; red wine; white wine; sherry and other fortified wines;    
liqueurs containing, on average, 16% ethanol; and (Dutch) gin, brandy, and whiskey. 
Total mean daily ethanol intake was calculated using the Dutch food composition  
table.31 Data on the folate content of foods were derived from a validated liquid chro-
matography trienzyme method32 used to analyze the 125 most important Dutch foods 
contributing to folate intake.33 
 We defined low alcohol consumption as drinking >0-≤10 g/day of ethanol; mod-
erate consumption as drinking >10-<30 g/day; and high consumption as drinking ≥30 
g/day. The definition of a standard glass of an alcoholic beverage used in the Nether-
lands is a beverage that contains approximately 10 g of ethanol.34 
 One question on the questionnaire requested information on the subject’s drink-
ing habits 5 years before baseline. For beer and for “other alcoholic beverages”, the 
subject could indicate whether, 5 years before baseline, he or she had consumed (a) 
more than at baseline, (b) equal amounts as at baseline, or (c) less than at baseline, or 
(d) never used those beverages. 
 The food frequency questionnaire had been validated and tested for reproducibil-
ity.30,35 For mean daily alcoholic beverage intake, the Spearman correlation coefficients 
for correlations between the 9-day diet record and the questionnaire were 0.89 for all 
subjects and 0.85 for users of alcoholic beverages.30 The absolute amount of ethanol 
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reported in the questionnaire by users of alcoholic beverages was, on average, 86% of 
that reported in the 9-day diet record.30 
 
Statistical analysis  
Age-adjusted and multivariable-adjusted incidence rate ratios and corresponding 95% 
confidence intervals were estimated using Cox proportional hazards models. The total 
person-years at risk estimated from the subcohort were used in the analyses.36 We 
estimated standard errors using the robust Huber-White sandwich estimator to     
account for the additional variance introduced by sampling from the cohort.37 We 
tested the proportional hazards assumption using the scaled Schoenfeld residuals.38 In 
case the proportional hazards assumption was violated with respect to alcohol con-
sumption, we performed a test for interaction between alcohol consumption and time, 
and we stratified the follow-up period into two periods (<7 years and ≥7 years, accord-
ing to the midpoint) to investigate further how risk estimates changed during follow-
up. Analyses were conducted for both sexes combined and separately for men and 
women. 
 Rate ratios were estimated for categories of ethanol intake, with the abstainers 
regarded as the reference group. Respondents who consumed alcohol beverages less 
than once per month were considered abstainers. In addition to considering the total 
amount of ethanol intake, we examined three types of alcoholic beverages – beer, 
wine (red wine, white wine, sherry, and other fortified wines), and liquor (liqueurs, gin, 
brandy, and whiskey) – relative to non-drinkers of beer, wine, and liquor, respectively. 
Total ethanol intake was divided into five categories: abstention (0 g/day) and con-
sumption of 0.1-<5, 5-<15, 15-<30, and ≥30 g/day. For beer, wine, and liquor, categ o-
ries included nonuser and 0.1-<1, 1-<5, and ≥5 glasses/week. Rate ratios were also 
estimated for continuous exposures, which we report in representative serving sizes; 
that is, for total ethanol intake, an increment of 10 g/day was used, and for the specific 
alcoholic beverages, an increment of 1 glass/day was used. On the basis of pilot study 
data, standard glass sizes were defined as 200 ml for beer, 105 ml for wine, and 45 ml 
for liquor, corresponding to 8 g, 10 g, and 13 g of ethanol, respectively.39 
 Besides age and sex, we included smoking in the multivariable-adjusted model, 
since this is a strong risk factor for pancreatic cancer.8 Other variables examined as 
potential confounders included body mass index (weight [kg]/height [m]2), energy 
intake, intakes of vegetables and fruit, level of education, non-occupational moderate 
physical activity, multivitamin use, family history of pancreatic cancer, history of di-
abetes mellitus, hypertension, cholecystectomy, gallstones, and gastric ulcer. These 
confounding variables were added to the multivariable-adjusted model if they (a) were 
associated with the disease and with ethanol intake and (b) changed the risk estimate 
by at least 10%. This resulted in a multivariable-adjusted model that included age at 
baseline (years), sex, cigarette smoking (smoking status [current smoking: yes/no]; 
number of cigarettes smoked per day by current and ex-smokers; number of years of 
smoking for current and ex-smokers), body mass index, total energy intake (kcal/day), 
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and vegetable and fruit intakes (g/day). We additionally adjusted analyses for beer, 
wine, and liquor for total ethanol intake (g/day) to evaluate the effect of each beve-
rage on pancreatic cancer risk independently of the beverage’s alcohol content. 
 To permit comparison, we restricted age-adjusted analyses to subjects included in 
multivariable-adjusted analyses, which left 3,980 subcohort members (1,954 men and 
2,026 women) and 350 exocrine pancreatic cancer cases (185 men and 165 women) 
for analyses. Sixty-seven percent of these pancreatic cancer cases were microscopically 
confirmed pancreatic cancer (MCPC; n = 234), whereas confirmation was lacking for 
33% (n = 116). Diagnosis of the latter group was made by the treating clinician and was 
based on clinical symptoms, physical examination, and imaging results, and data were 
abstracted and recorded by a trained tumor registrar.40 
 For each analysis, we evaluated trends with the Wald test by assigning partici-
pants the median value for each level of the categorical exposure variable among the 
subcohort members, and this variable was entered as a continuous term in the Cox 
regression model. To evaluate whether the association between alcohol consumption 
and pancreatic cancer risk was linear, we examined nonparametric regression curves 
using restricted cubic splines, using different numbers and positions of knots.41,42 Test-
ing the need for nonlinear terms in the models was done using the Wald χ2 statistic. In 
the present study, the overall analyses were conducted on all pancreatic cancer cases. 
We restricted additional analyses to MCPC cases in order to create a group with a 
higher degree of diagnostic certainty of pancreatic cancer, which was shown to be 
important in a previous study.43 
 Since early symptoms of disease may cause subjects to stop drinking alcohol or to 
continue their drinking at a lower level, baseline measurement of alcohol intake alone 
will categorize these drinkers as abstainers or low-level drinkers. This will result in 
underestimated disease risk. In additional analyses, we evaluated the relation between 
alcohol consumption and pancreatic cancer risk by restricting the analyses to alcohol 
drinkers who reported having consumed the same amount of alcohol 5 years before 
baseline as they did at baseline, using as a reference category the abstainers at base-
line who reported having also abstained from alcohol use 5 years before baseline. 
Hereafter, we refer to this subgroup as stable alcohol users. In addition, we restricted 
the analyses to alcohol drinkers who reported having consumed more alcohol or less 
alcohol 5 years before baseline as compared with baseline, using the same reference 
category as for the analysis in stable alcohol users. Heavy consumers of alcohol may 
have a reduced folate status, making the pancreas susceptible to carcinogenesis.3,6 In 
addition, it has been suggested that alcohol and tobacco enhance each other’s       
effects.44 Therefore, interactions between ethanol intake and cigarette smoking (never 
smoking, ex-smoking, current smoking) were investigated, as well as interactions   
between alcohol consumption and dietary folate intake (low and high intakes based on 
sex-specific median folate intake [212 μg/day for men and 187 μg/day for women]). 
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All analyses were performed using the STATA statistical software package.45 All p val-
ues were based on 2-sided tests and were considered statistically significant if they 
were less than 0.05. 
 
 
RESULTS 
 
At baseline, 79% of the pancreatic cancer cases consumed alcohol. As Table 3.1 shows, 
most baseline characteristics did not differ noticeably between pancreatic cancer cases 
and subcohort members, but there were more diabetics and smokers among pancrea-
tic cancer cases than among subcohort members. Table 3.2 shows the percentages of 
abstainers and heavy alcohol users (≥30 g/day of ethanol) according to drinking habits, 
which did not differ noticeably between pancreatic cancer cases and subcohort mem-
bers. 
 In a comparison of the highest category of ethanol intake (≥30 g/day) with ab-
stention, the age-adjusted rate ratio for pancreatic cancer was 1.83 (95% confidence 
interval [CI]: 1.24-2.71; Table 3.3). The p value from the trend test was significant (p 
for trend = 0.01), but there was no clear dose-response relation. When we repeated 
the analyses with adjustment for confounding variables, the risk estimate was atte-
nuated but still significant (rate ratio [RR] = 1.57, 95% CI: 1.03-2.39), again with no 
clear dose-response relation (p for trend = 0.12). When we restricted the analyses to 
MCPC cases, the point estimate remained similar but became non-significant (Table 
3.3). No significantly increased risk of pancreatic cancer was found per 10 g/day incre-
ment of ethanol intake in the continuous analyses. After stratification by sex (data not 
shown), we observed a significantly increased risk for men (heavy alcohol consumers 
versus abstainers: RR = 1.82, 95% CI: 1.03-3.23), but for women no association was 
observed (heavy alcohol consumers versus abstainers: RR = 1.07, 95% CI: 0.45-2.53). 
However, among women there were very few cases in the heavy alcohol consumption 
group (n = 7). 
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TABLE 3.1 Baseline characteristics of pancreatic cancer cases and subcohort* members; Netherlands Cohort Study on diet 
and cancer, 1986-1999 
Characteristic  
All pancreatic 
cancer cases 
(n = 350) 
 Microscopically 
verified pancreatic 
cancer cases 
(n = 234) 
  
 
Subcohort 
(n = 3,980) 
 Mean (SD) %  Mean (SD) %  Mean (SD) % 
Male sex  52.9   55.1   49.1 
Age, years  62.1 (4.1)   61.4 (4.0)   61.3 (4.2)  
Alcohol consumption         
 Abstainers  20.9   20.5   23.8 
 Ethanol, g/day 12.6 (15.6)   12.4 (15.5)   10.3 (14.4)  
 Beer, glasses/week 2.0 (5.9)   1.9 (5.7)   1.6 (5.0)  
 Wine, glasses/week 3.1 (5.8)   3.1 (5.7)   2.6 (5.1)  
 Liquor, glasses/week 3.0 (5.6)   3.0 (5.6)   2.5 (5.2)  
 Stable drinkers†  59.4   60.3   63.3 
Daily dietary intake         
 Energy, kcal 1946 (487)   1972 (486)   1926 (515)  
 Total fat‡, g 83.9 (16.2)   84.7 (15.9)   83.8 (15.9)  
 Total carbohydrates‡, g 201.4 (40.2)   202.7 (38.9)   201.9 (40.4)  
 Vegetables, g 203.6 (89.8)   206.5 (91.8)   194.6 (82.6)  
 Fruit, g 171.3 (117.4)   164.4 (107.1)   177.1 (119.8)  
Other characteristics         
 Current smoker  34.9   35.5   27.3 
 Years of smoking§ 33.5 (12.3)   33.3 (12.7)   31.6 (12.2)  
 Body mass index║ 25.4 (3.3)   25.8 (3.2)   25.0 (3.1)  
 Non-occupational physical activity, min/day         
 <30 
30-60 
61-90 
>90 
 19.1 
32.9 
24.6 
23.4 
  20.5 
31.2 
22.7 
25.6 
  20.3 
31.1 
21.4 
27.2 
 History of diabetes mellitus  7.1   6.8   3.4 
 Level of education         
 Primary school or lower vocational school  49.6   51.1   49.8 
 Intermediate vocational school or high school  36.1   35.6   35.8 
 Higher vocational school or college  14.3   13.3   14.4 
Abbreviation: SD, standard deviation. 
*A random sample of 5,000 subjects from the cohort chosen immediately after baseline and followed up for vital status 
information for estimation of the person-years in the entire cohort. †Stable drinkers were defined as subjects who re-
ported consuming equal total amounts of alcohol 5 years before baseline and at baseline. ‡Energy-adjusted intake. 
§Number of years of smoking among ever smokers. ║Weight (kg)/height (m)2. 
 
 In order to investigate whether participants changed their drinking patterns be-
cause of preclinical manifestations of disease, we performed some additional analyses. 
Among stable alcohol users, we found a significantly increased risk among high alcohol 
consumers compared with abstainers in the total pancreatic cancer group (Table 3.3). 
Among stable alcohol users in the MCPC group, the increased risk estimate was higher 
but of only borderline significance (RR = 1.92, 95% CI: 0.99-3.73), possibly because of 
small numbers of cases. When we restricted the analyses to subjects who reported 
having consumed more alcohol 5 years before baseline than at baseline (data not 
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shown), we found a similar pattern, with an increased pancreatic cancer risk only in 
the highest category of ethanol intake (RR = 2.36, 95% CI: 1.11-5.03). This risk estimate 
was attenuated (RR = 1.90) and became non-significant when we restricted the analys-
es to MCPC cases. For subjects who reported having consumed less alcohol 5 years 
before baseline than at baseline, no association was found (data not shown). 
 
TABLE 3.2 Alcohol drinking habits (%) of pancreatic cancer cases and subcohort* members; Netherlands Cohort 
Study on diet and cancer, 1986-1999 
 Drinking more alcohol 
5 years before 
baseline than at 
baseline 
Drinking equal amounts 
of alcohol 5 years 
before baseline and 
at baseline 
Drinking less alcohol 
5 years before 
baseline than at 
baseline 
 
Missing or 
inconsistent 
data 
All pancreatic cancer cases    
 Total population (n = 350) 14.9 59.4 11.7 14.0 
 Abstainers (n = 73) 4.1 79.5 0 16.4 
 Heavy users† (n = 52) 25.0 51.9 19.2 3.9 
Microscopically verified pancreatic cancer cases   
 Total population (n = 234) 15.4 60.2 10.7 13.7 
 Abstainers (n = 48) 4.2 79.2 0 16.6 
 Heavy users† (n = 36) 22.2 52.8 19.4 5.6 
Subcohort     
 Total population (n = 3980)  12.9 63.3 9.1 14.7 
 Abstainers (n = 947) 7.4 80.0 0 12.6 
 Heavy users† (n = 358) 16.5 54.8 19.8 8.9 
*A random sample of 5,000 subjects from the cohort chosen immediately after baseline and followed up for vital 
status information for estimation of the person-years in the entire cohort. †Heavy users were defined as subjects 
who consumed ≥30 g of ethanol per day. 
 
 In addition, since the proportional hazards assumption was violated for ethanol 
intake, we calculated the interaction between ethanol intake and time and stratified 
the follow-up period into two periods. In the first part of the follow-up period, cases 
who consumed ≥30 g/ day of ethanol had an approximately 2-fold increased cancer 
risk, both in the total case group and in the MCPC cases. This association was not ob-
served during the second part of follow-up (Table 3.4), although interaction with time 
was of borderline significance for MCPC cases (p for interaction = 0.05) and non-
significant for all pancreatic cancer cases (p for interaction = 0.07). For stable drinkers, 
the difference between early and later follow-up was more pronounced (the interac-
tion with time was statistically significant [p for interaction = 0.01]; Table 3.4). When 
we stratified the follow-up period into three time periods to investigate this further, 
we found a significantly increased risk for cases who consumed ≥30 g of ethanol daily 
during the first 5 years of follow-up; this risk gradually disappeared during the second 
and third parts of the follow-up period (data not shown), although the case numbers 
were quite small in different strata, especially in the third part of follow-up. 
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In addition to these analyses of total ethanol intake, we examined the intake of specific 
types of beverage, with total ethanol included in the multivariable-adjusted model. No 
clear associations were found between these beverages and pancreatic cancer risk 
(Table 3.5), indicating no specific effect of any particular beverage type on top of the 
general effect of ethanol. 
 No evidence for a nonlinear association was found for any of the exposure va-
riables in the analyses carried out using restricted cubic splines (no significant devia-
tion from linearity using the Wald test [p >0.05]; data not shown). Furthermore, no 
evidence for interaction of alcohol consumption with smoking or folate was found 
(Table 3.6). 
 
 
DISCUSSION 
 
We found no association between low-to-moderate alcohol intake and risk of pancrea-
tic cancer. We did, however, find a significantly increased risk for consumers of a high 
level of ethanol (≥30 g/day). 
 So far, most cohort and case-control studies have provided little or no support for 
a causal relation between low-to-moderate alcohol use and pancreatic cancer 
risk.3,12,13,15-18,20,23,24 If alcohol plays any role in the etiology of pancreatic cancer, it is 
likely to be among heavy drinkers,8 which is in agreement with our findings. Two co-
hort studies suggested an increased risk with higher alcohol intake,19,21 and two other 
prospective studies found significantly increased risks.22,25 A cohort study carried out in 
Japan found a significantly increased risk among former drinkers, while a significant 
inverse association was found among current drinkers as compared with never drink-
ers.46 Results of case-control studies have also been inconsistent,3 with most studies 
finding no association, while two studies found an increased risk of pancreatic cancer 
among heavy alcohol drinkers.47,48 Bagnardi et al.44 conducted a meta-analysis of epi-
demiologic data and found no association between ethanol intake and pancreatic 
cancer (for intake of 100 g/day versus abstention: RR = 1.18, 95% CI: 0.94-1.49). How-
ever, this meta-analysis was based on 13 case-control studies and only four cohort 
studies. 
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In our main analyses, the increased risk we found for high alcohol consumption was 
only present during the first part of follow-up; it was not observed during the second 
part. When we excluded from the analyses subjects who had changed their drinking 
habits before baseline, possibly because of preclinical manifestations of disease, the 
difference in effect estimates for early and later follow-up was more pronounced, 
showing a statistically significant interaction with time. This finding should be inter-
preted with some caution, since these analyses are based on low case numbers, espe-
cially in the highest category of ethanol intake during late follow-up among stable 
alcohol users in the MCPC group (n = 8). In addition, it could be that recent alcohol 
intake is of greatest etiologic importance. Moreover, people decrease their alcohol 
intake or even stop drinking when they become older.49 This could, in part, explain our 
findings. The food frequency questionnaire was tested for reproducibility by Goldbohm 
et al.35 with repeated measurements at 5 annual intervals in independent samples of 
the cohort. For alcohol, the estimated decrease of the correlation coefficient between 
baseline and repeated measurement amounted to 0.02 per year, indicating a rather 
stable measurement during the first 5 years of follow-up. Nevertheless, it is possible 
that our food frequency questionnaire may not have been representative of the drink-
ing habits of the participants during later follow-up. As far as we know, Michaud et 
al.23 were the first to prospectively investigate an early or late effect of alcohol intake 
on pancreatic cancer risk. They performed analyses in two US populations, comparing 
past heavy users of alcohol with never users and then adding an 8-year lag period 
between measurement of diet and the follow-up period; in neither of these analyses 
did they find an increased risk of pancreatic cancer.23 This should also be investigated 
in other observational studies with longer durations of follow-up. However, so far, 
studies that have observed an association between alcohol intake and pancreatic can-
cer risk and studies that have not observed an association have had similar follow-up 
times, ranging from 5 years to 20 years. 
 We did not observe any relation between intake of specific alcoholic beverages 
and pancreatic cancer risk. This is in agreement with most epidemiologic data, which 
suggest that it is ethanol itself and not the type of alcoholic beverage which plays a 
role in carcinogenesis.11 
 Many factors may contribute to the inconsistent results observed in the literature. 
Pancreatic cancer is particularly difficult to study in case-control studies, because poor 
survival leads to fewer direct interviews with cases, which could mean that investiga-
tors may have to rely on interviews with proxy respondents. In addition, half of the 
observational studies investigating the role of alcohol in the etiology of pancreatic 
cancer had low case numbers. Moreover, heavy alcohol drinkers may have lower par-
ticipation rates than non-drinkers in both population-based case-control studies and 
cohort studies.44 
 In some animal studies, ethanol consumption slightly enhanced pancreatic carci-
nogenesis, but in other studies it did not demonstrate any effect on pancreatic carci-
nogenicity.8,50-52 It is still not clear, though, whether ethanol plays a role at initiation or 
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at the promotion stage, since this has received limited attention among researchers in 
the field.10 
 The strengths of our study included the possibility of further restricting the ana-
lyses to MCPC cases and to stable alcohol drinkers. Selection bias due to differential 
follow-up is unlikely to have made a substantial contribution to our findings, since 
there was very little loss to follow-up.29 The prospective design helped us avoid the 
need to use next-of-kin respondents. 
 A potential limitation is that abstainers and ex-drinkers were not separated in our 
study but were included in our reference category of abstainers. Since ex-drinkers may 
differ from abstainers in terms of pancreatic cancer risk, our estimated risks might 
have been biased in either direction. The proportion of ex-drinkers was probably small, 
since only 7.2% of the cohort members and 4.6% of the cases who consumed less than 
one alcoholic drink per month reported having consumed alcohol 5 years before base-
line. Another limitation is that in some sensitivity analyses, the number of cases was 
too low to investigate relations in more depth – although, in comparison with other 
epidemiologic studies, our number of cases was substantial. 
 In conclusion, our findings suggest an increased risk of pancreatic cancer for per-
sons with a high ethanol intake (≥30 g/day). However, this increased pancreatic cancer 
risk was observed only during the first 7 years of follow-up. 
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ABSTRACT 
 
Background 
Recent studies of pancreatic cancer suggest a role for hyperinsulinemia in carcinoge-
nesis. Because insulin is secreted in response to elevated blood glucose concentra-
tions, dietary factors that increase these concentrations may be important in pancrea-
tic carcinogenesis.  
 
Objective 
The objective was to examine prospectively the relation between pancreatic cancer 
risk and dietary glycemic load (GL), overall glycemic index (GI), and intake of total car-
bohydrates and mono- and disaccharides. 
 
Design 
The Netherlands Cohort Study consisted of 120,852 men and women who completed a 
baseline questionnaire in 1986. After 13.3 years of follow-up, 408 pancreatic cancer 
cases were detected, 66% of which were microscopically confirmed. A validated 150-
item food frequency questionnaire, completed at baseline, was used to calculate car-
bohydrate and mono- and disaccharide intakes and the GL and GI of the diet.  
 
Results 
Dietary GL, GI, or intake of carbohydrates and mono- and disaccharides were not asso-
ciated with pancreatic cancer risk in this cohort. Also, the associations were not mod-
ified by sex. Our results did not change after the analysis was restricted to microscopi-
cally confirmed pancreatic cancer cases or after individuals who reported a history of 
diabetes at baseline were excluded from the analyses. 
 
Conclusion 
Overall, our findings do not support the hypothesis that GL, GI, or intake of carbohy-
drates and mono- and disaccharides are positively associated with pancreatic cancer 
risk. This is in agreement with previous prospective studies that investigated the rela-
tion between GL and GI and pancreatic cancer risk. 
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INTRODUCTION 
 
Pancreatic cancer is among the most rapidly fatal cancers worldwide, with a 5-year 
survival rate of ≤5%. 1,2 Few consistent risk factors for pancreatic cancer have been 
identified, with cigarette smoking and diabetes mellitus being the most consistent.3-5  
 Evidence indicates that insulin acts as a growth promoter and mitogen in the 
pancreas.6,7 Furthermore, recent observational studies of pancreatic cancer suggest 
that high insulin concentrations, glucose intolerance, and insulin resistance may play a 
role in carcinogenesis, even without a diagnosis of diabetes mellitus.8-10 Type 2       
diabetes seems to develop generally after prolonged periods of high insulin secretion 
rates, with a gradual increase in insulin resistance of the liver and peripheral tissues.10 
Because insulin is secreted into the blood in response to elevated blood glucose con-
centrations, dietary factors increasing these concentrations may be associated with 
pancreatic cancer risk. 
 The glycemic index (GI) is a measure that can be used to quantify the postprandial 
glycemic effects (compared with the glucose response of a reference food, usually 
white bread or glucose) of individual foods items.11 Consumption of high-GI diets, i.e., 
diets in which the carbohydrates in the foods are characterized by a high GI, have been 
shown to be associated with hyperglycemia and hyperinsulinemia,11 whereas low-GI 
meals have been shown to be associated with a lower postprandial rise in glucose and 
insulin, probably because of a reduced rate of glucose absorption and, therefore, a 
reduced postprandial rise in insulin.11 Studies that have established GI values for foods 
used portions that contain a fixed amount of carbohydrate (generally 50 g) rather than 
portions that are typically consumed.12 Hence, to estimate the total glycemic effect of 
the diet, the glycemic load (GL) is calculated by using both the overall GI of a diet as 
well as the actual amount of carbohydrates consumed in the diet.13 
 Studies of the influence of dietary GI and GL on pancreatic cancer have been li-
mited. To date, the relation between GL and GI and pancreatic cancer risk has been 
examined in four prospective studies.14-17 No associations have been found between GI 
and GL and pancreatic cancer risk, although Michaud et al.15 found a significantly posi-
tive association between a high GL and pancreatic cancer incidence in women who 
were both sedentary and overweight, factors that are associated with insulin resis-
tance.10 
 We examined the association between pancreatic cancer risk and dietary GL and 
GI, and total carbohydrate and mono- and disaccharide intakes, in men and women 
within The Netherlands Cohort Study (NLCS) on diet and cancer. 
Chapter 4 
 
72 
SUBJECTS AND METHODS 
 
Study population and follow-up of cancer 
The study design of the NLCS was reported in detail elsewhere.18 Briefly, the NLCS was 
initiated in September 1986 and included 58,279 men and 62,573 women aged 55-69 
years at the beginning of the study, which originated in 204 municipalities with compu-
terized population registries. A self-administered questionnaire on dietary habits, life-
style characteristics, medical history, and other potential risk factors for cancer was 
completed at baseline. For reasons of efficiency in questionnaire processing (which 
was very detailed and included open-ended questions) and follow-up, the case-cohort 
approach was used.19 Case subjects were enumerated from the entire cohort, whereas 
the person-years at risk were estimated from a random sample of 5,000 subjects 
(2,411 men and 2,589 women). This subcohort was selected immediately after base-
line and was followed-up for vital status information. The entire cohort is being moni-
tored for cancer occurrence by annual record linkage to the Netherlands Cancer Regi-
stry and the Netherlands Pathology Registry.20 The follow-up was restricted to the 
period from baseline to December 1999, a total of 13.3 years. No subcohort members 
were lost to follow-up, and completeness of the follow-up was estimated to be >96%.21  
 For cases and subcohort members, all prevalent cancer cases at baseline other 
than non-melanoma skin cancer were excluded. Additionally, subjects with incomplete 
and inconsistent dietary data were also excluded from the analyses. These subjects 
either (i) left >60 (of 150 items) questionnaire items blank and ate <35 items at least 
once per month or (ii) left one or more item blocks (grouping of items, e.g., beverages) 
blank. Additional details are given elsewhere.22 Of the incident pancreatic cancer cas-
es, all endocrine subtypes based on histology were excluded (Islet-cell carcinomas;       
n = 1). This resulted in a final subcohort of 4,438 subjects (2,191 men and 2,247 wom-
en) and 408 exocrine pancreatic cancer cases (217 men and 191 women). Of all pan-
creatic cancer cases, 66% were microscopically confirmed pancreatic cancer (MCPC;    
n = 269), whereas 34% were non-microscopically confirmed pancreatic cancer 
(NMCPC; n = 139). The diagnosis of the latter group was made by the treating clinician 
and was based on clinical symptoms, physical examinations, and imaging results and 
abstracted and recorded by a trained tumor registrar.23 The NLCS was approved by the 
institutional review boards of the TNO Nutrition and Food Research Institute (Zeist, 
Netherlands) and Maastricht University (Maastricht, Netherlands). 
 
Questionnaire 
The dietary section of the questionnaire was a 150-item semiquantitative food fre-
quency questionnaire (FFQ), which concentrated on the habitual consumption of food 
and beverages during the year preceding the start of the study. Questionnaire data 
were key-entered and processed for all incident cases in the cohort and subcohort 
members in a standardized manner blinded with respect to case and subcohort status. 
This was done to minimize observer bias in coding and interpretation of the data. Daily 
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mean nutrient intakes were calculated by summing the multiplied frequencies and 
portion sizes of all food items with their tabulated nutrient contents from the Dutch 
food composition table of 1986.24 
 GI values of foods were obtained from published estimates.13 The mean of     
reported GI values for a food was used if these reported values varied across studies.13 
Food items for which a GI had not been determined were assigned the GI of the near-
est comparable food (e.g., rusks, liquorice) or were calculated by using recipes (e.g., 
Dutch spiced cake). A GI for beer could not be found and was estimated by using the 
type of carbohydrates (65% maltose, 35% glucose). For some food items, no GI value 
could be determined because of the lack of published estimates (e.g., alcohol-free 
beer, croquettes). For >90% of the carbohydrate intake of each subject, a GI value was 
available. Lack of information about the GI of vegetables and legumes was resolved by 
calculating a mean GI for usually consumed vegetables and legumes in the NLCS. In 
case of multiple foods per FFQ item, a GI value was assigned to each composing food, 
and the GI of the item was estimated by using the weighted average of GI values based 
on carbohydrate content and prevalence of estimated population consumption of 
these foods.25 The overall dietary GI was estimated for each participant by calculating 
the weighted average GI of all food items eaten by using the carbohydrate intake from 
that item (g/day) as a weighting factor. The resulting value represents the overall qual-
ity of carbohydrate intake for each participant. In addition, the average dietary GL was 
calculated by multiplying the overall dietary GI by the total amount of carbohydrate, 
which was then divided by 100. Each unit of GL represents the equivalent of 1 g carbo-
hydrate from glucose. 
 The FFQ was validated and tested for reproducibility.22,26 Crude (and energy- and 
sex-adjusted) Pearson correlation coefficients between the 9-day diet record and the 
questionnaire for total carbohydrate and mono- and disaccharides were 0.77 (0.71) 
and 0.78 (0.79), respectively. For the most relevant food groups, Spearman correlation 
coefficients were 0.80 for bread, 0.74 for potatoes, and 0.84 for added sugar.22 
 
Statistical analysis 
Dietary GL and GI and intake of total carbohydrates, mono- and disaccharides, and 
fiber were all adjusted for energy intake by the residual method27 to enable compari-
son with previous studies.14-17 Pearson correlation coefficients (r) between energy-
adjusted GL, GI, carbohydrates, and mono- and disaccharides and food items contri-
buting most to energy-adjusted GL were calculated. 
 In the present study the overall analyses were executed on all pancreatic cancer 
cases. In additional analyses we restricted the analyses to MCPC cases to create a 
group with a higher degree of diagnostic certainty of pancreatic cancer. In a previous 
analysis of anthropometric measures and pancreatic cancer, a significant positive asso-
ciation was observed between body mass index (BMI) and pancreatic cancer risk 
among verified cases, which was obscured when NMCPC cases were included.28 
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All analyses were conducted for both sexes combined and separately for men and 
women. Age-adjusted and multivariable-adjusted incidence rate ratios, or relative risks 
(RRs), and corresponding 95% CIs were estimated by using Cox proportional hazards 
models. The total person-years at risk, estimated from the subcohort, were used in the 
analyses.29 SEs were estimated by using the robust Hubert-White sandwich estimator 
to account for additional variance introduced by sampling from the cohort. This     
method is equivalent to the variance-covariance estimator presented by Barlow et al.30 
The proportional hazards assumption was tested by using the scaled Schoenfeld resi-
duals.31 RRs for energy-adjusted dietary GL and GI and intake of energy-adjusted total 
carbohydrates and mono- and disaccharides were estimated for quintiles (with the 
lowest quintile of intake regarded as the reference group) based on the sex-specific 
distribution in the subcohort and as continuous variables. Total energy intake 
(kcal/day) was included in both the age- and multivariable-adjusted models in confor-
mity with the method described by Willett.27 The RRs for energy-adjusted total carbo-
hydrates and mono- and disaccharides can be interpreted as the effect of an increase 
in these variables relative to a decrease of an equivalent amount of energy from other 
energy-delivering nutrients (i.e., substituting these exposure nutrients for other ener-
gy-delivering nutrients). Age at baseline (years), cigarette smoking (current smoking: 
yes or no; number of cigarettes smoked per day; number of years of smoking), BMI 
(kg/m2), alcohol intake (g/day), fiber intake (energy-adjusted; g/day), history of      
diabetes mellitus (yes/no), history of hypertension (yes/no), intake of vegetables 
(g/day), and intake of fruit (g/day) were included in the confounder-adjusted models 
because they were associated with GL and affected the RR estimates. We also consi-
dered other potential confounders, including level of education, non-occupational 
moderate physical activity, multivitamin use, family history of pancreatic cancer, histo-
ry of cholecystectomy, history of gall-stones, and history of gastric ulcer, which were 
not included in the final model because these variables did not change the RR esti-
mates. To enable comparison, age-adjusted analyses were restricted to subjects in-
cluded in multivariable-adjusted analyses (e.g., with no missing values on confounders 
included in the multivariable-adjusted model). For each analysis, trends were eva-
luated with the Wald test by fitting ordinal exposure variables (quintiles of intake) as 
continuous terms. 
 As suggested by a previous study,15 we constructed combined categories of BMI 
(cutoff: 25 kg/m2) and physical activity (<30 versus ≥30 min/day) resulting in three 
subgroups: a lean and physically active group, an overweight and physically inactive 
group, and an intermediate group of either lean but physically inactive individuals or 
overweight but physically active individuals. We stratified our analyses by these com-
bined categories of BMI and physical activity and, in addition, performed a formal test 
for interaction by constructing multiplicative interaction terms for each of the expo-
sure variables and these combined categories. Although we used quintiles of the dieta-
ry intakes in our main analysis, for the stratified analyses we used tertiles to avoid 
small case numbers. In additional analyses, individuals who reported a history of   
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diabetes at baseline (n = 159) were excluded. To evaluate whether early symptoms of 
disease before diagnosis could have influenced the results, early cases (diagnosed 
within 2 years after baseline) were excluded in the additional analyses. All analyses 
were performed by using the STATA statistical software package (intercooled STATA, 
version 9; Stata Corp, College Station. TX). All p values were based on 2-sided tests and 
were considered statistically significant if <0.05. 
 
 
RESULTS 
 
Carbohydrate intake was positively correlated with GL (r = 0.96) and GI (r = 0.26). 
Mono- and disaccharide intake was positively correlated with GL (r = 0.67), but not 
with GI (r = -0.02). For the five food groups contributing most to the GL, correlation 
coefficients with GI were 0.27 for potatoes, 0.38 for added sugar, 0.31 for bread, 0.03 
for Chinese and Indonesian foods, and -0.14 for cookies, cake, and pastry. For GL, cor-
relation coefficients were 0.27 for potatoes, 0.59 for added sugar, 0.43 for bread, 0.14 
for Chinese and Indonesian foods, and 0.05 for cookies, cake, and pastry. 
 In Table 4.1, baseline characteristics (stratified by sex) are presented. A number 
of characteristics did not differ between pancreatic cancer cases and subcohort mem-
bers, including age, GL and GI of the diet, and physical activity level. However, in men, 
there were more diabetics and smokers among pancreatic cancer cases than among 
subcohort members. Within the pancreatic cancer case group, most characteristics did 
not differ between total pancreatic cancer cases and MCPC cases, although in women 
a history of hypertension was higher among total pancreatic cancer cases than among 
MCPC cases (32.1% compared with 24.8%). 
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No association was found when examining the association between GL, GI, carbohy-
drate, mono- and disaccharide intake, and the risk of pancreatic cancer in the total 
population (Table 4.2). After the NMCPC cases were excluded, these findings          
remained. When looking at men and women separately, no significant associations 
were observed for GL, GI, and carbohydrate intake (data not shown). Among men, an 
inverse association was observed for mono- and disaccharide intake, showing a statis-
tically significantly decreased risk of pancreatic cancer for the highest versus the low-
est quintile of mono- and disaccharide intake in the multivariable-adjusted analyses 
(RR = 0.56, 95% CI: 0.33-0.97, p for trend = 0.13). After the analyses were restricted to 
microscopically verified cases, this point estimate became non-significant (RR = 0.64. 
95% CI: 0.34-1.01). Among women, no association was observed for mono- and dis-
accharide intake. Our findings remained the same after individuals who reported a 
history of diabetes at baseline were excluded from the analyses (325 cases left for 
analyses; data not shown), although the significant decreased risk with increased 
mono- and disaccharide intake observed in men became non-significant (multivariable-
adjusted RR = 0.59, 95% CI: 0.34-1.02).  
 In additional analyses, we stratified by both BMI and physical activity level to test 
whether the risk estimates were more pronounced for overweight and inactive indi-
viduals. We observed no associations in the total pancreatic cancer case group (data 
not shown). When restricting the analyses to MCPC cancer cases (Table 4.3), we ob-
served no associations for GI, but observed non-significantly inverse associations for 
GL, carbohydrate, and mono- and disaccharide intake among physically inactive and 
overweight people; among physically active and lean individuals, we observed non-
significantly positive associations for these dietary measures. In addition, individuals 
who reported a history of diabetes at baseline were excluded from these analyses (218 
cases left for analyses; data not shown). We observed a statistically significant 2-fold 
increased risk of pancreatic cancer for the highest versus the lowest tertile of GL (p for 
trend = 0.03) among lean and physically active individuals. Among overweight and 
inactive individuals, we observed a statistically significant decreased pancreatic cancer 
risk for the highest versus the lowest tertile of mono- and disaccharide intake with an 
RR of 0.31 (95% CI: 0.10-0.93, p for trend = 0.03). However, the multiplicative interac-
tion terms for these stratified analyses were not statistically significant, although the 
interaction between mono- and disaccharide intake and the combined categories of 
BMI and physical activity, after exclusion of diabetics, was nearly significant (p = 0.06). 
 No associations were observed when we investigated whether an increased con-
sumption of high-GI food items, such as added sugar, soft drinks, sweet sandwich 
spreads (e.g., jam), and sweets, were associated with a higher risk of pancreatic cancer 
(data not shown). After the first 2 years of follow-up were excluded, the results were 
not substantially different (data not shown). 
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DISCUSSION 
 
Our results suggest that high GL and GI and a high intake of total carbohydrates are not 
associated with pancreatic cancer risk. These null findings are consistent with four 
prospective studies14-17 and with five32-36 of seven32-38 previous case-control studies 
that examined GL or GI and/or carbohydrate intake in relation to pancreatic cancer 
risk. As regards mono- and disaccharide intake, we found inverse associations for pan-
creatic cancer risk in men, although these became less pronounced when the analyses 
were restricted to MCPC cases only. 
 The 1980s dietary recommendations for diabetics no longer included low simple 
sugar intake,39,40 but probably not all diabetics and their practitioners were aware of 
these new guidelines at the time of our dietary data collection.40 Therefore, we      
excluded diabetics from our analyses. The observed inverse associations between 
increased mono- and disaccharide intake and pancreatic cancer risk in men became 
less pronounced, whereas all other findings remained the same. Eight studies have 
examined the intakes of simple (monosaccharide and disaccharide) sugars,34,41,42   
refined sugars,35 or sucrose.14-16,32,42 Of these studies, just a few found an increased risk 
of pancreatic cancer.35,41 
 We also examined whether the association between high GL, GI, and carbohy-
drate and mono- and disaccharide intake and the risk of pancreatic cancer is more 
pronounced for subjects who are overweight as well as inactive; we found no signifi-
cant association between GI and carbohydrate intake and pancreatic cancer risk. When 
the analyses were restricted to MCPC cases without diabetes, we observed a statisti-
cally significant decreased pancreatic cancer risk for mono- and disaccharide intake 
among overweight and inactive individuals. Only one previous study observed a non-
significant inverse association between increased mono- and disaccharide intake and 
pancreatic cancer risk among male smokers,42 whereas two other studies34,41 did not 
observe such an association. This finding was unexpected and needs to be confirmed, 
preferably by other cohort studies. Michaud et al.15 reported a significantly positive 
association between pancreatic cancer risk and GL among obese and sedentary wom-
en. We were unable to reproduce this result and even found the opposite when the 
analyses were restricted to MCPC cases without diabetes. We observed a statistically 
significant increased risk of pancreatic cancer among lean and physically active individ-
uals but no association among overweight and inactive individuals. This might have 
been due to a lack of power because of the small number of cases in the overweight 
and inactive group. This result should be interpreted with caution because this finding 
might have been due to chance because of the multiple comparisons that were made 
in the present study.  
 We observed no associations between increased intake of some high-GI foods 
(e.g., added sugar, soft drinks, sweet sandwich spreads, and sweets) and pancreatic 
cancer risk. Very few studies have examined these relations, and they reported no 
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associations for jam and marmalade43 and sweets,43 but positive associations for soft 
drinks43,44 and added sugar.38,43 
 So far, findings from prospective studies investigating the relation between GL 
and GI and several chronic conditions, such as type 2 diabetes, coronary heart disease, 
and breast and colorectal cancer, have been inconsistent, showing positive45-49 or   
no50-53 associations. Another study executed in this cohort, which examined the rela-
tion between GI and GL and colorectal cancer risk, did not find an association.54 
 Considerable evidence from in vitro, animal, and human observational studies 
supports a role for insulin in pancreatic cancer etiology; therefore, the investigation of 
dietary factors that influence plasma insulin concentrations seems rational. The major 
rationale for using GI values is based on the assumption that postprandial blood glu-
cose responses and insulin responses are highly correlated, but some studies have 
shown an inconsistency in glucose and insulin responses.12,55 Also, whereas GI values 
are determined on single food items, people eat meals or snacks consisting not only of 
carbohydrates, but also of other macronutrients. Protein stimulates insulin release, 
despite an unchanged or even lower blood glucose concentration, compared with 
carbohydrates alone.12 Dietary fat inhibits gastric emptying, which in turn slows down 
the absorption of carbohydrates,12 which also gives rise to a lower postprandial blood 
glucose response. In addition, the amount of rapidly available glucose and resistant 
starch, the degree of osmolality, the viscosity of the gut’s contents, are other impor-
tant factors influencing the degree of postprandial insulin secretion.12 
 The possibility to further restrict the analyses to microscopically verified cases 
only, where misclassification by disease status would be less likely than among NMCPC 
cases,56 was one of the strengths of this study.28 Other strengths included the large 
sample size and detailed information on potential risk factors for pancreatic cancer. 
Differential follow-up is unlikely to have made a material contribution to our findings, 
because the completeness of follow-up was high.21 The prospective design avoided 
recall bias and the need to use next-of-kin respondents, but non-differential misclassi-
fication of GL values could not be ruled out. However, because some main dietary 
nutrients and food items contributing to GI and GL were in general moderately to high-
ly correlated with both the FFQ22 and GI and GL, the questionnaire most likely ade-
quately ranked subjects according to GL and GI values. 
 A limitation of our study was the use of a single measure of dietary intake that 
may not have been representative of the dietary habits of the study participants over 
the course of follow-up. However, the FFQ was tested for reproducibility by Goldbohm 
et al.,26 who concluded that a single measurement of dietary intake in the NLCS could 
characterize dietary habits for a period of at least 5 years. Our estimated GI values 
were lower and narrower in range and variation than values reported in other large 
cohorts,14-16,47 which may have yielded too little contrast between the highest and 
lowest quintiles to detect differences in pancreatic cancer risk. Another issue concern-
ing the GI values should be mentioned. The GI values used for this FFQ were obtained 
from the table published by Foster-Powell et al.,13 as has been used by others. Howev-
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er, this GI table contains mostly items from Australian or American foods and not from 
European foods. Recently, Henley et al.57 established GI values for a variety of foods 
available in the United Kingdom, which concluded that most GI values compared well 
with previously published values;13 however, a few values were notably different from 
those of Foster Powell et al.13 It remains to be established whether values determined 
for American and Australian food items can be applied to European foods. 
 In summary, our findings do not support the hypothesis that a high GL, overall GI, 
and carbohydrate and mono- and disaccharide intake are associated with an increased 
risk of pancreatic cancer. This finding agrees with previous prospective studies that 
investigated the relation between GL and GI and pancreatic cancer risk. 
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ABSTRACT 
 
Meat contains numerous carcinogens, such as heterocyclic amines, polycyclic aromatic 
hydrocarbons, and N-nitroso compounds, which can be derived either from natural 
food or during the process of food preparation. These carcinogens may increase pan-
creatic cancer risk. Furthermore, studies in animals showed that polyunsaturated fatty 
acids, especially linoleic acid, increase pancreatic cancer risk. We examined prospec-
tively the relation between pancreatic cancer risk and intake of fresh meat, processed 
meat, fish, eggs, total fat, and different types of fat. The Netherlands Cohort Study 
consisted of 120,852 men and women who completed a baseline questionnaire in 
1986. After 13.3 years of follow-up, 350 pancreatic cancer cases (66% microscopically 
confirmed) were available for analysis. A validated 150-item food frequency question-
naire was used to calculate intake of fresh meat, processed meat, fish, eggs, fat and 
different types of fat. No association was found when examining the association be-
tween intake of fresh meat, other types of meat, fish, eggs, dietary intake of total fat 
and different types of fat and risk of pancreatic cancer. It is important for future stu-
dies to investigate the relation between different meat-cooking methods and pancrea-
tic cancer. 
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INTRODUCTION 
 
Pancreatic cancer is among the most rapidly fatal cancers worldwide, with a 5-year 
survival rate of 6% or less.1,2 Since there is no effective way to screen for this malig-
nancy, prevention could have a major impact on pancreatic cancer mortality. So far, 
cigarette smoking, diabetes mellitus, and body fatness are identified as risk factors.3-5 
 Based on ecological studies, international variation in incidence rates of pancrea-
tic cancer suggested that per capita intakes of animal protein, fat, and eggs were posi-
tively related to this type of cancer.6,7 Since then, numerous epidemiological studies 
have investigated the relation between meat, eggs, and different types of fat and pan-
creatic cancer, including 15 prospective cohort studies3,6,8-12 and 31 case-control stu-
dies.3,6,13-19 In a recent Expert Panel Report, it was concluded that there is limited evi-
dence suggesting that red meat is a cause of pancreatic cancer in humans.3 Data on 
processed meat, chicken, fish, eggs, dietary fat, and specific fatty acids were either of 
too low quality, too inconsistent, or the number of studies too few to allow conclu-
sions to be reached. 
 Meat contains numerous carcinogens, such as heterocyclic amines (HCAs), poly-
cyclic aromatic hydrocarbons (PAHs), and N-nitroso compounds, which can be derived 
either from natural food or during the process of food preparation. These carcinogens 
may increase pancreatic cancer risk.3,20,21 Regarding dietary fat, studies in animals 
showed that diets high in fat increased the risk of pancreatic cancer compared to low-
fat diets,22 and suggested that polyunsaturated fatty acids (PUFA), especially linoleic 
acid (LA), increases pancreatic cancer risk.22,23 
 Therefore, we investigated the association between intakes of fresh meat, 
processed meat, fish, and eggs, and dietary intake of fat and specific fatty acids, and 
the risk of pancreatic cancer in a large prospective cohort study in the Netherlands. 
 
 
MATERIAL AND METHODS  
 
Study population and cancer follow-up 
The study design of the Netherlands Cohort Study (NLCS) has been reported in detail 
elsewhere.24 Briefly, the NLCS was initiated in September 1986 and includes 58,279 
men and 62,573 women aged 55-69 years at the beginning of the study, originating 
from 204 municipalities with computerized population registries. A self-administered 
questionnaire on dietary habits, lifestyle characteristics, medical history, and other 
potential risk factors for cancer was completed at baseline. For reasons of efficiency in 
questionnaire processing (which was very detailed and included open-ended ques-
tions) and follow-up, the case-cohort approach was used (weighting of study subjects 
based on Prentice’s method).25 Case subjects were derived from the entire cohort, 
whereas the person-years at risk were estimated from a random sample of 5,000 sub-
jects (2,411 men and 2,589 women). This subcohort was chosen immediately after 
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baseline and followed up for vital status information. The entire cohort is being moni-
tored for cancer occurrence by annual record linkage to the Netherlands Cancer Regi-
stry and the Netherlands Pathology Registry.26,27 The completeness of cancer follow-up 
through linkage with the Netherlands Cancer Registry was estimated to be >96%.28 The 
follow-up was restricted to the period from baseline to December 1999, a total of 13.3 
years. Only two subcohort members were lost to follow-up at the end of the follow-up 
period. 
 For cases and subcohort members, all prevalent cancer cases at baseline other 
than non-melanoma skin cancer were excluded. Additionally, subjects with incomplete 
or inconsistent dietary data were excluded from the analyses as well. These subjects 
had either (i) left >60 (of the 150 items) questionnaire items blank and ate <35 items at 
least once a month or (ii) left one or more item blocks (grouping of items, e.g., beve-
rages) blank. Additional details are given elsewhere.29 Of the incident pancreatic can-
cer cases, all endocrine subtypes based on histology were excluded (Islet-cell carcino-
mas, n = 1). This resulted in a subcohort of 4,438 subjects (including 19 pancreatic 
cancer cases) and 408 exocrine pancreatic cancer cases. The NLCS has been approved 
by the institutional review boards of the TNO Nutrition and Food Research Institute 
(Zeist, the Netherlands) and Maastricht University (Maastricht, the Netherlands). 
 
Questionnaire 
The dietary section of the questionnaire was a 150-item semiquantitative food fre-
quency questionnaire (FFQ), which concentrated on the habitual consumption of food 
and beverages during the year preceding the start of the study. Questionnaire data 
were key-entered and processed for all incident cases in the cohort and subcohort 
members in a standardized manner, blinded with respect to case/subcohort status. 
This was done to minimize observer bias in the coding and interpretation of the data. 
Daily mean nutrient intakes were calculated by summing the multiplied frequencies 
and serving sizes of all food items with their tabulated nutrient contents from the 
Dutch food composition table.30 
 Intake of specific fatty acids was based on a separate database with specific fatty 
acids derived from the TRANSFAIR study.31,32 In the database used for the NLCS, the 
concentrations of fatty acids were based on the concentrations before 1995, when 
changes in the trans content of manufactured products, such as margarines, led to a 
substantial decrease in the intake of trans unsaturated fatty acids. 
 Average daily intakes of meat, fish and eggs were calculated by multiplying the 
intake frequency of individual items by their weights, using either standard serving 
sizes or reported portion sizes, and summing over the items within these food groups. 
Fresh meat consisted of the following items: beef, pork, minced meat (including beef 
and pork), chicken (including chicken and turkey), liver, and other meat (e.g., horse-
meat, lamb). Fresh red meat consisted of the fresh meat items minus the chicken item. 
Coding of fresh meat items was based on raw weight to take into account the amount 
of fat originally present in the meat but eventually ending up into the gravy, which is 
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usually consumed as well. Processed meat was defined as meat items that had under-
gone some form of preservation (mostly treatment with nitrite salt, sometimes 
smoked or fermented). 
 The FFQ had been validated and tested for reproducibility.29,33 Crude (energy- and 
gender-adjusted between brackets) Pearson correlation coefficients (r) between the 9-
day diet record and the questionnaire were 0.74 for energy, 0.72 (0.52) for total fat, 
0.73 (0.58) for saturated fatty acids (SFA), 0.73 (0.75) for PUFA, 0.66 (0.62) for choles-
terol, and 0.61 (0.59) for protein. The Spearman correlation coefficients for fresh meat, 
processed meat, and fish were 0.46, 0.54, and 0.53, respectively.29 
 
Statistical analysis  
Exposure variables in our analyses included the intake (in g/day) of fresh meat, fresh 
red meat, beef, pork, minced meat, chicken, liver, processed meat, fish, eggs, total fat, 
vegetable fat, fat from meat, SFA, monounsaturated fatty acids (MUFA), PUFA, choles-
terol (in mg/day), trans unsaturated fatty acids, and specific fatty acids, including LA, 
linolenic acid, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Because 
red meat is the main source of iron and heme, and because serum iron levels were 
directly related to pancreatic cancer in an exploratory case-control study,34 we ex-
amined total iron and heme intake.35 Other exposure variables were protein (total, 
vegetable and animal) and nitrite. Intake of fat, specific fatty acids, and protein were 
all adjusted for energy intake by the residual method.36 
 All analyses were conducted for both sexes combined and separately for men and 
women. Age-adjusted and multivariable-adjusted incidence relative risks (RRs) and 
corresponding 95% confidence intervals (95% CIs) were estimated using Cox propor-
tional hazards models. The total person-years at risk, estimated from the subcohort, 
were used in the analyses.37 Standard errors were estimated using the robust Huber-
White sandwich estimator to account for additional variance introduced by sampling 
from the cohort.38 The proportional hazards assumption was tested using the scaled 
Schoenfeld residuals.39 In case, the proportional hazards assumption was violated with 
respect to the determinant of primary interest, the follow-up period was stratified into 
three categories (<5; 5-10; ≥10 years of follow-up) and a test for interaction between 
the determinant and time was calculated to investigate further whether the risk esti-
mates changed during follow-up. Subjects were classified into quintiles of consumption 
(with the lowest quintile of intake regarded as the reference group) based on the 
gender-specific distribution in the subcohort and as continuous variables. The latter 
were reported in representative serving sizes, e.g., one serving size was defined as: 100 
g/week for meat, 15 g/day for processed meat, 120 g/week for fish, and 50 g/week for 
eggs. For some variables, categories were used instead of quintiles. For liver intake 
categories, there were a non-user and a user group (>0 g/day). For chicken and fish, 
intake categories were a non-user and three user categories (0-13.2, 13.2-22.8, and 
≥22.8 g/day for chicken; 0-10, 10-20, and ≥20 g/day for fish). For eggs, intake catego-
ries were three user groups (≤1, 2-3, and ≥4 eggs/week). 
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Based on literature, the following variables were considered as potential confounders: 
age, gender, smoking, body mass index (BMI), alcohol intake, intake of vegetables and 
fruit, level of education, moderate non-occupational physical activity, family history of 
pancreatic cancer, history of diabetes mellitus, hypertension, gall-stones, cholecys-
tectomy, and gastric ulcer. These potential confounding variables were added to the 
multivariable-adjusted model if they (i) were associated with the disease and with total 
fresh meat and energy-adjusted fat intake and (ii) changed the risk estimate by at least 
10% (using a backwards stepwise procedure) resulting in a multivariable-adjusted 
model including age at baseline (years), gender, cigarette smoking (current smoking: 
yes/no; number of cigarettes smoked per day; number of years of smoking), BMI 
(kg/m2), alcohol intake (0, 0.1-4, 5-14, 15-29, and ≥30 g/day), history of diabetes melli-
tus (yes/no), history of hypertension (yes/no), intake of vegetables (g/day) and fruit 
(g/day). Total energy intake (kcal/day) was included in both the age- as well as in the 
multivariable-adjusted model.36 The RRs for energy-adjusted total fat and fatty acids 
can be interpreted as the effect of an increase in these variables relative to a decrease 
of an equivalent amount of energy from other energy delivering nutrients (i.e., substi-
tuting these exposure nutrients for other energy delivering nutrients). In addition, to 
assess the independent contribution of SFA, MUFA, PUFA, and each specific fatty acid, 
total fat intake was also included in the multivariable-adjusted model. 
 To enable comparison, age- and gender-adjusted analyses were restricted to sub-
jects included in multivariable-adjusted analyses (e.g., with no missing values on con-
founding variables), leaving 3,980 subcohort members (1,954 men and 2,026 women) 
and 350 exocrine pancreatic cancer cases (185 men and 165 women) for analyses. 
Sixty seven percent of all pancreatic cancer cases were microscopically confirmed pan-
creatic cancer (MCPC; n = 234), whereas 33% were non-microscopically confirmed 
pancreatic cancer (NMCPC, n = 116). 
 For each analysis, trends were evaluated with the Wald test by assigning partici-
pants the median value for each level of the categorical exposure variable among the 
subcohort members and this variable was entered as a continuous term in the Cox 
regression model. 
 In the present study the overall analyses were performed on all pancreatic cancer 
cases. Additional analyses were restricted to MCPC cases, in order to create a group 
with a higher degree of diagnostic certainty of pancreatic cancer, which was shown to 
be of importance in previous analyses.40 
 In additional analyses, individuals who reported a history of diabetes at baseline 
(n = 159) were excluded. To evaluate whether early symptoms of disease before diag-
nosis could have influenced the results, early cases (diagnosed within 2 years after 
baseline) were excluded in additional analyses. We also investigated whether or not 
individuals that reported to have consumed equal number of eggs or equal amounts of 
fresh meat and processed meat 5 years before baseline compared to baseline eating 
habits, had different risk estimates than the total population. All analyses were per-
formed using the STATA statistical software package (intercooled STATA, version 9; 
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Stata Corporation, College Station, TX). All p values were based on two-sided tests and 
considered statistically significant if <0.05. 
 
 
RESULTS 
 
In Table 5.1, baseline characteristics (stratified by gender) are presented. Most charac-
teristics did not differ between pancreatic cancer cases and subcohort members; how-
ever, there were more subjects with a family history of pancreatic cancer among cases 
than among subcohort members, especially in women. In men, there were more di-
abetics and smokers among pancreatic cancer cases than among subcohort members. 
In Table 5.2, baseline dietary intakes of the exposures of interest are presented. No 
clear differences between cases and subcohort members were observed. The mean 
age at diagnosis (± SD) and median survival time for MCPC cases was 69.5 (± 5.0) years 
and 2.9 months, respectively. For NMCPC cases, mean age at diagnosis and median 
survival time was 72.1 (± 5.5) years and 4.5 months, respectively. 
 After adjustment for age and gender, no association was found when examining 
the association between the intake of total fresh meat, beef, pork, minced meat, liver, 
chicken, processed meat, fish, and eggs and the risk of pancreatic cancer in the total 
population (Table 5.3). These findings remained after inclusion of the confounding 
variables in the multivariable model. In addition, excluding NMCPC cases did not 
change the risk estimates appreciably. For fresh red meat, an inverse association was 
observed among microscopically verified cases, showing a statistically significant   
decreased risk of pancreatic cancer for the highest versus the lowest quintile of red 
meat intake in the multivariable model (Table 5.3). Also a statistically significant    
decreased pancreatic cancer risk per increment of 100 g of red meat intake per week 
was observed. Although, it should be mentioned that for red meat the proportional 
hazards assumption was violated. When stratifying the follow-up period into three 
categories (data not shown), only after 10 years of follow-up a significant decreased 
risk was observed for the highest versus lowest tertile (multivariable RR = 0.37, 95% CI: 
0.18-0.76, p for trend = 0.01). We observed no significant interaction with time (p for 
interaction = 0.18) and no decreased risk of such magnitude was seen in the total pan-
creatic cancer case group. 
Chapter 5 
 
94 
 TA
BL
E 
5.
1 
Ba
se
lin
e 
ch
ar
ac
te
ri
st
ic
s 
(m
ea
ns
 o
f p
er
ce
nt
) o
f p
an
cr
ea
tic
 c
an
ce
r 
ca
se
s 
an
d 
su
bc
oh
or
t m
em
be
rs
 
Ch
ar
ac
te
ri
st
ic
 
M
en
 
 
W
om
en
 
To
ta
l p
an
cr
ea
ti
c 
ca
nc
er
 c
as
es
 
M
ic
ro
sc
op
ic
al
ly
 v
er
ifi
ed
 
pa
nc
re
at
ic
 c
an
ce
r 
ca
se
s 
 
Su
bc
oh
or
t 
 
To
ta
l p
an
cr
ea
ti
c 
ca
nc
er
 c
as
es
 
M
ic
ro
sc
op
ic
al
ly
 v
er
ifi
ed
 
pa
nc
re
at
ic
 c
an
ce
r 
ca
se
s 
 
Su
bc
oh
or
t 
n 
18
5 
12
9 
1,
95
4 
 
16
5 
10
5 
2,
02
6 
A
ge
, m
ea
n 
± 
SD
 (y
ea
rs
) 
62
.1
 ±
 4
.0
 
61
.7
 ±
 3
.8
 
61
.2
 ±
 4
.2
 
 
62
.1
 ±
  4
.2
 
61
.1
 ±
 4
.3
 
61
.4
 ±
 4
.3
 
Cu
rr
en
t s
m
ok
er
s 
(%
) 
42
.2
 
42
.6
 
34
.0
 
 
26
.7
 
26
.7
 
20
.8
 
Ye
ar
s 
of
 s
m
ok
in
g,
 m
ea
n 
± 
SD
 (y
ea
rs
) 
33
.0
 ±
 1
4.
7 
33
.5
 ±
 1
4.
4 
29
.0
 ±
 1
5.
8 
 
14
.4
 ±
 1
6.
9 
13
.9
 ±
 1
6.
5 
11
.4
 ±
 1
5.
8 
BM
I, 
m
ea
n 
± 
SD
 (k
g/
m
2 )
 
25
.3
 ±
 3
.0
 
25
.6
 ±
 2
.7
 
24
.9
 ±
 2
.6
 
 
25
.6
 ±
 3
.6
 
26
.1
 ±
 3
.8
 
25
.0
 ±
 3
.5
 
Ph
ys
ic
al
 a
ct
iv
ity
 (n
on
-o
cc
up
at
io
na
l; 
%
) 
 
 
 
 
 
 
 
 
<3
0 
m
in
/d
ay
 
30
-6
0 
m
in
/d
ay
  
60
-9
0 
m
in
/d
ay
 
>9
0 
m
in
/d
ay
 
14
.1
 
35
.1
 
24
.3
 
26
.5
 
16
.3
 
31
.0
 
23
.2
 
29
.5
 
17
.7
 
30
.5
 
19
.4
 
32
.4
 
 
24
.8
 
30
.3
 
24
.9
 
20
.0
 
25
.7
 
31
.4
 
21
.9
 
21
.0
 
22
.8
 
31
.8
 
23
.2
 
22
.2
 
Fa
m
ily
 h
is
to
ry
 o
f p
an
cr
ea
tic
 c
an
ce
r 
(%
) 
1.
6 
1.
6 
0.
8 
 
3.
6 
2.
9 
0.
9 
H
is
to
ry
 o
f d
ia
be
te
s 
(%
) 
9.
2 
7.
8 
3.
3 
 
4.
9 
5.
7 
3.
4 
H
is
to
ry
 o
f h
yp
er
te
ns
io
n 
(%
) 
23
.8
 
18
.6
 
24
.2
 
 
32
.1
 
24
.8
 
29
.0
 
H
is
to
ry
 o
f g
al
ls
to
ne
s 
(%
) 
3.
2 
3.
1 
5.
3 
 
18
.8
 
15
.2
 
14
.0
 
H
is
to
ry
 o
f c
ho
le
cy
st
ec
to
m
y 
(%
) 
2.
2 
2.
3 
4.
5 
 
18
.2
 
15
.2
 
13
.2
 
H
is
to
ry
 o
f g
as
tr
ic
 u
lc
er
 (%
) 
4.
3 
3.
9 
4.
5 
 
1.
8 
1.
0 
0.
9 
Le
ve
l o
f e
du
ca
tio
n 
(%
) 
 
 
 
 
 
 
 
  
Lo
w
 
M
ed
iu
m
  
H
ig
h 
43
.8
 
36
.2
 
20
.0
 
44
.2
 
38
.0
 
17
.8
 
43
.9
 
36
.3
 
19
.8
 
 
56
.1
 
36
.0
 
7.
9 
59
.6
 
32
.7
 
7.
7 
55
.4
 
35
.4
 
9.
2 
D
ai
ly
 in
ta
ke
, m
ea
n 
± 
SD
 
 
 
 
 
 
 
 
  
En
er
gy
 (k
ca
l) 
2,
15
3 
± 
45
7 
2,
19
2 
± 
44
2 
2,
17
1 
± 
51
0 
 
1,
71
3 
± 
40
9 
1,
70
1 
± 
39
4 
1,
68
9 
± 
39
5 
 
To
ta
l c
ar
bo
hy
dr
at
es
*  (
g)
 
22
3.
3 
± 
37
.3
 
22
3.
8 
± 
35
.1
 
22
6.
4 
± 
37
.4
 
 
17
6.
9 
± 
27
.0
 
17
6.
9 
± 
25
.4
 
17
8.
2 
± 
26
.7
 
 
A
lc
oh
ol
 (g
) 
17
.4
 ±
 1
7.
6 
16
.8
 ±
 1
7.
7 
14
.9
 ±
16
.9
 
 
7.
1 
± 
10
.9
 
7.
0 
± 
10
.1
 
4.
9 
± 
9.
6 
 
Ve
ge
ta
bl
es
 (g
) 
19
5.
3 
± 
94
.6
 
19
9.
2 
± 
99
.2
 
19
2.
3 
± 
83
.7
 
 
21
2.
9 
± 
83
.3
 
21
5.
6 
± 
81
.2
 
19
6.
7 
± 
81
.5
 
 
Fr
ui
t (
g)
 
14
8.
1 
± 
11
9.
5 
14
0.
6 
± 
10
6.
8 
15
6.
4 
± 
11
5.
2 
 
19
7.
2 
± 
10
9.
8 
19
3.
6 
± 
10
0.
4 
19
7.
0 
± 
12
0.
8 
N
et
he
rl
an
ds
 c
oh
or
t s
tu
dy
 o
n 
di
et
 a
nd
 c
an
ce
r,
 1
98
6-
19
99
. 
* E
ne
rg
y-
ad
ju
st
ed
 in
ta
ke
. 
Meat and fat intake and pancreatic cancer risk 
 
95 
 TA
BL
E 
5.
2 
Ba
se
lin
e 
di
et
ar
y 
in
ta
ke
 (m
ea
ns
) o
f e
xp
os
ur
es
 o
f i
nt
er
es
t o
f p
an
cr
ea
tic
 c
an
ce
r 
ca
se
s 
an
d 
su
bc
oh
or
t m
em
be
rs
 
D
ie
ta
ry
 fa
ct
or
s 
M
en
 
 
W
om
en
 
 
 
To
ta
l p
an
cr
ea
ti
c 
ca
nc
er
 c
as
es
 
M
ic
ro
sc
op
ic
al
ly
 v
er
ifi
ed
 
pa
nc
re
at
ic
 c
an
ce
r 
ca
se
s 
 
Su
bc
oh
or
t 
 
To
ta
l p
an
cr
ea
ti
c 
ca
nc
er
 c
as
es
 
M
ic
ro
sc
op
ic
al
ly
 v
er
ifi
ed
 
pa
nc
re
at
ic
 c
an
ce
r 
ca
se
s 
 
Su
bc
oh
or
t 
n 
18
5 
12
9 
1,
95
4 
 
16
5 
10
5 
2,
02
6 
D
ai
ly
 in
ta
ke
, m
ea
n 
± 
SD
 
 
 
 
 
 
 
 
 
Ty
pe
s 
of
 fr
es
h 
m
ea
t*
, p
ro
ce
ss
ed
 m
ea
t,
 fi
sh
 a
nd
 e
gg
s 
 
 
 
 
 
 
To
ta
l f
re
sh
 m
ea
t (
g)
 
10
5.
3 
± 
37
.2
 
10
3.
0 
± 
35
.0
 
10
5.
7 
± 
43
.0
 
 
94
.5
 ±
 4
3.
8 
94
.6
 ±
 4
7.
1 
93
.1
 ±
 3
9.
5 
 
Fr
es
h 
re
d 
m
ea
t (
g)
 
93
.2
 ±
 3
7.
3 
88
.8
 ±
 3
4.
3 
93
.4
 ±
 4
1.
6 
 
79
.9
 ±
 4
0.
9 
80
.6
 ±
 4
1.
7 
80
.4
 ±
 3
8.
0 
 
Be
ef
 (g
) 
27
.8
 ±
 2
2.
1 
24
.2
 ±
 1
9.
0 
24
.5
 ±
 2
3.
7 
 
25
.6
 ±
 2
4.
6 
24
.9
 ±
 2
5.
0 
24
.2
 ±
 2
1.
5 
 
Po
rk
 (g
) 
39
.7
 ±
 2
7.
0 
39
.5
 ±
 2
5.
4 
40
.7
 ±
 3
0.
1 
 
32
.5
 ±
 2
6.
1 
32
.8
 ±
 2
4.
8 
35
.3
 ±
 2
8.
2 
  
M
in
ce
d 
m
ea
t (
g)
 
19
.1
 ±
 1
6.
2 
18
.6
 ±
 1
3.
4 
20
.2
 ±
 1
8.
2 
 
16
.7
 ±
 1
6.
9 
18
.3
 ±
 1
7.
2 
16
.7
 ±
 1
5.
0 
 
Li
ve
r 
(g
) 
2.
8 
± 
6.
5 
2.
8 
± 
5.
6 
2.
3 
± 
4.
9 
 
1.
8 
± 
3.
5 
1.
7 
± 
3.
4 
1.
7 
± 
4.
2 
 
Ch
ic
ke
n 
(g
) 
13
.5
 ±
 1
6.
1 
15
.4
 ±
 1
8.
0 
13
.6
 ±
 1
4.
6 
 
15
.2
 ±
 1
5.
8 
14
.7
 ±
 1
6.
1 
13
.5
 ±
 1
5.
5 
 
O
th
er
 m
ea
t (
e.
g.
, h
or
se
m
ea
t,
 la
m
b;
 g
) 
3.
7 
± 
10
.8
 
3.
6 
± 
8.
1 
2.
7 
± 
6.
1 
 
3.
3 
± 
10
.0
 
2.
9 
± 
9.
8 
2.
4 
± 
6.
8 
  
Pr
oc
es
se
d 
m
ea
t (
g)
 
15
.8
 ±
 1
6.
0 
16
.2
 ±
 1
7.
2 
15
.9
 ±
 1
6.
8 
 
10
.5
 ±
 1
1.
6 
9.
9 
± 
10
.7
 
10
.4
 ±
 1
1.
6 
 
Fi
sh
 (g
) 
14
.9
 ±
 1
7.
8 
13
.2
 ±
 1
3.
2 
14
.1
 ±
 1
6.
6 
 
11
.2
 ±
 1
4.
9 
11
.2
 ±
 1
6.
6 
11
.7
 ±
 1
3.
9 
 
Eg
gs
 (g
) 
16
.9
 ±
 1
1.
9 
17
.1
 ±
 1
1.
4 
17
.0
 ±
 1
2.
5 
 
14
.4
 ±
 9
.6
 
14
.3
 ±
 9
.8
 
14
.8
 ±
 9
.8
 
 
To
ta
l f
at
 a
nd
 s
pe
ci
fic
 fa
tt
y 
ac
id
s†
 
 
 
 
 
 
 
 
 
To
ta
l f
at
 (g
) 
93
.1
 ±
 1
4.
1 
93
.8
 ±
 1
3.
8 
94
.0
 ±
 1
4.
1 
 
73
.5
 ±
 1
1.
4 
73
.7
 ±
 1
0.
4 
74
.0
 ±
 1
0.
3 
 
Ve
ge
ta
bl
e 
fa
t (
g)
 
10
.4
 ±
 7
.7
 
10
.4
 ±
 8
.0
 
11
.3
 ±
 9
.3
 
 
8.
9 
± 
6.
3 
9.
0 
± 
6.
6 
9.
1 
± 
7.
0 
 
M
ea
t f
at
 (g
) 
19
.9
 ±
 7
.8
 
19
.1
 ±
 7
.8
 
20
.0
 ±
 8
.4
 
 
15
.6
 ±
 7
.7
 
16
.0
 ±
 8
.0
 
15
.8
 ±
 7
.1
 
 
Sa
tu
ra
te
d 
fa
tt
y 
ac
id
s 
(g
) 
36
.0
 ±
 6
.9
 
36
.3
 ±
 6
.8
 
36
.9
 ±
 7
.6
 
 
30
.1
 ±
 6
.1
 
30
.2
 ±
 5
.8
 
29
.8
 ±
 5
.8
 
 
M
on
ou
ns
at
ur
at
ed
 fa
tt
y 
ac
id
s 
(g
) 
35
.0
 ±
 6
.8
 
35
.4
 ±
 7
.1
 
35
.5
 ±
 6
.7
 
 
27
.3
 ±
 5
.4
 
27
.6
 ±
 5
.3
 
27
.5
 ±
 5
.0
 
 
Po
ly
un
sa
tu
ra
te
d 
fa
tt
y 
ac
id
s 
(g
) 
20
.3
 ±
 8
.0
 
20
.2
 ±
 8
.0
 
19
.6
 ±
 8
.1
 
 
14
.4
 ±
 6
.4
 
14
.3
 ±
 6
.3
 
15
.0
 ±
 6
.1
 
 
Ch
ol
es
te
ro
l (
m
g)
 
27
5.
5 
± 
70
.3
 
27
5.
3 
± 
66
.6
 
27
8.
2 
± 
75
.8
 
 
23
8.
1 
± 
53
.0
 
23
8.
1 
± 
55
.9
 
23
6.
7 
± 
60
.9
 
 
tr
an
s 
U
ns
at
ur
at
ed
 fa
tt
y 
ac
id
s 
(g
) 
3.
3 
± 
1.
3 
3.
4 
± 
1.
4 
3.
3 
± 
1.
4 
 
2.
6 
± 
1.
3 
2.
6 
± 
1.
2 
2.
5 
± 
0.
9 
 
Li
no
le
ic
 a
ci
d 
(g
) 
18
.9
 ±
 8
.2
 
18
.7
 ±
 8
.3
 
18
.2
 ±
 8
.1
 
 
13
.1
 ±
 6
.5
 
13
.1
 ±
 6
.4
 
13
.7
 ±
 6
.1
 
 
Li
no
le
ni
c 
ac
id
 (g
) 
1.
4 
± 
0.
6 
1.
5 
± 
0.
7 
1.
4 
± 
0.
6 
 
1.
0 
± 
0.
5 
1.
0 
± 
0.
4 
1.
1 
± 
0.
5 
 
Ei
co
sa
pe
nt
ae
no
ic
 a
ci
d 
 (g
) 
0.
05
 ±
 0
.0
6 
0.
04
 ±
 0
.0
4 
0.
04
 ±
 0
.0
6 
 
0.
03
 ±
 0
.0
4 
0.
03
 ±
 0
.0
5 
0.
03
 ±
 0
.0
4 
 
D
oc
os
ah
ex
ae
no
ic
 a
ci
d 
(g
) 
0.
09
 ±
 0
.1
0 
0.
08
 ±
 0
.0
7 
0.
08
 ±
 0
.0
9 
 
0.
06
 ±
 0
.0
7 
0.
07
 ±
 0
.0
8 
0.
07
 ±
 0
.0
7 
 
Chapter 5 
 
96 
 TA
BL
E 
5.
2 
co
nt
in
ue
d 
 
 
 
 
 
 
 
 
 
M
en
 
 
W
om
en
 
 
 
To
ta
l p
an
cr
ea
ti
c 
ca
nc
er
 c
as
es
 
M
ic
ro
sc
op
ic
al
ly
 v
er
ifi
ed
 
pa
nc
re
at
ic
 c
an
ce
r 
ca
se
s 
 
Su
bc
oh
or
t 
 
To
ta
l p
an
cr
ea
ti
c 
ca
nc
er
 c
as
es
 
M
ic
ro
sc
op
ic
al
ly
 v
er
ifi
ed
 
pa
nc
re
at
ic
 c
an
ce
r 
ca
se
s 
 
Su
bc
oh
or
t 
 
To
ta
l p
ro
te
in
 a
nd
 s
pe
ci
fic
 ty
pe
s 
of
 p
ro
te
in
†  
 
 
 
 
 
 
 
To
ta
l p
ro
te
in
 (g
) 
76
.5
 ±
 1
2.
2 
75
.9
 ±
 1
1.
6 
75
.9
 ±
 1
1.
2 
 
66
.1
 ±
 1
1.
6 
66
.0
 ±
 1
2.
2 
65
.6
 ±
 1
0.
6 
 
Ve
ge
ta
bl
e 
pr
ot
ei
n 
(g
) 
27
.7
 ±
 5
.5
 
28
.0
 ±
 5
. 5
 
28
.0
 ±
 6
.2
 
 
22
.0
 ±
 3
.6
 
22
.3
 ±
 3
.4
 
22
.2
 ±
 4
.6
 
 
A
ni
m
al
 p
ro
te
in
 (g
) 
49
.4
 ±
 1
2.
1 
48
.5
 ±
 1
1.
1 
48
.6
 ±
 1
1.
7 
 
44
.5
 ±
 1
1.
8 
44
.1
 ±
 1
2.
4 
43
.8
 ±
 1
0.
9 
 
M
in
er
al
s 
 
 
 
 
 
 
 
 
To
ta
l i
ro
n 
(m
g)
 
13
.4
 ±
 3
.2
 
13
.5
 ±
 3
.0
 
13
.3
 ±
  3
.2
 
 
12
.1
 ±
 2
.8
 
12
.1
 ±
 2
.5
 
11
.7
 ±
 2
.7
 
 
H
em
e 
ir
on
 (m
g)
 
1.
2 
± 
0.
6 
1.
1 
± 
0.
5 
1.
2 
± 
0.
5 
 
1.
0 
± 
0.
5 
1.
0 
± 
0.
6 
1.
0 
± 
0.
5 
 
N
itr
ite
 (m
g)
 
0.
2 
± 
0.
2 
0.
2 
± 
0.
2 
0.
2 
± 
0.
2 
 
0.
1 
± 
0.
1 
0.
1 
± 
0.
1 
0.
1 
± 
0.
1 
N
et
he
rl
an
ds
 c
oh
or
t s
tu
dy
 o
n 
di
et
 a
nd
 c
an
ce
r,
 1
98
6-
19
99
. 
* In
ta
ke
 b
as
ed
 o
n 
ra
w
 m
ea
t w
ei
gh
t.
 † E
ne
rg
y-
ad
ju
st
ed
 in
ta
ke
. 
Meat and fat intake and pancreatic cancer risk 
 
97 
In additional analyses, we investigated whether or not individuals who reported to 
have consumed equal number of eggs or equal amounts of fresh meat and processed 
meat 5 years preceding baseline compared to baseline, showed different risk esti-
mates. This was not the case, although among microscopically verified cases (n = 175), 
multivariable-adjusted red meat intake still showed an inverse association, but this 
was no longer significant (highest versus lowest quintile RR = 0.61, 95% CI: 0.34-1.08). 
Here the proportional hazards assumption was not violated anymore. 
 No association was found when examining the association between the risk of 
pancreatic cancer in the total population and the dietary intake of total fat, vegetable 
fat, SFA, MUFA, PUFA, cholesterol, trans unsaturated fatty acids, LA, linolenic acid, 
EPA, and DHA in the age- and gender-adjusted or multivariable-adjusted model (Table 
5.4). After excluding NMCPC cases, these findings remained. For fat from meat, we 
observed a significantly decreased risk comparing the highest quintile with the lowest 
(Table 5.4) after multivariable-adjustment. In addition, a decreased pancreatic cancer 
risk was observed per isocaloric increment of 10 g of meat fat per day, but this was not 
statistically significant. 
 We did not observe any association between the intake of protein, total iron, 
heme and nitrite and pancreatic cancer risk (data not shown). Our findings remained 
the same when looking at men and women separately and after excluding individuals 
who reported a history of diabetes at baseline from the analyses (data not shown). 
After excluding the first 2 years of follow-up, the results were not substantially differ-
ent (data not shown), although per isocaloric increment of 10 g of meat fat intake per 
day the decreased risk estimate for pancreatic cancer became significant (multivariable 
RR = 0.81, 95% CI: 0.67-0.98). 
 
 
DISCUSSION 
 
In the present study no association was observed between the intake of total fresh 
meat, beef, pork, minced meat, chicken, liver, and eggs and pancreatic cancer risk. So 
far, inconsistent findings have been observed in humans concerning meat intake.3 
 To date, 11 cohort studies have investigated the relation between the intake of 
total meat, different meat types and eggs and pancreatic cancer risk.3,6,8-12 Two studies 
have observed a positive association with total meat intake,3,11 the Multiethnic Cohort 
Study has observed increased risks with the intake of beef and pork,3 and a cohort 
among 7th-day Adventists has observed a positive association with egg intake.3 Inverse 
associations were observed with the intake of pork in a study of Swedish twins8 and 
with the intake of poultry among Swedish women.3 Other cohort studies did not ob-
serve an association with pancreatic cancer risk.3,6,9,10,12 
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Findings in the 20 case-control studies, examining the relation between the intake of 
meat and eggs and pancreatic cancer risk,3,6,13-16,19 were even more diverse. On one 
hand, positive associations with meat intake were observed in at least eight case-
control studies. The meat items reported in these studies were total meat,3,16 
beef,3,6,15,16 pork,3 chicken,16 and liver.3 On the other hand, inverse associations were 
observed with the intake of different kinds of animal products, including total meat 
(including fish and processed meat), white meat (chicken and fish), and chicken.3,15 
Regarding egg intake, both positive3,14,15 and inverse associations3 have been observed. 
However, because pancreatic cancer is rapidly fatal, many case-control studies have 
relied on next-of-kin interviews to determine exposures, which may have introduced 
differential misclassification of the exposure in these types of study.  
 During the process of food preparation, numerous carcinogens are produced. 
Heterocyclic amines (HCAs) are formed by cooking meat at high temperature. Grilling 
or barbecuing meat and fish with intense heat over a direct flame, results in fat drip-
ping on the hot fire; this produces polycyclic aromatic hydrocarbons (PAHs) that stick 
to the surface of the food.20,21 In our study, the true association might be masked since 
we could not investigate the association between meat-cooking methods and pancrea-
tic cancer. In the original FFQ of this cohort, data on meat preparation was not col-
lected. Future studies should carefully distinguish cooking methods to investigate the 
extent to which different cooking methods are associated with pancreatic carcinoge-
nesis. Some observational studies have already evaluated meat-cooking methods. A 
Finnish cohort of male smokers (ATBC Study) has observed no association with fried 
meat intake,12 whereas four case-control studies have observed positive associations 
with higher consumption of grilled and fried foods, such as meat.6,16,19 Recently, two 
epidemiological studies specifically assessed meat-cooking methods with respect to 
pancreatic cancer risk, finding positive associations with the intake of grilled/barbe-
cued meat, high-temperature cooked meat, and broiled meat, but not with meat pre-
pared differently.11,13 In addition, some other studies have observed positive associa-
tions with meat-derived HCAs and benzo(a)pyrene, a marker of PAHs, and pancreatic 
cancer risk.11,41,42 
 Regarding fresh red meat intake, we observed a statistically significant inverse 
association with pancreatic cancer among microscopically verified cases, although this 
decrease was only observed for the highest versus the lowest quintile. The risk esti-
mates for red meat intake seemed to change, however, during follow-up, although the 
interaction with time was not significant. In the subgroup of individuals who reported 
to have consumed equal amounts of meat 5 years preceding baseline compared to 
baseline, the inverse association for red meat intake was no longer statistically signifi-
cant. In addition, because red meat is a rich source of iron and heme, a similar de-
creased pancreatic cancer risk would be expected with the intake of total iron and 
heme, but this was not the case. 
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Eight cohort studies3,6,10-12 and eight case-control studies3,6,13,15 reported specifically on 
red meat intake in relation to pancreatic cancer risk. Five cohort studies have showed 
an increased risk for the highest versus lowest intake,3,11 which was statistically signifi-
cant in four.3,11 Of the case-control studies, six have observed an increased risk for the 
highest versus the lowest intake,3,6,13,15 which was statistically significant in two.3   
Recently, in a systematic literature review of pancreatic cancer by an Expert Panel 
Report, a pooled risk estimate of 1.00 (95% CI: 0.95-1.05) for cohort studies and of 
1.11 (95% CI: 1.08-1.15) for case-control studies on red meat intake was reported,3 but 
these estimates were only based on two of the eight cohort studies and three of the 
eight case-control studies. The inverse association we observed has not been reported 
in previous studies. This result should be interpreted with caution because this finding 
might have been due to chance because of the multiple comparisons that were made 
in the present study. 
 Dietary N-nitroso compounds can be formed endogenously or are preformed in 
foods preserved with nitrite, such as processed meat. These compounds may play a 
role in human pancreatic cancer as well.21 In a population-based case-control study, 
Coss et al. have observed an increased pancreatic cancer risk with the consumption of 
dietary nitrite from animal sources.43 No association was observed in the four studies 
that investigated the relation between nitrite intake and pancreatic cancer risk,12,14,17,18 
while of the 20 epidemiological studies investigating processed meat,3,6,8-13,15,19 only 
the Multiethnic Cohort Study and five case-control studies have observed a positive 
association.3,6,15,19 We observed in our study neither an increased pancreatic cancer 
risk with processed meat intake nor with dietary nitrite intake. 
 Animal studies have shown that the development of tumors is generally enhanced 
by long-chain ω-6 polyunsaturated fatty acids (PUFA), especially linoleic acid (LA), but 
inhibited by ω-3 PUFA. LA promotes pancreatic carcinogenesis via an accelerated pros-
taglandin synthesis, caused by metabolism of LA-derived arachidonic acid,23,44 whereas 
ω-3 PUFAs can lead to a reduction in the availability of prostaglandins.22 Prostaglandins 
may be involved in the development of pancreatic carcinogenesis in animals.23,44 Satu-
rated fatty acids (SFA), on the other hand, seems not to be involved in the enhance-
ment or promotion of pancreatic carcinogenesis in rats.45 
 In our study, we observed no association when examining the relation between 
dietary intake of total fat, vegetable fat, SFA, monounsaturated fatty acids (MUFA), 
PUFA, cholesterol, LA, and linolenic acid, and the risk of pancreatic cancer. So far, 18 
case-control studies have analyzed dietary fat, and different types of fatty acids.3,6,14, 
15,17,18 Positive associations were observed for the following: total fat,3,6,15,17 SFA,15,17 
MUFA,15 and cholesterol.3,14,15 Inverse associations were observed with intake of total 
fat,3,6 SFA,3 MUFA,3 PUFA,3,14 and LA.3 Of the four prospective studies that investigated 
the relation between dietary fat and risk of pancreatic cancer,3,6,10,12 only the ATBC 
Study has observed a positive association with the intake of SFA.12 
 The association between fatty acids from fish and pancreatic cancer has not been 
investigated often and so far, no association has been observed.3,16 Of the 15 case-
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control studies that analyzed the intake of fish and shellfish,3,6,15,16 only two have   
observed an inverse association,3,6 whereas three studies have observed a positive 
association.3 The nine cohort studies investigating the relation between fish intake and 
pancreatic cancer risk, have all observed no association.3,6,8-10,12 In the current study, 
we observed no association for intake of fish and the fish n-3 PUFA, EPA and DHA. 
 For fat from meat, we observed a significantly decreased risk. Because red meat 
intake and fat from meat are strongly correlated (r = 0.73), we assume that this      
decreased risk can, in part, be explained by the decreased risk we observed with red 
meat intake. So far, only animal fat has been examined, observing a positive associa-
tion in only one15 of the three studies.3,10,15 
 A limitation of our study is the use of a single measure of dietary intake that may 
not have been representative of the dietary habits of the study participants over the 
course of follow-up. However, the FFQ was tested for reproducibility by Goldbohm et 
al., who concluded that the single measurement of intake of diet in the NLCS can cha-
racterize dietary habits for a period of at least 5 years.33 In addition, meat and egg 
intake appeared to be stable over time as indicated by the analyses restricted to indi-
viduals who reported to have consumed equal amounts of meat or equal number of 
eggs 5 years preceding baseline compared to baseline, which showed similar findings 
compared to the overall analyses. 
 Strengths of this study include the possibility to further restrict the analyses to 
MCPC cases only,40 the large sample size, and detailed information on potential risk 
factors of pancreatic cancer. Differential follow-up is unlikely to have made a material 
contribution to our findings, as completeness of follow-up was high.28 The prospective 
design avoided recall bias and the need to use next-of-kin respondents, but misclassifi-
cation of exposure may have occurred. However, from our validation study it was con-
cluded that the questionnaire could satisfactorily rank subjects according to the intake 
of meat and dietary fat.29 If misclassification has occurred, we expect this to be non-
differential and risk estimates will be most likely biased towards the null value. 
 In conclusion, we observed no association between a high intake of meat, types of 
meat, fish, eggs, dietary total fat and different types of fat and pancreatic cancer risk in 
the NLCS. It is possible that the true association between meat intake and pancreatic 
cancer might be masked because we could not investigate the relation with meat-
cooking methods. Therefore it is important for future studies to investigate the rela-
tion between different meat-cooking methods and pancreatic cancer. 
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ABSTRACT 
 
Epidemiological data investigating the relation between fruit and vegetable consump-
tion and pancreatic cancer risk have shown inconsistent results so far. Most case-
control studies observed an inverse association with total fruit and vegetable con-
sumption, whereas results from most cohort studies have largely been null. We     
examined prospectively the relation between pancreatic cancer risk and intake of veg-
etables, fruits, carotenoids and vitamins C and E. The Netherlands Cohort Study con-
sisted of 120,852 men and women who completed a questionnaire at baseline in 1986, 
including a validated 150-item food frequency questionnaire. After 16.3 years of fol-
low-up, 423 cases were available for analysis. Total vegetable and total fruit consump-
tion were not associated with pancreatic cancer risk (highest versus lowest quintile, 
multivariable-adjusted hazard rate ratio = 1.23, 95% confidence interval: 0.86-1.75 and 
multivariable-adjusted hazard rate ratio = 0.90, 95% confidence interval: 0.66-1.24, 
respectively). Also, for cooked vegetables, raw vegetables, and vegetables and fruits 
classified into subgroups, no associations were observed. Dietary carotenoids, vitamin 
C and E intake and supplements containing vitamin C or E were not associated with 
pancreatic cancer risk. The results were not modified by sex, smoking status and body 
mass index. In conclusion, we observed no association between a high consumption of 
vegetables and fruits and pancreatic cancer risk in this large cohort study, which is in 
agreement with previous prospective studies. Furthermore, we observed no associa-
tion between the intake of carotenoids, vitamins and vitamin supplements and pan-
creatic cancer risk. 
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INTRODUCTION 
 
Pancreatic cancer is the 5th leading cause of death in Europe and 4th in the United 
States.1,2 Pancreatic cancer is diagnosed most often at advanced stages and patients 
diagnosed with pancreatic cancer have a 5-year survival rate of 6% or less.2,3 So far, 
cigarette smoking, diabetes mellitus, and body fatness are identified as risk factors.4-6 
 Fruits and vegetables contain numerous substances with potential anticarcino-
genic activity (including vitamins, carotenoids, and Allium compounds)7 and could 
therefore play a role in prevention of pancreatic cancer. Potential mechanisms of  
action include antioxidant protection against free-radical damage to DNA, enhancing 
immune function, and inhibiting insulin-like growth factor (IGF) binding to IGF-
receptors.4,7 In addition, short-term animal experiments suggest that beta-carotene 
and the vitamins C and E hinder the development of preneoplastic lesions in both rats 
and hamster pancreas,8 but long-term studies demonstrated this inhibiting effect only 
for beta-carotene and vitamin C and only in rat pancreas.8,9 
 Epidemiological data have shown inconsistent results so far. Most case-control 
studies have observed an inverse association with total fruit and vegetable consump-
tion.10-15 Among specific subgroups of vegetables, the most consistent association has 
been found for cruciferous or Brassica vegetables.11,12,15 On the other hand, results 
from most cohort studies have largely been null.16-22 The results from the Multiethnic 
Cohort Study suggests that vegetables may afford some protection against pancreatic 
cancer in high-risk subgroups, namely current smokers and overweight/obese per-
sons.18 Regarding the relation between antioxidant intake and pancreatic cancer risk, 
intake of vitamin C and beta-carotene have been investigated most often, showing 
both inverse associations11,14,23 and no association.15,19,20,24,25 Data on use of vitamin 
supplements has been very sparse;10,15,20,24 of these studies only one observed an  
inverse association with vitamin C supplement use.15 A recent Expert Panel Report 
found only suggestive evidence that fruits protect against pancreatic cancer, whereas 
the evidence was inconclusive for vegetables and vitamin C.4 
 In the current study, we investigated the association between pancreatic cancer 
risk and the overall consumption of vegetables and fruits and consumption of sub-
groups of vegetables and fruits in a large prospective cohort study in the Netherlands. 
In addition, we investigated the relation between pancreatic cancer risk and dietary 
carotenoids, vitamins C and E, and supplements containing vitamin C and E. 
 
 
MATERIAL AND METHODS 
 
Study population and cancer follow-up 
The study design of the Netherlands Cohort Study (NLCS) has been reported in detail 
elsewhere.26 Briefly, the NLCS was initiated in September 1986 and included initially 
58,279 men and 62,573 women aged 55-69 years from 204 Dutch municipalities with 
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computerized population registries. A self-administered food frequency and lifestyle 
questionnaire was completed at baseline. For efficiency in the processing of the ques-
tionnaire and follow-up, the case-cohort approach was used.27 Incident cases were 
derived from the entire cohort, whereas the person-years at risk were estimated from 
a random sample of 5,000 subjects (2,411 men and 2,589 women). This subcohort was 
chosen immediately after baseline and followed up for vital status information. The 
entire cohort is being monitored for cancer occurrence by annual record linkage to the 
Netherlands Cancer Registry and the Netherlands Pathology Registry.28,29 A total of 
16.3 years of follow-up (baseline to December 2002) was used for the current analysis. 
Only one subcohort member was lost to follow-up and completeness of follow-up was 
estimated to be >96%.30 
 All prevalent cancer cases at baseline other than skin cancer were excluded,   
resulting in a subcohort of 4,774 men and women. Of the 567 incident pancreatic can-
cer cases (ICD-O-3 code C25), cases with endocrine subtypes (ICD-O-3 code C25.4;        
n = 1) were excluded. Sixty two percent of the 566 pancreatic cancer cases were mi-
croscopically confirmed pancreatic cancer (MCPC, n = 350), whereas such confirmation 
was lacking for 38% (n = 216). Diagnosis of the latter group was made by the treating 
clinician and was based on clinical symptoms, physical examination and imaging    
results, and data were abstracted and recorded by a trained tumor registrar.31 The 
NLCS has been approved by the institutional review boards of the TNO Nutrition and 
Food Research Institute (Zeist, the Netherlands) and Maastricht University (Maastricht, 
the Netherlands). 
 
Questionnaire 
The dietary section of the baseline questionnaire was a 150-item semiquantitative 
food frequency questionnaire (FFQ), which concentrated on habitual consumption 
during the year preceding the start of the study. Questionnaire data were key-entered 
and processed for all incident cases in the cohort and subcohort members in a stan-
dardized manner, blinded with respect to case/subcohort status. This was done to 
minimize observer bias in the coding and interpretation of the data. 
 Data were obtained concerning consumption frequency of vegetables (i.e., Brus-
sels sprouts, cauliflower, cabbage [white/green], kale, string beans, broad beans, spi-
nach, endive [raw and cooked], lettuce, carrots [raw and cooked], sweet peppers, 
sauerkraut, tomatoes, red beets, mushrooms, gherkins, rhubarb, leek, and onions), for 
summer and winter separately, and fruits (i.e., mandarins, oranges, grapefruits, 
orange/grapefruit juice, grapes, bananas, apples/pears, and strawberries). Based on 
data from the Dutch Nutrition Survey,32 onions and sweet peppers were considered to 
be eaten cooked, whereas tomatoes were considered to be eaten raw. The question-
naire covered most vegetables and fruits eaten regularly in 1986, with the exception of 
chicory, red cabbage, and cucumber. In the Netherlands, broccoli was a rarely available 
vegetable in 1986 and therefore not included. Furthermore, in an open-ended ques-
tion, participants could enter which other foods they consumed on a regular basis as 
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well as the frequency (number of times per week) and amount of consumption on 
each occasion. 
 Consumption frequency was specified by using categories ranging from “never or 
less than once per month” to “three to seven times per week” for vegetable consump-
tion and to “six or seven times per week” for fruit consumption. In addition, for indi-
vidual fruit items, the amount consumed on each consumption day was asked. For 
onions and tomatoes, participants were asked to report the number they usually ate 
per week; for sweet peppers per month; and for mushrooms, how many 250-g boxes 
per month. Frequency of consumption and usual serving size of tomato/vegetable 
juice, processed orange/grapefruit juice and other fruit juices was also asked. 
 Participants were asked about usual serving sizes for string beans and cooked 
endive only; the mean of these serving sizes were used as a representative of solid and 
leafy vegetables, respectively. This average individual serving size was multiplied with a 
vegetable-specific factor calculated from pilot study data, to derive an individual serv-
ing size for each vegetable. This procedure was chosen because in a pilot study it was 
shown that serving sizes of different types of cooked vegetables were correlated with-
in subjects. Mean daily vegetable consumption (g/day) was calculated by multiplying 
the frequency of consumption and serving size. Frequency of intake and standard serv-
ing sizes were used to calculate consumption of individual fruit items in g/day. 
 The mean daily intake of vitamins C and E were calculated by using the compute-
rized Dutch food composition table.33 For calculating the intake of specific carotenoids, 
an additional food composition table was used. Briefly, foods that are the main sources 
of carotenoids (e.g., vegetables) were sampled and analyzed for alpha-carotene, beta-
carotene, lutein, zeaxanthin, and lycopene; the database was completed with data 
from the literature and information from food manufacturers.34 In the carotenoids 
food composition table, lutein and zeaxanthin were combined, because most literature 
sources had not distinguished these two carotenoids. Most vegetables, however, con-
tain primarily lutein and only minor amounts of zeaxanthin. Information on dietary 
supplement use was collected with an open-ended question with space for four differ-
ent supplements.35 Participants were asked whether they used vitamin tablets, drops, 
or other supplements during the 5 years before baseline. Furthermore, they were 
asked what type of supplement they have used, type of brand, what dosage and for 
how long they have used the supplement. 
 Subjects with incomplete or inconsistent dietary data (336 subcohort members, 
46 cases) were excluded from analyses.36 Throughout the FFQ data cleaning was con-
ducted using standardized algorithms to detect and, in some cases, correct likely   
errors, while tallying the errors for each person. Questions on vegetable consumption 
appeared early in the food frequency questionnaire. This led to some subjects’ making 
mistakes on these particular items (e.g., improbably high summed frequencies for 
vegetable consumption, errors in separate consumption frequencies for summer and 
winter, and improbably high or low reported portion sizes), while items on other food 
groups appearing later in the questionnaire were filled out without any problems. 
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When more than three errors were encountered on the vegetable items, that subject 
was excluded from the analyses of vegetable consumption (241 subcohort members, 
26 cases). The FFQ had been validated and tested for reproducibility.36,37 Crude Pear-
son correlation coefficients between the 9-day diet record and the questionnaire were 
0.74 for energy and 0.58 for vitamin C. The Spearman correlation coefficients for total 
vegetables and total fruits were 0.38 and 0.60, respectively.36 On average, vegetable 
consumption appeared to be slightly overestimated and fruit consumption to be    
under-estimated by the FFQ as compared with the diet records.36 
 
Statistical analysis  
Analyses were performed for total vegetable consumption, total fruit consumption, 
consumption of vegetables and fruits combined, cooked and raw vegetables, vegeta-
bles categorized in subgroups (Brassica vegetables, cooked and raw leafy vegetables, 
Allium vegetables, and legumes), total fruit, citrus fruit and consumption of individual 
vegetables and fruits as listed in the questionnaire. “Total vegetable consumption” is 
the summed total for all vegetables mentioned in the questionnaire and in the open-
ended question, excluding dried pulses. Dried pulses were considered only in the anal-
ysis of legumes. The composition of each vegetable and fruit group is given in the  
“Appendix” section. In addition, analyses were performed for tomato/vegetable juice, 
processed orange/grapefruit juice, and other juices. Other exposure variables were the 
carotenoids alpha-carotene, beta-carotene, lutein + zeaxanthin, lycopene, and beta-
cryptoxanthin, the vitamins C and E and use of any supplement — including multivita-
mins — containing vitamin C or E. 
 Participants were categorized according to quintile of intake of relevant food 
groups or nutrients (with the lowest quintile of intake regarded as the reference 
group), depending on the sex-specific distribution in the subcohort. For vitamin C, 
however, the validation study had pointed out that quintiles 2 and 3 and quintiles 4 
and 5 could not be distinguished; therefore, we reduced vitamin C intake to three 
categories.36 Participants were categorized as users or nonusers of supplements con-
taining vitamin C or E. Continuous variables were constructed as well. For vegetables 
and fruits an increment of 25 g/day was used based on data of the pilot study. This 
increment corresponds to a consumption frequency of approximately once per week 
for cooked vegetables. 
 Age- and sex-adjusted and multivariable-adjusted hazard rate ratios (HRs) and 
corresponding 95% confidence intervals (95% CIs) were estimated by using Cox pro-
portional hazards models. The total person-years at risk, estimated from the subco-
hort, were used in the analyses.38 Standard errors were estimated by using a robust 
covariance matrix estimator to account for increased variance due to sampling from 
the cohort.39 All analyses were conducted for both sexes combined and separately for 
men and women. 
 Based on literature, the following variables were considered as potential con-
founders: age, sex, smoking, body mass index (BMI), intake of energy, coffee and alco-
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hol, total red meat consumption, level of education, non-occupational physical activity, 
family history of pancreatic cancer, history of diabetes mellitus, hypertension, gall-
stones, cholecystectomy, and gastric ulcer. These potential confounding variables were 
added to the multivariable-adjusted model if they (i) were associated with the disease 
and with total vegetable and total fruit intake and (ii) changed the age- and sex      
adjusted regression coefficients by at least 10 percent (using a backwards stepwise 
procedure). This resulted in a multivariable-adjusted model including age at baseline 
(years), sex, cigarette smoking (current smoking: yes/no; number of cigarettes smoked 
per day; number of years of smoking), BMI (kg/m2), intake of energy (kcal/day), coffee 
(number of cups/day) and alcohol (g/day), total red meat consumption (g/day), family 
history of pancreatic cancer (yes/no), and history of diabetes mellitus (yes/no). The 
independent contribution of each vegetable subgroup was assessed by an analysis in 
which all vegetable subgroups were included in the model simultaneously. For analysis 
on antioxidant intake, the independent contribution of each specific vitamin and caro-
tenoid to the risk of pancreatic cancer was assessed by an analysis in which all these 
were included in the model simultaneously. In additional analyses, the HRs were   
adjusted for total vegetable and fruit intake. For each analysis, trends were evaluated 
with the Wald test by assigning participants the median value for each level of the 
categorical exposure variable among the subcohort members and this variable was 
entered as a continuous term in the Cox regression model. 
 To permit comparison, we restricted age-adjusted analyses to subjects included in 
multivariable-adjusted analyses (e.g., with no missing values on confounding va-
riables), which left 3,937 subcohort members (1,930 men and 2,007 women) and 448 
exocrine pancreatic cancer cases (240 men and 208 women) for analysis on fruit con-
sumption and on intake of carotenoids, vitamins and vitamin supplements. For the 
analysis on vegetable consumption, 3,734 subcohort members and 428 exocrine pan-
creatic cancer cases were available. The proportional hazards assumption, which was 
tested using the scaled Schoenfeld residuals,40 was violated for many of the exposure 
variables. Because early symptoms of disease before diagnosis could have influenced 
the results, the early cases (diagnosed within 2 years after baseline) were excluded; 
this resolved our problem of assumptions being violated. Therefore, all analyses were 
done excluding the first 2 years of follow-up: 69 subcohort members and 25 pancreatic 
cancer cases were excluded for the analysis on fruits, juices, carotenoids, and vitamin 
intake and use of vitamin supplements. For the analysis on vegetable intake, 64 subco-
hort members and 22 pancreatic cancer cases were excluded. 
 In the present study the overall analyses were performed on all pancreatic cancer 
cases. We restricted additional analyses to MCPC cases to create a group with a higher 
degree of diagnostic certainty of pancreatic cancer, which was shown to be important 
in previous studies.41,42 We also conducted analyses separately for current, former, and 
never smokers to determine whether smoking modifies the association of total vege-
table and total fruit intake with risk of pancreatic cancer. Also, analyses for total vege-
table and fruit intake were conducted stratified by BMI level (cutoff: 25 kg/m2) to  
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examine whether fruit and vegetable intake may differentially affect those at higher 
risk. In addition, interactions on a multiplicative scale of total vegetable and total fruit 
consumption with smoking status and BMI were tested. All analyses were performed 
using the STATA statistical software package (intercooled STATA, version 9; Stata Cor-
poration, College Station, TX). All p values were based on two-sided tests and consi-
dered statistically significant if <0.05. 
 
 
RESULTS 
 
In Table 6.1, baseline characteristics are presented. Most characteristics did not differ 
between pancreatic cancer cases and subcohort members; however, there were more 
current smokers and more subjects with a family history of pancreatic cancer among 
pancreatic cancer cases than among subcohort members. In Table 6.2, we present 
baseline dietary intakes of the specific vegetables and fruits as listed in the question-
naire. Because the specific vegetables and fruits had a right-skewed distribution, we 
present the median and interquartile range. The specific vegetables and fruits are 
presented in increasing order of the percentage of nonusers. The most eaten vegeta-
bles in our population were string beans, cauliflower and lettuce, whereas gherkins 
and raw carrots were only consumed by approximately 30% of our participants.     
Apples, pears, strawberries, and oranges were the most consumed fruits, whereas 
grapefruits, raisins and other dried fruit were the least consumed fruits in our popula-
tion. No real differences were observed between cases and subcohort members    
regarding the intake of specific vegetables and fruits. 
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TABLE 6.1 Baseline characteristics (means or percent) of pancreatic cancer cases and subcohort members; 
Netherlands Cohort Study on diet and cancer, 1986-2002* 
Characteristic All pancreatic cancer cases Subcohort 
n 423 3,868 
Male sex (%) 52.7 48.7 
Age, mean ± SD (years) 62.1 ± 4.1 61.3 ± 4.2 
Current smokers (%) 34.0 27.0 
Years of smoking†, mean ± SD (years) 33.3 ± 12.6 31.5 ± 12.2 
BMI, mean ± SD (kg/m2) 25.4 ± 3.2 25.0 ± 3.1 
Physical activity (non-occupational) (%)   
  <30 min/day 
30-60 min/day  
60-90 min/day 
>90 min/day 
20.3 
32.1 
25.8 
21.8 
20.1 
31.3 
21.4 
27.2 
Family history of pancreatic cancer (%) 3.1 0.8 
History of diabetes mellitus (%) 5.4 3.4 
History of hypertension (%) 25.1 26.3 
History of gallstones (%) 10.2 9.8 
History of cholecystectomy (%) 9.2 9.0 
History of gastric ulcer (%)  8.3 8.2 
Level of education (%)   
  Low 
Medium  
High 
51.1 
34.2 
14.7 
49.7 
36.0 
14.3 
Daily intake, mean ± SD   
 Energy (kcal) 1,928 ± 476 1,924 ± 514 
 Total fat‡ (g) 83.7 ± 15.5 83.8 ± 15.8 
 Total carbohydrates‡ (g) 202.0 ± 39.9 201.7 ± 40.1 
 Alcohol (g) 12.6 ± 16.1 10.3 ±14.3 
 Coffee (number of cups) 4.5 ± 2.3 4.3 ± 2.2 
 Total red meat intake (g) 86.1 ± 38.8 86.7 ± 40.3 
*First 2 years of follow-up excluded from the analysis; numbers of cases and subcohort members adjusted 
accordingly. †Never smokers excluded. ‡Energy-adjusted intake. 
 
 In Table 6.3, HRs are presented for quintiles of total vegetable and fruit intake, 
total vegetable intake, intake of vegetable subgroups, total fruit intake and citrus fruit 
intake. After adjustment for age and sex, trends in risk for cooked vegetables and Bras-
sica vegetables were (statistically significantly) positive; however, none of the HRs in 
the categorical analyses were significant (Table 6.3). When the confounders were 
included in the model, these positive trends became non-significant. For all other veg-
etable and fruit groups, we observed no associations. All HRs for an increment in daily 
mean intake of 25 g/day for vegetables and fruits, were approximately one (Table 6.3). 
When we included simultaneously all vegetable subgroups (continuously) in the mod-
el, results were similar (results not shown). Additional adjustment for fruit and vegeta-
ble consumption did also not alter the results (results not shown). We have also inves-
tigated whether specific vegetables and fruits were associated with pancreatic cancer 
risk; no associations were observed (results not shown). Also the intake of toma-
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to/vegetable juice, processed orange/grapefruit juice and other fruit juices were not 
associated with pancreatic cancer risk (results not shown). 
 
TABLE 6.2 Daily (median) intake of specific vegetable and fruit items of subcohort members and pancreatic 
cancer cases; Netherlands Cohort Study on diet and cancer, 1986-2002* 
Dietary factors Subcohort  All pancreatic cancer cases 
% nonusers Median (P25-P75)†  % nonusers Median (P25-P75)† 
Vegetable consumption n = 3,670  n = 406 
 String beans (g) 1.6 17.2 (10.4-25.2)  3.9 18.0 (11.7-29.9) 
 Cauliflower (g) 7.2 13.3 (8.3-20.2)  8.9 14.0 (8.4-21.2) 
 Lettuce (g) 9.2 7.1 (3.6-10.7)  12.6 7.1 (3.6-10.7) 
 Carrots, prepared (g) 11.5 8.1 (4.4-13.5)  12.6 7.8 (5.0-13.6) 
 Endive, prepared (g) 14.1 11.8 (6.6-18.7)  15.5 12.1 (6.8-20.4) 
 Brussels sprouts (g) 15.2 8.0 (4.7-12.2)  12.3 8.2 (5.4-12.5) 
 Sauerkraut (g) 16.2 5.9 (3.2-9.0)  15.0 6.0 (3.7-9.2) 
 Tomatoes (g) 18.2 23.5 (14.1-32.9)  17.2 23.5 (14.1-37.6) 
 Onions (g) 19.8 21.9 (11.0-32.9)  19.0 21.9 (11.0-32.9) 
 Spinach (g) 20.0 10.1 (6.1-16.0)  20.0 9.7 (5.6-16.0) 
 Beetroot (g) 24.6 8.9 (5.0-13.6)  26.1 9.2 (5.2-14.3) 
  Kale (g) 25.1 3.6 (1.9-5.3)  21.7 3.9 (1.9-5.5) 
 Cabbage (white/green; g) 28.6 7.7 (4.2-12.7)  29.6 7.4 (4.4-13.1) 
 Leek (g) 31.8 10.2 (5.4-16.7)  28.8 11.2 (6.8-18.9) 
 Dried pulses (g) 38.5 10.7 (4.3-17.3)  38.4 8.5 (4.3-16.0) 
 Mushrooms (g) 39.0 4.4 (4.4-8.9)  36.2 4.4 (4.4-8.9) 
 Broad beans (g) 43.3 5.6 (2.9-10.5)  46.1 5.7 (2.8-10.3) 
 Sweet peppers (g) 46.2 3.5 (2.6-6.1)  46.3 3.5 (2.6-6.1) 
 Endive, raw (g) 55.6 4.3 (2.0-7.4)  56.9 4.3 (2.0-7.4) 
 Rhubarb (g) 58.7 3.4 (1.4-5.9)  60.8 3.4 (1.4-6.2) 
 Carrots, raw (g) 67.2 4.7 (2.0-10.0)  70.9 5.0 (2.8-10.0) 
 Gherkins (g) 69.3 3.1 (1.4-6.3)  66.3 1.8 (1.4-5.4) 
Fruit consumption n = 3,868  n = 423 
 Apples, pears (g) 13.4 80.1 (44.5-115.8)  15.8 80.1 (44.5-115.8) 
 Strawberries (g) 14.0 7.1 (3.6-11.2)  13.9 7.1 (3.6-8.9) 
 Oranges and fresh orange juice (g) 16.2 42.7 (14.8-83.3)  17.7 45.4 (12.8-83.3) 
 Grapes (g) 36.9 3.3 (1.3-8.5)  36.4 3.3 (1.6-7.1) 
 Mandarins (g) 40.5 3.8 (1.9-8.2)  40.9 3.3 (1.9-8.2) 
 Bananas (g) 46.9 10.7 (4.3-18.5)  50.1 10.7 (4.3-18.5) 
 Grapefruits and fresh grapefruit 
juice (g) 
 
70.0 
 
16.0 (7.4-40.1) 
  
71.4 
 
16.0 (7.4-40.1) 
 Raisins/other dried fruit (g) 74.8 1.3 (0.7-2.8)  76.4 1.3 (0.7-2.8) 
*First 2 years of follow-up excluded from the analysis; numbers of cases and subcohort members adjusted 
accordingly. †In users only. 
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TABLE 6.3 Age- and sex-adjusted and multivariable-adjusted hazard rate ratios (HRs) and 95% CIs for pan-
creatic cancer according to quintiles of vegetable and fruit consumption; Netherlands Cohort Study on diet 
and cancer, 1986-2002* 
Food item Median intake† Person-
years 
   
Men Women Cases HR (95% CI)‡ HR (95% CI)§ 
Vegetables and fruit combined‖ (g/day)     
 1¶ 
2 
3 
4 
5 
p for trend 
175.1 
255.4 
321.1 
397.0 
528.6 
213.7 
300.2 
371.2 
451.0 
589.8 
9,002 
9,293 
9,844 
9,305 
8,870 
97 
72 
72 
85 
80 
1.00 
0.70 (0.51-0.97) 
0.67 (0.48-0.92) 
0.82 (0.60-1.11) 
0.80 (0.58-1.10) 
0.49 
1.00 
0.74 (0.53-1.03) 
0.71 (0.51-0.99) 
0.89 (0.64-1.23) 
0.89 (0.64-1.24) 
0.94 
 Continuous (25 g/day intake increment)   0.99 (0.98-1.01) 1.00 (0.98-1.02) 
Total vegetables‖ (g/day)     
 1¶ 
2 
3 
4 
5 
p for trend 
103.6 
144.4 
178.3 
217.2 
287.5 
106.2 
149.2 
182.9 
224.0 
299.4 
8,977 
9,653 
9,783 
9,575 
8,326 
69 
78 
92 
89 
78 
1.00 
1.07 (0.76-1.51) 
1.24 (0.89-1.73) 
1.23 (0.88-1.72) 
1.24 (0.88-1.75) 
0.15 
1.00 
1.09 (0.77-1.55) 
1.26 (0.90-1.77) 
1.27 (0.90-1.78) 
1.23 (0.86-1.75) 
0.20 
 Continuous (25 g/day intake increment)   1.02 (0.99-1.05) 1.02 (0.98-1.05) 
Prepared vegetables (g/day)     
 1¶ 
2 
3 
4 
5 
p for trend 
79.3 
115.0 
143.6 
177.0 
236.5 
80.5 
115.9 
144.0 
177.7 
234.1 
9,062 
9,406 
10,002 
9,518 
8,326 
75 
71 
79 
96 
85 
1.00 
0.92 (0.65-1.29) 
0.96 (0.69-1.36) 
1.25 (0.90-1.72) 
1.25 (0.90-1.74) 
0.04 
1.00 
0.96 (0.68-1.36) 
0.99 (0.71-1.39) 
1.31 (0.95-1.82) 
1.23 (0.88-1.72) 
0.07 
 Continuous (25 g/day intake increment)   1.03 (0.99-1.07) 1.02 (0.98-1.07) 
Raw vegetables (g/day)     
 1¶ 
2 
3 
4 
5 
p for trend 
6.7 
19.2 
30.6 
45.5 
73.3 
9.4 
24.7 
36.5 
52.0 
77.7 
9,209 
9,024 
9,451 
9,586 
9,044 
75 
86 
84 
85 
76 
1.00 
1.16 (0.83-1.61) 
1.10 (0.79-1.53) 
1.08 (0.78-1.50) 
1.04 (0.74-1.46) 
0.95 
1.00 
1.15 (0.83-1.61) 
1.13 (0.80-1.57) 
1.08 (0.77-1.52) 
1.06 (0.75-1.49) 
0.99 
 Continuous (25 g/day intake increment)   1.00 (0.91-1.09) 1.00 (0.91-1.10) 
Brassica vegetables (g/day)     
 1¶ 
2 
3 
4 
5 
p for trend 
10.6 
21.0 
29.4 
39.8 
58.7 
10.6 
19.8 
28.1 
38.2 
57.9 
8,968 
9,669 
9,541 
9,443 
8,694 
71 
70 
85 
97 
83 
1.00 
0.92 (0.65-1.30) 
1.13 (0.81-1.58) 
1.32 (0.96-1.83) 
1.24 (0.88-1.73) 
0.05 
1.00 
0.94 (0.66-1.34) 
1.13 (0.80-1.58) 
1.37 (0.99-1.91) 
1.24 (0.88-1.74) 
0.06 
 Continuous (25 g/day intake increment)   1.08 (0.96-1.22) 1.07 (0.95-1.21) 
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TABLE 6.3 continued      
 Median intake† Person-
years 
   
Men Women Cases HR (95% CI)‡ HR (95% CI)§ 
Leafy vegetables, prepared (g/day)     
 1¶ 
2 
3 
4 
5 
p for trend 
4.3 
12.3 
18.8 
27.1 
41.8 
4.2 
11.8 
19.2 
26.8 
41.6 
9,235 
9,551 
9,299 
9,368 
8,861 
85 
75 
67 
101 
78 
1.00 
0.84 (0.61-1.17) 
0.78 (0.56-1.10) 
1.17 (0.86-1.59) 
0.96 (0.69-1.32) 
0.53 
1.00 
0.84 (0.60-1.18) 
0.79 (0.56-1.11) 
1.24 (0.90-1.69) 
0.96 (0.69-1.34) 
0.48 
 Continuous (25 g/day intake increment)   1.02 (0.87-1.19) 1.02 (0.87-1.20) 
Leafy vegetables, raw (g/day)     
 1¶ 
2 
3 
4 
5 
p for trend 
0.8 
4.1 
7.1 
11.6 
21.6 
1.0 
4.4 
7.6 
13.0 
22.8 
8,862 
9,683 
9,100 
9,653 
9,016 
92 
70 
85 
88 
71 
1.00 
0.72 (0.52-1.01) 
0.93 (0.68-1.27) 
0.91 (0.66-1.24) 
0.79 (0.57-1.10) 
0.47 
1.00 
0.74 (0.53-1.04) 
0.96 (0.69-1.32) 
0.94 (0.68-1.29) 
0.82 (0.59-1.16) 
0.63 
 Continuous (25 g/day intake increment)   0.93 (0.68-1.25) 0.96 (0.71-1.30) 
Allium vegetables (g/day)     
 1¶ 
2 
3 
4 
5 
p for trend 
5.5 
15.5 
23.7 
36.7 
61.0 
4.1 
16.1 
25.9 
40.0 
60.3 
12,562 
5,852 
10,318 
8,734 
8,849 
101 
46 
85 
87 
87 
1.00 
1.00 (0.69-1.44) 
1.04 (0.77-1.41) 
1.26 (0.93-1.71) 
1.25 (0.92-1.70) 
0.07 
1.00 
0.97 (0.67-1.41) 
0.98 (0.72-1.33) 
1.20 (0.88-1.64) 
1.14 (0.83-1.56) 
0.25 
 Continuous (25 g/day intake increment)   1.10 (1.00-1.22) 1.07 (0.96-1.19) 
Legumes** (g/day)     
 1¶ 
2 
3 
4 
5 
p for trend 
11.5 
21.5 
29.9 
41.0 
63.1 
10.2 
18.0 
26.6 
37.0 
59.0 
9,.031 
9,678 
9,358 
9,608 
8,640 
88 
77 
80 
87 
74 
1.00 
0.84 (0.61-1.17) 
0.90 (0.65-1.24) 
0.96 (0.70-1.32) 
0.91 (0.65-1.26) 
0.89 
1.00 
0.88 (0.64-1.22) 
0.92 (0.66-1.28) 
1.00 (0.73-1.38) 
0.91 (0.65-1.28) 
0.84 
 Continuous (25 g/day intake increment)   0.97 (0.86-1.09) 0.96 (0.85-1.08) 
Total fruit‖ (g/day)     
 1¶ 
2 
3 
4 
5 
p for trend 
31.3 
89.4 
135.2 
186.4 
292.8 
64.1 
124.6 
176.7 
237.4 
344.2 
9,347 
9,598 
9,757 
10,110 
9,941 
97 
89 
69 
82 
86 
1.00 
0.89 (0.66-1.21) 
0.67 (0.49-0.93) 
0.76 (0.56-1.04) 
0.79 (0.58-1.08) 
0.17 
1.00 
0.93 (0.68-1.28) 
0.74 (0.53-1.03) 
0.88 (0.63-1.21) 
0.90 (0.66-1.24) 
0.63 
 Continuous (25 g/day intake increment)   0.98 (0.96-1.00) 0.99 (0.97-1.02) 
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TABLE 6.3 continued      
 Median intake† Person-
years 
   
Men Women Cases HR (95% CI)‡ HR (95% CI)§ 
Citrus fruit (g/day)     
 1¶ 
2 
3 
4 
5 
p for trend 
0 
8.5 
29.5 
64.1 
128.7 
3.7 
27.7 
59.9 
90.8 
170.4 
9,130 
9,915 
10,047 
9,659 
10,004 
91 
79 
82 
95 
76 
1.00 
0.80 (0.58-1.10) 
0.80 (0.58-1.10) 
0.94 (0.69-1.28) 
0.73 (0.53-1.01) 
0.31 
1.00 
0.84 (0.60-1.16) 
0.87 (0.63-1.21) 
1.04 (0.76-1.42) 
0.79 (0.57-1.10) 
0.56 
 Continuous (25 g/day intake increment)   0.99 (0.95-1.03) 0.99 (0.96-1.03) 
*First 2 years of follow-up excluded from the analysis. †Median intake in subcohort. ‡The model included age 
(years) and sex. §The model included age (years), sex, smoking (current smoking: yes/no; number of ciga-
rettes smoked per day; number of years of smoking), body mass index (kg/m2), family history of pancreatic 
cancer (yes/no), history of diabetes mellitus (yes/no), intake of energy (kcal/day), red meat (g/day), coffee 
(number of cups/day), and alcohol (g/day). ‖Including vegetables/fruits originating from an open-ended 
question on frequently consumed items not listed in the questionnaire. ¶Reference category. **Also includes 
dried pulses, which were not included in total vegetables. 
 
 In Table 6.4, HRs are presented for carotenoids and vitamin intake. We did not 
observe any association for the intake of carotenoids, vitamin C and E and intake of 
supplements containing vitamin C or E. We simultaneously included the carotenoids 
and vitamins in a model; this did not alter the HRs (data not shown). Also, additional 
adjustment for fruit and vegetable consumption did not alter the results (results not 
shown). 
 Results did not differ between men and women and using the total follow-up 
period including the first 2 years of follow-up (results not shown). The exclusion of 
participants without histological confirmed pancreatic cancer did not change the null 
findings (results not shown). We investigated whether smoking status (nev-
er/ex/current) and BMI (<25 kg/m2 versus ≥25 kg/m2) modified the associations be-
tween vegetable and fruit intake and pancreatic cancer risk; risk estimates were not 
different for never, former and currents smokers and for normal versus overweight 
persons (results not shown). In addition, the multiplicative interaction terms were not 
statistically significant (p for interaction = 0.60 for vegetables and 0.79 for fruit). 
Chapter 6 
 
124 
 
TABLE 6.4 Age- and sex-adjusted and multivariable-adjusted hazard rate ratios (HRs) and 95% CIs for pan-
creatic cancer according to quintiles or categories of carotenoids and vitamins C and E intake; Netherlands 
Cohort Study on diet and cancer, 1986-2002* 
Nutrient Median intake† Person-
years 
   
Men Women Cases HR (95% CI)‡ HR (95% CI)§ 
Alpha-carotene (mg/day)     
 1‖ 
2 
3 
4 
5 
p for trend 
0.2 
0.4 
0.6 
0.8 
1.3 
0.2 
0.4 
0.6 
0.8 
1.3 
9,260 
9,507 
9,908 
10,130 
9,950 
74 
89 
74 
102 
84 
1.00 
1.16 (0.84-1.61) 
0.92 (0.66-1.30) 
1.26 (0.92-1.73) 
1.06 (0.77-1.48) 
0.67 
1.00 
1.23 (0.88-1.71) 
1.00 (0.70-1.41) 
1.39 (1.00-1.94) 
1.21 (0.86-1.71) 
0.24 
 Continuous (0.1 mg/day intake increment)   1.00 (0.98-1.01) 1.00 (0.99-1.02) 
Beta-carotene (mg/day)     
 1‖ 
2 
3 
4 
5 
p for trend 
1.5 
2.1 
2.7 
3.4 
4.7 
1.4 
2.0 
2.6 
3.3 
4.7 
9,152 
9,841 
9,693 
10,100 
9,968 
77 
74 
94 
84 
94 
1.00 
0.89 (0.64-1.25) 
1.15 (0.84-1.59) 
1.02 (0.73-1.41) 
1.14 (0.83-1.57) 
0.29 
1.00 
0.92 (0.65-1.29) 
1.24 (0.89-1.72) 
1.12 (0.80-1.57) 
1.28 (0.91-1.80) 
0.08 
 Continuous (1 mg/day intake increment)   1.00 (0.94-1.06) 1.02 (0.96-1.09) 
Lutein + Zeaxanthin (mg/day)     
 1‖ 
2 
3 
4 
5 
p for trend 
1.4 
1.9 
2.4 
2.9 
3.8 
1.3 
1.8 
2.3 
2.8 
3.8 
9,326 
9,861 
9,879 
9,883 
9,806 
89 
72 
83 
85 
94 
1.00 
0.77 (0.55-1.07) 
0.89 (0.65-1.22) 
0.92 (0.67-1.27) 
1.03 (0.76-1.41) 
0.42 
1.00 
0.79 (0.57-1.10) 
0.95 (0.69-1.31) 
0.98 (0.71-1.36) 
1.08 (0.78-1.50) 
0.29 
 Continuous (1 mg/day intake increment)   1.02 (0.93-1.11) 1.03 (0.94-1.12) 
Beta-cryptoxanthin (mg/day)     
 1‖ 
2 
3 
4 
5 
p for trend 
0.01 
0.04 
0.10 
0.20 
0.36 
0.03 
0.09 
0.17 
0.27 
0.50 
9,116 
10,068 
9,736 
9,904 
9,931 
89 
85 
75 
96 
78 
1.00 
0.86 (0.63-1.19) 
0.78 (0.56-1.08) 
0.96 (0.70-1.30) 
0.77 (0.56-1.07) 
0.41 
1.00 
0.92 (0.66-1.28) 
0.87 (0.62-1.22) 
1.06 (0.77-1.46) 
0.85 (0.61-1.18) 
0.73 
 Continuous (0.05 mg/day intake increment)  0.99 (0.96-1.03) 1.00 (0.97-1.03) 
Lycopene (mg/day)     
 1‖ 
2 
3 
4 
5 
p for trend 
0.1 
0.4 
0.7 
1.1 
2.0 
0.2 
0.6 
0.9 
1.3 
2.3 
9,177 
9,846 
9,858 
10,043 
9,830 
81 
82 
73 
97 
90 
1.00 
0.92 (0.67-1.28) 
0.84 (0.60-1.17) 
1.08 (0.79-1.47) 
1.04 (0.76-1.43) 
0.46 
1.00 
0.91 (0.65-1.27) 
0.85 (0.61-1.20) 
1.10 (0.80-1.52) 
1.03 (0.74-1.43) 
0.46 
 Continuous (0.5 mg/day intake increment)   1.01 (0.98-1.05) 1.02 (0.98-1.05) 
Vitamin C¶ (mg/day)     
 1‖ 
2 
3 
p for trend 
52.1 
82.0 
130.1 
58.9 
93.0 
140.5 
9,138 
19,807 
19,809 
85 
163 
175 
1.00 
0.85 (0.65-1.13) 
0.92 (0.70-1.21) 
0.86 
1.00 
0.91 (0.68-1.21) 
1.00 (0.74-1.33) 
0.74 
 Continuous (10 mg/day intake increment)   1.00 (0.98-1.02) 1.01 (0.98-1.03) 
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TABLE 6.4 continued      
 Median intake† Person-
years 
   
Men Women Cases HR (95% CI)‡ HR (95% CI)§ 
Vitamin E (mg/day)     
 1‖ 
2 
3 
4 
5 
p for trend 
7.2 
10.6 
13.5 
17.2 
23.7 
6.1 
8.5 
11.0 
14.4 
19.6 
9,430 
9,644 
9,552 
9,993 
10,135 
90 
80 
94 
80 
79 
1.00 
0.90 (0.66-1.24) 
1.08 (0.79-1.47) 
0.86 (0.63-1.18) 
0.84 (0.61-1.16) 
0.23 
1.00 
0.93 (0.66-1.29) 
1.12 (0.80-1.56) 
0.91 (0.64-1.30) 
0.93 (0.64-1.36) 
0.63 
 Continuous (5 mg/day intake increment)   0.97 (0.89-1.05) 1.00 (0.90-1.11) 
Vitamin C-containing supplement     
 No‖ 
Yes 
- - 43,350 
5,404 
383 
40 
1.00 
0.84 (0.59-1.18) 
1.00 
0.83 (0.58-1.18) 
Vitamin E-containing supplement     
 No‖ 
Yes 
- - 45,481 
3,273 
397 
26 
1.00 
0.92 (0.60-1.40) 
1.00 
0.89 (0.58-1.37) 
*First 2 years of follow-up excluded from the analysis. †Median intake in subcohort. ‡The model included age 
(years) and sex. §The model included age (years), sex, smoking (current smoking: yes/no; number of ciga-
rettes smoked per day; number of years of smoking), body mass index (kg/m2), family history of pancreatic 
cancer (yes/no), history of diabetes mellitus (yes/no), intake of energy (kcal/day), red meat (g/day), coffee 
(number of cups/day), and alcohol (g/day). ‖Reference category. ¶Category 2 = quintiles 2 + 3 and category 3 
= quintiles 4 + 5. 
 
 
DISCUSSION 
 
In the present study no association was observed between pancreatic cancer risk and 
consumption of vegetables, fruits and juices. We also observed no association        
between pancreatic cancer risk and the intake of carotenoids, vitamins and vitamin 
supplements. These results are in agreement with other cohort studies. Results were 
not modified by sex, smoking status and BMI.  
 Inverse associations have been observed with vegetable intake in several case-
control studies. The vegetable items reported in these studies were diverse, including 
total vegetable plus fruit,12,13 total vegetables,11,12,15 Brassica vegetables,11,13,15 dark 
green leafy vegetables,12 Allium vegetables,12 carrots,12,13 and raw vegetables.11,13,15 
Also for fruit items inverse associations have been reported for several types of fruit, 
including total fruit,10,11,13 citrus fruit,13 oranges,14 and bananas.14 Cohort studies on the 
other hand, have mainly reported null associations.16-22 Only a few prospective studies 
observed protective effects of vegetables and fruits on pancreatic cancer, showing 
inverse associations for total fruit in Japanese men (not in women),43 cabbage con-
sumption among Swedish women,44 vegetarian protein products, beans, lentils and 
peas and dried fruit intake among Adventists.45 However, two of these studies had low 
case numbers (<150).44,45 The Multiethnic Cohort Study observed an increased pan-
creatic cancer risk for high intake of fruit; this was, however, most apparent among 
non-smokers and no association has been found for citrus fruit.46 For fruit juices mixed 
Chapter 6 
 
126 
results have been observed as well, showing inverse associations12,43 and no associa-
tions.11,21 
 The Multiethnic Cohort Study found no association between total vegetable   
intake and pancreatic cancer risk overall; they found, however, some protection 
against pancreatic cancer in high-risk subgroups (i.e., current smokers and over-
weight/obese persons). They observed a significantly inverse association with dark 
green vegetable consumption among current smokers.18 They also observed an inverse 
association with total vegetables in overweight/obese persons (≥25 kg/m2). We, as 
well as others,21,47 did not observe such findings. 
 For carotenoids and vitamins, case-control studies observed inverse associations 
for beta-carotene,11,23 lycopene (in men),25 vitamin C,11,14,23 and E;14,23 cohort studies 
reported only null findings on these carotenoids and vitamin intake.19,20 Other carote-
noids, such as alpha-carotene, lutein plus zeaxanthin and beta-cryptoxanthin, have 
only been investigated in case-control studies so far,15,25 showing no associations with 
pancreatic cancer risk. 
 Inconsistencies could have occurred because case-control studies are prone to 
more biases compared with cohort studies, including recall bias; risk estimates might 
be either exaggerated or underestimated because dietary intake is assessed in cases 
after diagnosis. Also selection bias is a problem due to high and rapid fatality rates of 
pancreatic cancer cases. Differential misclassification of the exposure could also have 
occurred due to the need to use next-of-kin interviews in case-control studies because 
pancreatic cancer is rapidly fatal. In addition, for several studies no dietary information 
was available on individual vegetables or fruits16,17,22 and some studies had small sam-
ple sizes (n cases <150).19,22,44,45 
 In the current study, an extensive list of vegetables and fruits was assessed. On 
the other hand, dietary assessment is liable to error and may have resulted in misclas-
sification of exposure. Vegetables are generally considered as food items that are not 
very easy to assess in FFQs, particularly if portion sizes have to be estimated. We have 
intended to minimize the amount of uninformative data. Subjects with incomplete or 
inconsistent dietary data and, specifically, those participants who appeared not to 
have understood how to answer the questions on vegetable consumption, were ex-
cluded. If misclassification has occurred, we expect this to be non-differential and risk 
estimates will be most likely biased towards the null value. In the NLCS validation 
study, the correlation coefficient between the 9-day diet record and the FFQ for total 
vegetable consumption was 0.38.36 This correlation is low, but comparable to the fig-
ure reported for other prospective studies.43,44,48 One of the reasons for the low corre-
lation could be that our study population may have been too homogeneous regarding 
intake and therefore may have yielded too little contrast between highest and lowest 
quintile of total vegetable consumption to detect differences in pancreatic cancer risk. 
Due to individual preferences, however, contrast in consumption frequency of many 
specific vegetables as well as for fruit is much higher. Although we cannot entirely 
exclude the possibility that the absence of protective effects of vegetables and fruits 
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on pancreatic cancer is due to measurement error or too little contrast in our data, this 
can not be unique for our study and it does not explain why especially case-control 
studies observed protective associations. A large European cohort study — which also 
did not observe an association between pancreatic cancer risk and fruit and vegetable 
consumption — has a wider range of fruit and vegetable intake compared with other 
prospective cohort studies, caused by inclusion of participants from Northern to 
Southern Europeans countries.21 However, their range of fruit and vegetable intake 
was comparable to ours. 
 Strengths of this study include the possibility to further restrict the analyses to 
MCPC cases only42 and the large sample size. Differential follow-up is unlikely to have 
made a material contribution to our findings, as completeness of follow-up was high.30 
The prospective design avoided recall bias and the need to use next-of-kin respon-
dents. 
 In conclusion, we observed no association between pancreatic cancer risk and a 
high consumption of vegetables and fruits in the NLCS, which is in agreement with 
previous prospective studies. Furthermore, we observed no association between the 
intake of alpha-carotene, beta-carotene, lutein plus zeaxanthin, beta-cryptoxanthin, 
lycopene, and vitamins C and E and pancreatic cancer risk. 
 
APPENDIX Composition of vegetable and fruit groups 
Food group Composition  
Total vegetables Cooked vegetables plus raw vegetables 
Cooked vegetables Brussels sprouts, cauliflower, cabbage (white/green), kale, spinach, cooked 
endive, leek, onions, string beans, broad beans, cooked carrots, sweet peppers, 
sauerkraut, beetroot, mushrooms, rhubarb, and other cooked vegetables origi-
nating from an open-ended question on frequently consumed items not listed in 
the questionnaire 
Raw vegetables Raw endive, lettuce, raw carrots, tomatoes, gherkins, and other raw vegetables 
originating from an open-ended question on frequently consumed items not 
listed in the questionnaire 
Brassica vegetables Brussels sprouts, cauliflower, cabbage (white/green), kale 
Leafy vegetables, cooked Spinach, cooked endive  
Leafy vegetable, raw Raw endive, lettuce 
Allium vegetables Leek, onions 
Legumes String beans, broad beans, dried pulses 
Total fruit Mandarins, oranges and fresh orange juice, grapefruits and fresh grapefruit 
juice, grapes, bananas, apples/pears, strawberries, raisins/other dried fruit, and 
other fruits originating from an open-ended question on frequently consumed 
items not listed in the questionnaire 
Citrus fruit Mandarins, oranges and fresh orange juice, grapefruits and fresh grapefruit 
juice, fresh lemon juice 
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ABSTRACT 
 
Background 
To date, cigarette smoking is the most consistent risk factor for pancreatic cancer. We 
prospectively examined the role of active cigarette smoking, smoking cessation, and 
passive smoking as determinants for pancreatic cancer. 
 
Methods 
The Netherlands Cohort Study consisted of 120,852 men and women who completed a 
baseline questionnaire in 1986. After 16.3 years of follow-up, 520 incident pancreatic 
cancer cases were available for analysis. A case-cohort approach was employed using 
the person-years of follow-up of a random subcohort (n = 5,000), which was chosen 
immediately after baseline.  
 
Results 
Compared with never cigarette smokers, both former and current cigarette smokers 
had an increased pancreatic cancer risk (multivariable-adjusted hazard rate ratio [HR] = 
1.34, 95% confidence interval [CI]: 1.02-1.75 and HR = 1.82, 95% CI: 1.40-2.38, respec-
tively). We observed an increased pancreatic cancer risk per increment of 10 years of 
smoking (HR = 1.15, 95% CI: 1.08-1.22) and an HR of 1.08 per increment of 10 ciga-
rettes/day (95% CI: 0.98-1.19). Quitting smoking gradually reduced pancreatic cancer 
risk and approached unity after ≥20 years of quitting. No association was observed for 
passive smoking exposure and pancreatic cancer risk in women; in men, this associa-
tion was not investigated because >90% of the men were ever smokers.  
 
Conclusions 
Overall, our findings confirmed that cigarette smoking is an important risk factor for 
pancreatic cancer, whereas quitting smoking reduced risk. No association was ob-
served between passive smoking exposure and pancreatic cancer risk in women. 
 
Impact 
Quitting smoking would benefit the burden on pancreatic cancer incidence. 
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INTRODUCTION 
 
To date, cigarette smoking is the most consistent risk factor for pancreatic cancer.1 
Most studies, including several cohort studies, a meta-analysis, and a pooled analysis 
of eight cohorts, indicated that current smokers had about a 2-fold increased pancrea-
tic cancer risk compared with never smokers.2-6 Former smokers experience lower 
increased risks of pancreatic cancer as compared with current smokers, with risks 
ranging from 1.1 to 1.6.2,7-11 Pancreatic cancer risk increases with both number of ciga-
rettes smoked daily3,5-8,12 and duration of smoking.3,5,8,10,11 After quitting cigarette 
smoking, the risk decreases gradually within 10 to 15 years towards unity.5,8,12,13 
 Data on the effect of passive smoking on pancreatic cancer risk is scarce because 
studies have been hindered by the relatively few non-smokers of any type of tobacco. 
Exclusion of tobacco smokers from such studies is important to estimate the indepen-
dent effect of passive smoking. Thus far, four case-control14-17 and four cohort stu-
dies7,9,18,19 have examined the relationship between passive smoking exposure and the 
risk of pancreatic cancer. Three of these studies observed a positive association with 
passive smoking in never smokers.7,15,18 
 In the current study, we examined active cigarette smoking, smoking cessation, 
and passive smoking as determinants for pancreatic cancer in a large prospective  
cohort study in the Netherlands. 
 
 
MATERIALS AND METHODS  
 
Study population and cancer follow-up  
The study design of the Netherlands Cohort Study has been reported in detail else-
where.20 Briefly, the Netherlands Cohort Study was begun in September 1986 and 
included initially 58,279 men and 62,573 women ages 55 to 69 years from 204 Dutch 
municipalities with computerized population registries. A self-administered food fre-
quency and lifestyle questionnaire was completed at baseline. For increased efficiency 
in the processing of the questionnaire and follow-up, the case-cohort approach was 
used.21 Incident cases were derived from the entire cohort, whereas the person-years 
at risk were estimated from a random sample of 5,000 subjects (2,411 men and 2,589 
women). This subcohort was chosen immediately after baseline and followed up for 
vital status information. The entire cohort is being monitored for cancer occurrence by 
annual record linkage to the Netherlands Cancer Registry and the Netherlands Pathol-
ogy Registry.22,23 A total of 16.3 years of follow-up (baseline to December 2002) was 
used for the current analysis. Only one subcohort member was lost to follow-up and 
completeness of follow-up was estimated to be >96%.24 
 All prevalent cancer cases at baseline other than skin cancer were excluded, re-
sulting in a subcohort of 4,774 men and women. Of the 567 incident pancreatic cancer 
cases (International Classification of Diseases for Oncology-3 code C25), cases with 
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endocrine subtypes (International Classification of Diseases for Oncology-3 code C25.4; 
n = 1) were excluded. Sixty-two percent of the 566 pancreatic cancer cases were    
microscopically confirmed pancreatic cancer (n = 350), whereas confirmation was 
lacking for 38% (non-microscopically confirmed pancreatic cancer; n = 216). Diagnosis 
of the latter group was made by the treating clinician and was based on clinical symp-
toms, physical examination, and imaging results. Data were abstracted and recorded 
by a trained tumor registrar.25 The Netherlands Cohort Study has been approved by 
the institutional review boards of the TNO Nutrition and Food Research Institute (Zeist, 
the Netherlands) and Maastricht University (Maastricht, the Netherlands). 
 
Exposure assessment 
In the questionnaire, tobacco smoking was addressed through questions on smoking 
status (never, former, or current smoker) and inhalation for cigarette, cigar, and pipe 
smokers.26,27 In addition, open-ended questions were asked on the ages at first and last 
exposure to smoking, smoking frequency, and smoking duration for cigarette, cigar, 
and pipe smokers. Furthermore, questions were asked about the cigarette brand most 
commonly smoked with or without filter-tip and the proportion of a cigarette actually 
smoked (using a visual analog scale).27 Using cigarette brand-specific information   
obtained from the Dutch Inspectorate for Health Protection, the Dutch Foundation on 
Smoking and Health, and the Dutch Foundation of the Tobacco Industry in combination 
with daily cigarette smoking frequency and the proportion of a cigarette actually 
smoked, we calculated the daily exposure to tar and nicotine for ever cigarette smok-
27 Passive smoking exposure was investigated using questions on smoking habits of 
parents and spouses, exposure to passive smoking at work (past or present), and dura-
tion of current daily exposure to passive smoking (open-ended question; private and 
occupational settings combined).27 The dietary section of the questionnaire was a 150-
item semiquantitative food frequency questionnaire. Questionnaire data were key-
entered and processed for all incident cases in the cohort and subcohort members in a 
standardized manner, blinded with respect to case/subcohort status. This was done to 
minimize observer bias in the coding and interpretation of the data. Subcohort mem-
bers and cases with incomplete or inconsistent dietary data were excluded from ana-
lyses. These subjects had either (i) left >60 (of the 150 items) questionnaire items 
blank and ate <35 items at least once a month or (ii) left one or more item blocks 
(groups of items, e.g., beverages) blank. Additional details are given elsewhere.28 This 
resulted in a final subcohort of 4,438 subjects (2,191 men and 2,247 women) and 520 
exocrine pancreatic cancer cases (280 men and 240 women) available for analysis.  
ers.
 
Statistical analysis 
Age-adjusted and multivariable-adjusted hazard rate ratios (HR) and corresponding 
95% confidence intervals (95% CI) were estimated using Cox proportional hazards 
models. The total person-years at risk estimated from the subcohort were used in the 
analyses.29 Standard errors were estimated using a robust covariance matrix estimator 
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to account for increased variance due to sampling from the cohort.30 We tested the 
proportional hazards assumption using the scaled Schoenfeld residuals.31 Interactions 
on a multiplicative scale between sex and any of the smoking variables used in the 
current study were tested for pancreatic cancer and never found to be statistically 
significant (p for interaction >0.05). Therefore, results for analyses on cigarette smok-
ing are presented for both sexes combined. No analyses were done on cigar and pipe 
smoking because among never cigarette smokers, only three cases ever smoked cigars 
or pipes. For passive smoking exposure, analyses were restricted to women (124 cases, 
1,312 subcohort members) who never smoked cigarettes, cigars, or pipes. We        
excluded men in these analyses because >90% of the men were ever smokers. 
 Based on questionnaire data, the following categorical variables were constructed 
for active cigarette smoking: status (former smoker/current smoker), frequency (0.1-
<10, 10-<20, ≥20 cigarettes/day), inhalation (no/yes), filter usage (fi lter-tipped/non-
filter-tipped), duration (0.1-<20, 20-<40, ≥40 years), time since cessation (quit ≥20, 15-
<20, 10-<15, 0.1-<10 years, or current smoker), and tar (0.1-<200, 200-<400, ≥400 
mg/day) and nicotine exposure (0.1-<10, 10-<20, 20-<30, ≥30 mg/day). HRs for pan-
creatic cancer were estimated accordingly, with subjects who never smoked cigarettes 
regarded as the reference group. HRs were also estimated for continuous exposures 
using an increment of 10 cigarettes per day for frequency. For duration and years since 
cessation, an increment of 10 years was used. For tar and nicotine exposure, we used 
an increment of 100 mg and 10 mg/day, respectively. Passive smoking exposure was 
operationalized in four separate variables: spouse smoking status (never smoked/ 
former smokers/current smokers), parental smoking (no/yes), exposure to passive 
smoking at work (never exposed/occasionally exposed/regularly or always exposed), 
and duration of passive smoking exposure (categorical variable: never, 0.1-<3, ≥3 
hours/day; continuous variable: increments of 1 hour/day).  
 Based on the literature, the following variables were considered as potential con-
founders: age, sex, body mass index (BMI), energy intake, alcohol intake, intake of 
vegetables and fruit, level of education, moderate non-occupational physical activity, 
family history of pancreatic cancer, history of diabetes mellitus, and hypertension. 
These potential confounding variables were added to the multivariable-adjusted mod-
el if they (i) were associated with the disease and with the exposure of interest and (ii) 
changed the risk estimate by at least 10% (using a backwards stepwise procedure). For 
analyses on cigarette smoking, the following confounders were included in the first 
multivariable-adjusted model: age at baseline (years), sex, BMI (kg/m2), alcohol intake 
(g/day), and intake of fruit (g/day). For analyses on passive smoking, the following 
confounders were included in the multivariable-adjusted model: age at baseline 
(years), BMI (kg/m2), and level of education (primary school or lower vocational 
school/intermediate vocational school or high school/higher vocational school or col-
lege). In additional analyses on cigarette smoking, we included smoking status, dura-
tion, and frequency simultaneously into the model to identify which factor of smoking 
in this model is most important to pancreatic cancer risk. In additional analyses on the 
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categorical variable of time since cessation, frequency and duration were included in 
the model. For the continuous variable of time since cessation, frequency, duration, 
and current smoking status (yes/no) were additionally included in the model. Further-
more, we investigated whether inhalation and filter usage had any effect on top of 
duration, frequency, and current smoking status. We also investigated this for tar and 
nicotine exposure; however, we did not include frequency in these models because the 
variables of tar and nicotine exposure were calculated by multiplying the number of 
cigarettes per day by the amount of tar and nicotine per cigarette. In additional ana-
lyses, we excluded cigar or pipe smokers. To enable comparison, age- and sex-adjusted 
analyses were restricted to subjects included in multivariable-adjusted analyses. For 
each analysis, trends were evaluated with the Wald test by assigning participants the 
median value for each level of the categorical exposure variable among the subcohort 
members and this variable was entered as a continuous term in the Cox regression 
model. For the trend analysis on cigarette smoking variables, never cigarette smokers 
were excluded to evaluate whether a large amount of exposure was measurably worse 
than a small amount of exposure. 
 In the present study, the overall analyses included all pancreatic cancer cases. We 
restricted additional analyses to microscopically confirmed pancreatic cancer cases to 
create a group with a higher degree of diagnostic certainty of pancreatic cancer, which 
was shown to be important in previous studies.32,33 In additional analyses, individuals 
who reported a history of diabetes at baseline (n = 185) were excluded. To evaluate 
whether early symptoms of disease before diagnosis could have influenced the results, 
early cases (diagnosed within 2 years after baseline) were excluded in additional ana-
lyses.  
 In addition, we calculated the population-attributable fraction (PAF) of pancreatic 
cancer cases to estimate how many cases theoretically could be prevented if no indi-
viduals would smoke. The PAF was calculated according to the following equation: PAF 
= Pd×([RR–1]/RR).
34,35 Pd is the proportion of smokers among all pancreatic cancer 
cases, and RR is the adjusted risk estimate of pancreatic cancer risk comparing ever 
versus never smokers. The confidence limits were estimated using: ln(1-PAF).34 All 
analyses were done using the STATA statistical software package (Intercooled STATA, 
version 9). All p values were based on two-sided tests and considered statistically sig-
nificant if p <0.05. 
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RESULTS 
 
In Table 7.1, baseline characteristics (stratified by sex) are presented. Most characte-
ristics did not differ between pancreatic cancer cases and subcohort members; how-
ever, there were more current smokers among cases than among subcohort members, 
especially in men.  
 
TABLE 7.1 Baseline characteristics (means or percent) of pancreatic cancer cases and subcohort members; 
Netherlands Cohort Study on diet and cancer (1986-2002) 
Characteristics Men  Women 
 
Total pancreatic 
cancer cases 
 
Subcohort 
 Total pancreatic 
cancer cases 
 
Subcohort 
n 280 2,191  240 2,247 
Age, mean ± SD (years) 62.0 ± 3.9 61.3 ± 4.2  62.5 ± 4.3 61.4 ± 4.3 
Use of tobacco products, n (%)      
 Never tobacco smoker 
Ever cigarette smoker 
Ever cigar smoker 
Ever pipe smoker 
Ever cigar and pipe smoker 
Ever cigarette and other type of tobacco 
smoker 
14 (5.0) 
181 (64.6) 
1 (0.4) 
2 (0.7) 
3 (1.1) 
 
79 (28.2) 
201 (9.2) 
1,322 (60.3) 
46 (2.1) 
8 (0.4) 
23 (1.0) 
 
591 (27.0) 
 124 (51.7) 
115 (47.9) 
- 
- 
- 
 
1 (0.4) 
1,312 (58.4) 
930 (41.4) 
- 
- 
- 
 
5 (0.2) 
Cigarette smoking features      
 Smoking status, n (%)      
  Never 
Former smoker 
Current smoker 
20 (7.1) 
128 (45.7) 
132 (47.2) 
278 (12.7) 
1,130 (51.6) 
783 (35.7) 
 124 (51.7) 
50 (20.8) 
66 (27.5) 
1,312 (58.4) 
463 (20.6) 
472 (21.0) 
 Duration*, mean ± SD (years) 36.1 ± 11.9 33.7 ±11.8  29.0 ± 12.2 27.8 ± 12.5 
 Frequency*, mean ± SD (cigarettes/day) 17.3 ± 11.5 17.0 ± 10.6  11.4 ± 8.0 11.4 ± 8.3 
 Age at first exposure*, mean ± SD (years) 17.3 ± 4.4 17.1 ± 3.8  23.3 ± 7.7 23.7 ± 8.9 
 Age at cessation*, mean ± SD (years) 48.2 ± 11.0 46.6 ± 10.2  49.2 ± 10.3 46.8 ± 11.1 
 Years since cessation*, mean ± SD 7.0 ± 10.4 8.8 ± 10.4  5.9 ± 9.7 7.0 ± 10.3 
 Inhalation*, n (%)      
  No 
Yes  
57 (23.0) 
191 (77.0) 
385 (20.7) 
1,478 (79.3) 
 57 (49.6) 
58 (50.4) 
424 (46.5) 
487 (53.5) 
 Filter usage*, n (%)      
  Filter-tipped 
Non-filter-tipped 
40 (20.9) 
151 (79.1) 
244 (17.4) 
1,158 (82.6) 
 68 (70.8) 
28 (29.2) 
530 (72.0) 
206 (28.0) 
 Tar*, mean ± SD (mg/day) 357.3 ± 237.3 348.0 ± 227.2  165.4 ± 149.1 156.8 ± 148.5 
 Nicotine*, mean ± SD (mg/day) 31.3 ± 25.7 30.2 ± 24.3  12.5 ± 11.1 12.3 ± 11.4 
Passive smoking†      
 Spouse smoking status, n (%)      
  Never 
Ever 
12 (92.3) 
1 (7.7) 
128 (69.2) 
57 (30.8) 
 21 (18.9) 
90 (81.1) 
182 (15.8) 
972 (84.2) 
 Parental smoking, n (%)      
  No parent smoked 
One or both parents smoked  
1 (7.1) 
13 (92.9) 
47 (24.0) 
149 (76.0) 
 20 (16.5) 
101 (83.5) 
193 (15.2) 
1,079 (84.8) 
 Passive smoking exposure at work (past or present), n (%)     
  Low exposure 
High exposure 
5 (41.7) 
7 (58.3) 
97 (53.3) 
85 (46.7) 
 64 (71.1) 
26 (28.9) 
578 (60.0) 
386 (40.0) 
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TABLE 7.1 continued      
  Men  Women 
  Total pancreatic 
cancer cases 
 
Subcohort 
 Total pancreatic 
cancer cases 
 
Subcohort 
 Duration current passive smoking expo-
sure, mean ± SD (hours/day) 
 
8.2 ± 4.7 
 
3.7 ± 4.1 
  
4.7 ± 5.5 
 
4.4 ± 4.7 
BMI, mean ± SD (kg/m2) 25.2 ± 3.0 25.0 ± 2.6  25.5 ± 3.6 25.1 ± 3.6 
Physical activity (non-occupational), n (%)      
  <30 min/day 
30-60 min/day  
60-90 min/day 
>90 min/day 
50 (17.9) 
94 (33.6) 
66 (23.6) 
70 (25.0) 
396 (18.3) 
675 (31.2) 
405 (18.7) 
689 (31.8) 
 57 (23.9) 
77 (32.2) 
62 (25.9) 
43 (18.0) 
553 (24.9) 
691 (31.2) 
498 (22.5) 
476 (21.5) 
Family history of pancreatic cancer, n (%) 5 (1.8) 22 (1.0)  9 (3.8) 20 (0.9) 
History of diabetes, n (%) 21 (7.5) 75 (3.4)  10 (4.2) 80 (3.6) 
History of hypertension, n (%) 58 (20.7) 512 (23.4)  73 (30.4) 662 (29.5) 
Level of education, n (%)      
  Low 
Medium  
High 
132 (47.5) 
89 (32.0) 
57 (20.5) 
997 (45.7) 
775 (35.6) 
408 (18.7) 
 137 (57.3) 
83 (34.7) 
19 (8.0) 
1,266 (56.7) 
771 (34.5) 
197 (8.8) 
Daily intake, mean ± SD      
 Energy (kcal) 2,164 ± 466 2,166 ± 511  1,688 ± 397 1,686 ± 398 
 Total carbohydrates‡ (g) 224.0 ± 38.5 226.7 ± 37.5  177.3 ± 26.8 178.8 ± 26.7 
 Total fat‡ (g) 92.7 ± 13.4 93.9 ± 14.3  74.1 ± 10.9 74.0 ± 10.3 
 Alcohol (g) 18.0 ± 19.2 15.0 ±16.8  6.6 ± 10.3 5.9 ± 9.5 
 Vegetables (g) 192.8 ± 86.1 191.6 ± 84.9  205.1 ± 85.4 195.5 ± 81.3 
 Fruit (g) 148.6 ± 120.6 154.0 ± 114.1  192.6 ± 107.8 196.4 ± 121.1 
*Never smokers excluded. †Ever smokers excluded. ‡Energy-adjusted intake. 
 
 Compared with never cigarette smokers, both former and current cigarette 
smokers had an increased pancreatic cancer risk (age-adjusted HR = 1.37, 95% CI: 1.05-
1.78 and HR = 1.88, 95% CI: 1.44-2.44, respectively; Table 7.2). We observed an     
increased pancreatic cancer risk of 51% (95% CI: 1.12-2.04) with smoking ≥20 ciga-
rettes/day compared with never cigarette smoking (Table 7.2), but no clear dose-
response relation was present (p for trend = 0.96). Smokers smoking one package per 
day (i.e., 20 cigarettes/day) had a similar risk, showing an increased risk of 49% (95% 
CI: 1.05-2.12; data not shown). Most pancreatic cancer cases smoked <40 ciga-
rettes/day; only 15 cases smoked ≥40 cigarettes. For duration of smoking, we observed 
a significantly increased pancreatic cancer risk per increment of 10 years (age-adjusted 
HR = 1.15, 95% CI: 1.08-1.22; Table 7.2), with a clear dose-response effect observing a 
2-fold increased cancer risk comparing ≥40 years of smoking to never cigarette smok-
ing. Quitting smoking gradually reduced the risk of pancreatic cancer and approached 
unity after ≥20 years of quitting smoking (Table 7.2). 
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TABLE 7.2 Age- and sex-adjusted and multivariable-adjusted HRs for pancreatic cancer according to cigarette 
smoking status, frequency, duration and time since cessation (categorical and continuous analyses); Nether-
lands Cohort Study on Diet and Cancer (1986-2002) 
All pancreatic cancer cases 
Cigarette smoking variable   Age- and sex- 
adjusted 
Multivariable- 
adjusted†  Person-
years* 
No. of  
cases* HR (95% CI) HR (95% CI) 
Smoking status     
 Never‡ 22,003 130 1.00 1.00 
 Former smoker 20,383 165 1.37 (1.05-1.78) 1.34 (1.02-1.75) 
 Current smoker 14,782 155 1.88 (1.44-2.44) 1.82 (1.40-2.38) 
Frequency (cigarettes/day)     
 Never‡ 22,003 130 1.00 1.00 
 0.1-<10 10,103 83 1.42 (1.05-1.91) 1.43 (1.06-1.93) 
 10-<20 12,068 129 1.89 (1.42-2.52) 1.83 (1.37-2.45) 
 ≥20 12,993 108 1.51 (1.12-2.04) 1.38 (1.01-1.87) 
 p for trend§   0.96 0.55 
 Continuous (increment of 10 cigarettes/day) 1.12 (1.03-1.23) 1.08 (0.98-1.19) 
Duration (years)     
 Never‡ 22,003 130 1.00 1.00 
 0.1-<20 6,693 47 1.29 (0.90-1.86) 1.30 (0.90-1.86) 
 20-<40 16,965 130 1.41 (1.07-1.86) 1.38 (1.04-1.83) 
 ≥40 11,507 143 2.13 (1.61-2.82) 2.03 (1.53-2.70) 
 p for trend§   0.01 0.02 
 Continuous (increment of 10 years)  1.16 (1.09-1.23) 1.15 (1.08-1.22) 
Time since cessation     
 Never‡ 22,003 130 1.00 1.00 
 Quit ≥20 years 6,311 45 1.17 (0.81-1.71) 1.19 (0.81-1.73) 
 Quit 15-<20 years 3,073 27 1.43 (0.89-2.27) 1.42 (0.89-2.27) 
 Quit 10-<15 years 3,890 32 1.45 (0.95-2.22) 1.42 (0.92-2.18) 
 Quit 0.1-<10 years 7,055 61 1.49 (1.06-2.08) 1.41 (1.00-1.98) 
 Current smoker 14,782 155 1.88 (1.45-2.44) 1.83 (1.40-2.39) 
 Continuous (increment of 10 years)§  0.85 (0.75-0.97) 0.87 (0.76-0.99) 
*Number of cases and person-years do not add up to the total number because of missing values for cova-
riables. †Adjusted for age, sex, fruit intake (g/day), BMI (kg/m2), and alcohol intake (g/day). ‡Reference 
group: never cigarette smokers. §Never cigarette smokers excluded. 
 
 Our findings remained after the inclusion of the confounding variables in the mul-
tivariable model (Table 7.2). However, results were modified when smoking variables 
were included simultaneously into the model. The increased risk estimates observed 
for current smoking status, frequency, and years of cessation diminished and became 
non-significant after including other aspects of smoking in the model (data not shown). 
However, additional adjustment for other smoking aspects had little influence on the 
risk estimates of years of smoking cigarettes, showing just slightly attenuated HRs 
compared with the age- and sex-adjusted and the multivariable-adjusted HRs (data not 
shown). 
 It made little difference whether subjects did or did not inhale cigarette smoke; 
we observed in both situations a significantly increased pancreatic cancer risk after 
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adjustment for age and sex (Table 7.3). In addition, both filter-tipped and non-filter-
tipped cigarettes significantly increased pancreatic cancer risk. Exposure to tar and 
nicotine significantly increased pancreatic cancer risk, but did not show dose-
dependent relations (p for trend >0.05). After inclusion of the confounding variables 
and the smoking variables duration, current smoking status, and frequency (frequency 
was only included in the models on inhalation and filter usage), the increased pancrea-
tic cancer risks disappeared (Table 7.3). 
 
TABLE 7.3 Age- and sex-adjusted and multivariable-adjusted HRs for pancreatic cancer according to inhala-
tion, filter usage, and tar and nicotine exposure to cigarettes (categorical and continuous analyses); Nether-
lands Cohort Study on Diet and Cancer (1986-2002) 
All pancreatic cancer cases 
Exposure variable   Age- and sex- 
adjusted 
Multivariable- 
adjusted†  Person-
years* 
No. of  
cases* HR (95% CI) HR (95% CI) 
Inhalation     
 Never† 22,003 130 1.00 1.00‡ 
 No 10,010 96 1.63 (1.23-2.17) 1.16 (0.75-1.81) 
 Yes 24,870 219 1.58 (1.22-2.06) 1.06 (0.64-1.78) 
Filter usage     
 Never† 22,003 130 1.00 1.00‡ 
 Filter-tipped 9,756 93 1.74 (1.31-2.32) 1.06 (0.64-1.76) 
 Non-filter-tipped 16,701 155 1.61 (1.19-2.18) 1.02 (0.58-1.79) 
Tar (mg/day)     
 Never† 22,003 130 1.00 1.00§ 
 0.1-<200 9,406 91 1.72 (1.28-2.30) 0.88 (0.49-1.56) 
 200-<400 6,616 65 1.75 (1.24-2.47) 0.77 (0.37-1.62) 
 ≥400 5,089 53 1.85 (1.25-2.73) 0.79 (0.34-1.86) 
 p for trend║   0.95 0.60 
 Continuous (increment of 100 mg/day)  1.08 (1.03-1.14) 1.05 (0.92-1.20) 
Nicotine (mg/day)     
 Never† 22,003 130 1.00 1.00§ 
 0.1-<10 6,078 53 1.55 (1.10-2.19) 0.87 (0.48-1.56) 
 10-<20 4,973 49 1.78 (1.22-2.58) 0.94 (0.47-1.88) 
 20-<30 3,752 41 1.97 (1.32-2.92) 0.99 (0.45-2.20) 
 ≥30 6,407 67 1.88 (1.30-2.70) 0.96 (0.42-2.19) 
 p for trend║   0.59 0.96 
 Continuous (increment of 10 mg/day)  0.85 (0.75-0.97) 1.07 (1.02-1.12) 
*Number of cases and person-years do not add up to the total number because of missing values for cova-
riables. †Reference group: never cigarette smokers. ‡Adjusted for age, sex, fruit intake (g/day), BMI (kg/m2), 
alcohol intake (g/day), frequency (cigarettes/day), duration (years), and current smoking status (yes/no). 
§Adjusted for age, sex, fruit intake (g/day), BMI (kg/m2), alcohol intake (g/day), duration (years), and current 
smoking status (yes/no). ║Never cigarette smokers excluded. 
 
 When the association between the abovementioned cigarette smoking variables 
and pancreatic cancer risk were examined for men and women separately (data not 
shown), the risk estimates seemed to be stronger in men than in women. However, 
only 7% (n = 19) of the male cases never smoked cigarettes. Excluding non-
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microscopically confirmed pancreatic cancer cases did not change the risk estimates 
appreciably (data not shown). Also, risk estimates were not affected when excluding 
current cigar or pipe smokers (43 cases, 342 subcohort members) except for former 
smokers who still showed an increased but non-significant pancreatic cancer risk (mul-
tivariable-adjusted HR = 1.25, 95% CI: 0.94-1.66). The PAF of pancreatic cancer due to 
ever smoking for men and women combined was estimated as 27% (95% CI: 15-37), 
using a HR which was adjusted for age, sex, fruit intake, BMI, and alcohol intake (HR = 
1.58, 95% CI: 1.25-2.01). Stratified by sex, the PAF of pancreatic cancer due to ever 
smoking was estimated as 46% (95% CI: 17-65) for men and as 16% (95% CI: 5-27) for 
women. 
 Regarding passive smoking in women, after adjusting for age, we observed no 
association between pancreatic cancer risk  and smoking status from the spouse,   
parental smoking, being exposed at work to passive smoking (past or present), or dura-
tion of current passive smoking exposure (both in occupational and private setting; 
Table 7.4). Results were similar when including confounders into the model (Table 7.4) 
or when restricting the analyses to microscopically verified cases (data not shown). Our 
findings remained the same after excluding individuals who reported a history of   
diabetes at baseline from the analyses or after excluding the first 2 years of follow-up 
(data not shown). 
 
TABLE 7.4 Age-adjusted and multivariable-adjusted HRs for pancreatic cancer according to passive smoking 
exposure in never-smoking women; Netherlands Cohort Study on Diet and Cancer (1986-2002) 
All pancreatic cancer cases 
Passive smoking   Age- and sex- 
adjusted 
Multivariable- 
adjusted†  Person-
years* 
No. of  
cases* HR (95% CI) HR (95% CI) 
Spouse smoking status     
 Never‡ 2,625 20 1.00 1.00 
 Former smoker 8,055 46 0.72 (0.41-1.26) 0.67 (0.38-1.17) 
 Current smoker 6,198 42 0.87 (0.49-1.53) 0.78 (0.44-1.39) 
Parental smoking     
 No parents smoked‡ 2,815 20 1.00 1.00 
 One or both parents smoked 15,645 97 0.91 (0.55-1.50) 0.90 (0.54-1.50) 
Passive smoking exposure at work (past or present)   
 Never‡ 3,943 28 1.00 1.00 
 Occasionally exposed 4,611 34 1.10 (0.64-1.86) 1.08 (0.64-1.84) 
 Regularly or always exposed 5,600 25 0.64 (0.36-1.12) 0.61 (0.34-1.07) 
Duration current passive smoking exposure (hours/day; occupational and private)  
 No exposure‡ 5,463 34 1.00 1.00 
 >0-<3 4,969 35 1.14 (0.70-1.87) 1.14 (0.70-1.88) 
 ≥3 4,698 32 1.17 (0.70-1.95) 1.07 (0.64-1.80) 
 p for trend   0.64 0.93 
 Continuous (increment of 1 hour/day)  0.85 (0.75-0.97) 1.02 (0.98-1.07) 
*Missing values for passive smoking characteristics gave rise to diminished numbers of person-years and 
pancreatic cancer cases for the different passive smoking variables. †Adjusted for age, BMI (kg/m2), and level 
of education (primary school or lower vocational school/intermediate, vocational school or high school/ 
higher vocational school or college). ‡Reference group. 
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DISCUSSION 
 
In the current analysis, we observed an 80% increased risk of pancreatic cancer for 
current smokers compared with never cigarette smokers, which is in agreement with 
other studies.3-5,7-11,36 In addition, we observed an increased pancreatic cancer risk for 
former smokers compared with never smokers and for incremental increases in num-
ber of years smoked, as found in previous research.8,10,11,37 For cigarettes smoked per 
day, we observed an increased risk as well; however, the magnitude was less strong 
than in other cohort studies observing 2- to 3-fold increased risks for ≥20 ciga-
rettes/day.5,7-9,12 Based on the current study, 27% of pancreatic cancer cases could 
hypothetically be prevented if people would not smoke. Similar estimates were found 
in previous studies (24%,37 25%,12 and 27%10). A few studies, however, found lower 
PAF values (15%5 and 7%38). This might be due to the fact that the PAF is very depen-
dent on the prevalence of smoking in a population. This was also shown when we  
estimated the PAF separately for men and women, observing a PAF of 46% for men 
(93% ever smokers among male cases) and of 16% for women (50% ever smokers 
among female cases). 
 After ≥20 years of quitting smoking, pancreatic cancer risk approached the risk of 
never smokers. This was observed by one previous cohort as well,8 whereas other 
studies observed risk estimates similar to never smokers after 5 to 10 years.7,12,13,36 A 
pooled cohort analysis observed a risk similar to that of never smokers after 15 years 
of cessation.5 
 It is not yet clear how the risk of pancreatic cancer is affected by different aspects 
of smoking behavior. When we investigated which smoking aspect was most important 
in pancreatic cancer etiology by including smoking variables simultaneously in the 
model, only duration had a significant effect on pancreatic cancer risk. Accordingly, we 
concluded that duration seemed to affect pancreatic cancer risk the most in our    
cohort. 
 Not many studies included other aspects of smoking factors into a model, when 
examining smoking in relation to pancreatic cancer. Of the few studies that included 
smoking factors simultaneously in the model, however, all used a different model. 
Lynch et al.5 adjusted for years of cessation in the analysis on number of cigarettes and 
duration, observing for both smoking factors an increased pancreatic cancer risk. Fuchs 
et al.12 and Vrieling et al.7 corrected for pack-years investigating the relation with time 
since quitting, observing risks comparable to that of never smokers after ≥10 and ≥5 
years of quitting smoking, respectively. Vrieling et al.7 also corrected for pack-years in 
the analyses on number of cigarettes and duration, observing similar risk estimates as 
for the model not including pack-years: a significant increased pancreatic cancer risk 
for number of cigarettes in current smokers, but no association for duration in current 
and former smokers. Jee et al.37 corrected in a similar way we did, by including dura-
tion and frequency simultaneously in a model of current smokers. However, their  
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results were different from ours: they observed a clear dose-response relation for 
frequency, but no association with duration in their Korean population. 
 However, when highly intercorrelated smoking factors are included simultaneous-
ly into a model, the problem of multi-collinearity may arise.39 In our analyses, some of 
the confidence intervals widened because some of the smoking variables were highly 
correlated (e.g., correlation of quitting smoking and duration = -0.71), which indicates 
that multi-collinearity might have played a role to a certain degree. 
 After adjustment for duration, frequency, and smoking status, no association was 
observed for filter usage, inhalation, and exposure to tar and nicotine. Silverman et 
al.10 observed an approximately 50% increased risk both for filter- and non-filter-
tipped cigarettes compared with non-smokers. Although they did not adjust for fre-
quency or duration. As far as we know, no previous studies investigating pancreatic 
cancer risk in relation to nicotine and tar exposure have been conducted. For lung 
cancer, most epidemiologic studies showed an increased lung cancer risk after expo-
sure to tar, including studies that adjusted for number of cigarettes smoked per day 
and duration of smoking.40 
 The amounts of nicotine and tar were established using a smoking machine and 
were, besides the amount of nicotine in tobacco, dependent on cigarette design fea-
tures such as type of filter, combustion rate, and paper porosity.41 The amount of nico-
tine to which a smoker is exposed is mainly dependent on the smoking behavior of the 
individual smoker, which is always focused on reaching a nicotine level in the blood 
that is satisfying for a smoker. Therefore, filter cigarettes or less nicotine per cigarette 
will probably lead to deeper inhalation, more cigarettes per day, or blocking the vents 
in the filter of a filter cigarette with the fingers or lips to establish the desired nicotine 
levels in the blood.41 This means that the exposure to tar and nicotine used in the 
present study, which were established by a smoking machine, might not reflect the 
real dose that the subjects in our cohort were exposed to. This may have influenced 
(most probably underestimated) our results. However, subjects smoking filter-tipped 
cigarettes were far less heavy smokers (≥20 cigarettes/day) than non-filter-tipped 
smokers (26.8% versus 43.8%, respectively). 
 It is not clear yet when smoking exerts its effects on the pancreatic carcinogenic 
process.1 Our smoking cessation results, together with results from other stu-
dies,5,8,10,12,38 might support more a late-stage mechanistic effect. However, we do not 
know the minimal time required for the carcinogenic process to occur for pancreatic 
cancer; it could take place in a relatively short amount of time.1 
 Despite the fact that smoking is an established risk factor for pancreatic cancer, 
the mechanism behind this causal relation remains unclear. Nicotine itself is not carci-
nogenic; however, it is very addictive, resulting in a continuous exposure to a mixture 
of known (and unknown) carcinogens.42 The only pancreatic carcinogens known to be 
present in tobacco products are 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) 
and its metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol.42 NNK induced   
tumors of the pancreas when administered in drinking water to rats,43 and autopsy 
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studies have shown substantial pancreatic tissue damage among smokers compared 
with non-smokers.44 In addition, NNK levels in the pancreatic cancer juice of smokers 
were significantly higher than those in the juice of non-smokers.45 Regarding tar, expe-
rimental evidence showed that tobacco tar could induce skin cancer in mice and rab-
bits.46 
 It has been hypothesized that the solvent properties of alcohol may enhance the 
effects of exposure to carcinogens in tobacco.47 In a previous report, we reported that 
current smokers who consumed ≥30 g of ethanol/day experienced a HR of 2.4 (95% CI: 
1.06-5.41) compared with abstainers who never smoked, when we investigated the 
interaction between ethanol intake and cigarette smoking.48 However, the interaction 
term was not found to be significant (p for interaction = 0.97). 
 Similar to other previous studies,9,14,16,17,19 we did not find any association be-
tween passive smoking exposure and pancreatic cancer risk. However, three previous 
studies did observe a positive association for passive smoking. A prospective study in 
women, investigating both adult passive exposure and exposure during childhood, 
observed an increased risk only for maternal smoking (RR = 1.52, 95% CI: 0.97-2.39).18 
A small Egyptian case-control study observed a positive association between adult 
passive exposure and pancreatic cancer risk.15 And a prospective study among Euro-
peans observed an increased pancreatic cancer risk among never smokers who were 
exposed during childhood to passive smoking on a daily basis (HR = 2.61, 95% CI: 0.96-
7.10) and a borderline statistically significant 54% increased risk for never   smokers 
exposed to passive smoking at home and/or at work.7 
 Environmental tobacco smoke is composed of sidestream smoke released by the 
burning tip of a cigarette or other smoking device and of mainstream smoke exhaled 
by the smoker.49 Sidestream smoke is the main component of this mixture and con-
tains many of the same toxic constituents as mainstream smoke inhaled by smokers. 
However, sidestream smoke dilutes quickly; consequently, exposures to non-smokers 
are much lower than to smokers.49 Studies have shown that non-smokers exposed to 
passive smoke take up and metabolize NNK, which provides experimental support for 
the hypothesis that passive smoking can cause smoking-related cancer.50 In addition, 
pooled analyses showed that spousal and workplace exposure to passive smoking was 
associated with a 20 to 25% excess risk of lung cancer.51 
 In the current analysis, we were unable to adequately investigate pipe and cigar 
smoking because among never cigarettes smokers, only three cases ever smoked  
cigars or pipes and just 1.7% of all subcohort members smoked cigars or pipes only. Of 
the studies that have investigated pipe and cigar smoking in relation to pancreatic 
cancer,3,14,52 only three studies have been able to investigate pipe and cigar smoking 
separately, excluded lifelong cigarette smokers, or have been able to stratify by fre-
quency or duration of pipe or cigar smoking.14,52-54 Pooled estimates for pipe smoking 
showed a non-significantly increased pancreatic cancer risk of 39% whereas for cigar 
smoking, a significantly increased risk of 53% was observed.3 
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The case-cohort approach was used because this is a more efficient design compared 
with a full-cohort analysis in which all questionnaires have to be entered before the 
analyses could be performed, whereas in the case-cohort approach, only the data for 
cases and subcohort members need to be entered. In our situation, this was most 
profitable because our questionnaire is very detailed and only the first page could be 
optically scanned. Also, another advantage is that exposure data can be processed 
during rather than after case ascertainment in comparison with a nested case-control 
design. One of the limitations of the case-cohort design is that the variance estimates 
will not be as small as compared with a full cohort analysis, leading to slightly larger 
confidence intervals. Another disadvantage might be the difficulty of analyzing data in 
a case-cohort study; however, more and more statistical software packages, such as 
the statistical package we used (Intercooled STATA, version 9), which contains soft-
ware for analysis of case-cohort data, are becoming available. 
 One of the limitations regarding the analysis on passive smoking is that we were 
unable to perform the analysis using individuals never exposed in any way to smoking 
as reference group, as only one female case was never exposed to smoke. In addition, 
misclassification could have occurred because we did not have any information on the 
number of smokers and of cigarettes smoked, room volume, ventilation, and duration 
of the different exposures.49 Future studies should incorporate a more comprehensive 
and more accurate measure of passive smoking exposure. Another limitation of our 
study is that no information was collected about changes in cigarette smoking status 
during the follow-up period. After years of declining, especially among men, smoking 
rates leveled off in the late 1980s and have not changed until 2000.55 Few people ages 
≥50 years will start smoking, but more people will quit while ageing.55 A substantial 
proportion of the cohort members might have stopped smoking during the 16 years of 
follow-up, although they would still be classified as current smokers in the current 
analysis. This may have resulted in an underestimation of the smoking effect. 
 The possibility to further restrict the analyses to microscopically verified cases 
only, in which misclassification by disease status would be less likely than among non-
microscopically confirmed pancreatic cancer cases,32 was one of the strengths of this 
study. Other strengths include the large sample size and detailed information on   
potential risk factors of pancreatic cancer. Differential follow-up is unlikely to have 
made a material contribution to our findings because the completeness of follow-up 
was high.24 The prospective design avoided recall bias and the need to use next-of-kin 
respondents. 
 In summary, our findings confirmed that cigarette smoking is an important risk 
factor for pancreatic cancer, whereas quitting smoking reduced risk. Therefore from a 
public health perspective, quitting smoking could decrease the incidence of pancreatic 
cancer. On the other hand, we did not observe any association between passive smok-
ing exposure and pancreatic cancer risk in women. 
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In this chapter, we will discuss the main findings on the associations between pancrea-
tic cancer risk and the lifestyle factors investigated in the current thesis in light of the 
existing literature. Additionally, we will discuss the literature regarding mechanistic 
evidence and we will make a final conclusion on the strength of the evidence – both 
epidemiological and mechanistic – so far. Furthermore, we will discuss some important 
strengths and weaknesses of the study design of the Netherlands Cohort Study (NLCS) 
and the analyses performed in this thesis. Finally, recommendations for future epide-
miological research are given. 
 
 
MAIN FINDINGS  
In this thesis, we investigated several hypotheses regarding lifestyle factors, including 
dietary factors in the NLCS. A modest decreased pancreatic cancer risk has been ob-
served in participants who have participated in sports during the past but not for other 
types of physical activity (Chapter 2). Findings with respect to proxies for energy re-
striction did not support our hypothesis that energy restriction may reduce pancreatic 
cancer risk (Chapter 2). Regarding alcohol intake, a low-to-moderate intake was not 
associated with pancreatic cancer risk, but a high alcohol intake (≥30 g of ethanol/day) 
increased pancreatic cancer risk with 57% (Chapter 3). No association was observed 
between the intake of specific beverage types and pancreatic cancer risk apart from 
alcohol. Also, no association was observed with other dietary factors investigated in 
this thesis, including glycemic index (GI), glycemic load (GL), intake of carbohydrates, 
meat, fat, vegetables, fruits, carotenoids, and vitamins C and E (Chapter 4-6). For   
active cigarette smoking we observed a 2-fold increased risk, whereas quitting smoking 
reduced pancreatic cancer risk and approached the risk of never smokers after ≥20 
years of quitting smoking (Chapter 7). No association was observed with passive smok-
ing. All the above mentioned findings were based on all pancreatic cancer cases. When 
we restricted the analyses to microscopically verified pancreatic cancer cases, to 
create a group with a higher degree of diagnostic certainty of pancreatic cancer,    
results were similar to the findings described above. 
 
Evaluation evidence on risk factors for pancreatic cancer  
In the sections below, we will summarize the strength of the evidence, both epidemio-
logical and mechanistic, for the lifestyle factors that were investigated in this thesis. 
Additionally, we will make a final conclusion on the strength of the evidence so far, by 
using 5 levels of judgment: “convincing”, “probable”, “limited – suggestive”, “limited – 
no conclusion”, or “unlikely” cause of pancreatic cancer (see Table 8.1). The criteria we 
used to grade the evidence are presented in the footnote of Table 8.1.1 
Discussion 
 
151 
 
TABLE 8.1 Judgment of evidence for causality for lifestyle factors, including dietary factors 
Risk factors Levels of evidence 
 Increased risk Decreased risk 
Environmental and lifestyle factors    
 Cigarette smoking Convincing  
 Passive smoking Limited – no conclusion  
 Physical activity  Limited – suggestive 
   
Diet   
 Energy restriction  Limited – no conclusion 
 Glycemic index and glycemic load Unlikely  
 Alcohol Probable  
 Carbohydrates Unlikely  
 Meat Unlikely  
 Fat Unlikely  
 Vegetables  Unlikely 
 Fruits  Unlikely 
 Vitamins C and E and carotenoids  Limited – no conclusion 
Convincing: evidence for a relation is “convincing” if there is evidence from more than one study type, if the 
majority of independent cohort studies showed a relation with a consistent direction of effect, if evidence 
comes from good quality studies to exclude the possibility that the observed association results from ran-
dom or systematic errors, or if there is strong evidence for biological plausibility. 
Probable: evidence for a relation is “probable” if there is evidence from at least two independent cohort 
studies or at least five case-control studies that showed a relation with a consistent direction of effect, if 
evidence comes from good quality studies to exclude the possibility that the observed association results 
from random or systematic errors, or if there is evidence for biological plausibility. 
Limited – suggestive: evidence for a relation is “limited – suggestive” if there is evidence from at least two 
independent cohort studies or at least five case-control studies that showed a relation with a generally 
consistent direction of effect or if there is evidence for biological plausibility. 
Limited – no conclusion: evidence for a relation is “limited – no conclusion” if epidemiological studies 
showed inconsistent effects, if evidence comes from studies of poor quality, or if number of studies available 
are too low to reach a conclusion at this time point.  
Unlikely: evidence for a relation is “unlikely” if there is evidence from more than one study type, if the 
majority of independent cohort studies showed an effect close to 1.0, if evidence comes from good quality 
studies to exclude the possibility that the observed association results from random or systematic errors, or 
if there is absence of biological plausibility.1 
 
In our final judgments, more emphasize will be put on evidence from epidemiological 
data than on mechanistic evidence because it is difficult to extrapolate data from ani-
mal and in vitro studies to humans.2 These difficulties include the fact that the Interna-
tional Agency for Research on Cancer was unable to classify many substances as carci-
nogenic to humans due to insufficient evidence whereas many of these substances 
were shown to be carcinogenic in rodents.2 Also, in most used animal models of pan-
creatic carcinogenesis the induced tumors do not closely resemble the human tumors.3 
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Active cigarette smoking and passive smoking 
Mechanistic evidence 
The mechanism behind the relation between active smoking and pancreatic cancer 
remains unclear. Nicotine itself is not carcinogenic; however, it is very addictive, which 
results in a regular use of tobacco and hence in a continuous exposure of human tis-
sues to a mixture of known (and unknown) carcinogens.4 Two pancreatic carcinogens 
are known to be present in tobacco products: 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) and its metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL).4,5 NNK and NNAL induced tumors of the pancreas when administered in drink-
ing water to rats,5 and autopsy studies have shown substantial pancreatic tissue dam-
age among smokers compared with non-smokers.6 In addition, NNK levels in pancrea-
tic cancer juice of smokers were shown to be significantly higher than those in juice of 
non-smokers.7 
 It is not clear yet when smoking exerts its effects on pancreatic carcinogenic 
process.8 Our smoking cessation results together with results from other studies,9-12 
might support more a late-stage mechanistic effect. However, we do not know the 
minimal time required for the carcinogenic process to occur for pancreatic cancer; it 
could take place in a relatively short period of time.8 
 Environmental tobacco smoke is mainly composed of sidestream smoke and con-
tains many of the same toxic constituents as mainstream smoke inhaled by smokers.13 
However, sidestream smoke dilutes quickly; consequently exposure to non-smokers is 
much lower than to smokers.13 Studies have shown that non-smokers exposed to pas-
sive smoke take up and metabolize NNK, which provides experimental support for the 
hypothesis that passive smoking can cause smoking-related cancer.14  
 
Epidemiological evidence 
A meta-analysis indicated that current cigarette smokers have about a 2-fold increased 
pancreatic cancer risk compared with never smokers.15 For cohort studies, a pooled 
estimate of 1.70 (95% confidence interval [CI]: 1.53-1.90; n = 26) and for case-control 
studies a pooled estimate of 1.77 (95% CI: 1.59-1.97; n = 33) was observed. We could 
confirm this finding in the NLCS, were an 80% increased risk of pancreatic cancer for 
current cigarette smokers compared with never cigarette smokers was observed. In 
addition, we observed an increased pancreatic cancer risk for former cigarette smokers 
compared with never smokers and per increment of 10 years of smoking, as found in 
previous research.12,15 For cigarettes smoked per day we observed an increased risk as 
well, however, the magnitude was less strong than in other cohort studies observing 2- 
to 3-fold increased risks for ≥20 cigarettes/day.9-11,16,17 Studies, including our study, 
showed that quitting smoking reduced pancreatic cancer risk, although the time period 
in which levels were approaching the risk of never smokers differed across these stu-
dies ranging from 5 to 20 years.9,10,17 
 Similar to previous epidemiological studies,16,18,19 we did not observe an associa-
tion between passive smoking exposure and the risk of pancreatic cancer. On the other 
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hand, three studies did observe a positive association with passive smoking in never 
smokers.17,20,21 Misclassification in our and other studies could have occurred, howev-
er, because no information on number of smokers and of cigarettes smoked, room 
volume, ventilation, and duration of the different exposures were available.13 
 
Conclusion 
Judging the evidence, we conclude that there is convincing evidence from both epide-
miological and mechanistic studies that active cigarette smoking is a risk factor for 
pancreatic cancer (Table 8.1). In addition, quitting smoking reduces pancreatic cancer 
risk. Mechanistic evidence seem to support the hypothesis that passive smoking    
increases pancreatic cancer risk; however, results from epidemiological studies are too 
inconsistent to allow conclusions to be reached. 
 
Physical activity 
Mechanistic evidence 
Even though the mechanism underlying the possible relation between pancreatic can-
cer risk and physical activity is not clear, it has been suggested that insulin and the 
insulin-like growth factor (IGF) axis might play a role. Human intervention studies 
showed that a short bout of exercise increases IGF-1 levels, whereas regular exercise 
(“training”), leading to a negative energy balance, seems to lower IGF-1 levels.22 Also, 
studies have shown that higher physical activity levels reduce insulin resistance.1,22 
Experimental studies showed that insulin acts as a growth promoter and mitogen in 
the pancreas.23,24 Furthermore, excess insulin can increase growth hormone receptor 
levels in the liver which is a key stimulator of IGF-1 production.22 Also, insulin can 
downregulate IGF binding proteins (IGBPs), which would result in more bioavailable 
IGF-1. IGF-1 can then bind to IGF-1 receptor (IGF-1R), activating intracellular signaling 
pathways which could lead to increased proliferation in pancreatic cancer cell lines.22,25 
Observational studies on pancreatic cancer suggest that high insulin concentrations, 
glucose intolerance and insulin resistance may play a role in pancreatic carcinogene-
sis.22,26 A few nested case-control studies have investigated whether IGF-1 and IGFBP-3 
levels were associated with pancreatic cancer risk in humans. These studies showed 
inconsistent results, observing no27,28 and positive29 associations with pancreatic can-
cer risk. Moreover, two of these studies were rather small, with case numbers 
<150.27,29 Further studies are needed to elucidate the role of insulin and the IGF axis in 
the pathogenesis of pancreatic cancer. 
 
Epidemiological evidence 
Some epidemiological studies suggest that higher physical activity levels might de-
crease risk, especially in overweight or obese persons.30,31 Other epidemiological stu-
dies, however, did not observe an association with pancreatic cancer risk.32,33 Two 
meta-analyses observed only for occupational physical activity a modest significantly 
decreased pancreatic cancer risk – which was only based on a few cohort studies (i.e., 
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three and four, respectively) – and no association with leisure-time physical activi-
ty.34,35 Within the NLCS, we were unable to confirm this finding. We observed no asso-
ciation with occupational physical activity and non-occupational physical activity at 
baseline. We observed, however, a modestly decreased pancreatic cancer risk for 
participants who reported to have participated in sports in the past compared with 
participants reporting never to have participated in sports during the past. So far, the 
findings on physical activity are too inconsistent because different methods have been 
used in epidemiological studies.34 In addition, measuring physical activity in epidemio-
logical studies is difficult because physical activity is a complex behavior that accumu-
lates many short unstructured activities that occur in varying contexts.34 The challenge 
of future studies is to accurately measure all components of physical activity (i.e., both 
exercise and non-exercise physical activity, with the latter including occupational, 
household and lifestyle physical activity). 
 
Conclusion 
Although there seems to be support mechanistically, we conclude that there is only 
suggestive evidence that physical activity is associated with pancreatic cancer risk 
(Table 8.1). In the future, studies are needed that accurately measure all components 
of physical activity. 
 
Energy restriction  
Mechanistic evidence 
It has been shown that energy restriction suppresses tumor development in experi-
mental animals.36 Also in rat models for pancreatic cancer, it was shown that moderate 
energy restriction decreased cancer risk.37,38 Insulin and IGF might be mechanistically 
involved in this relation.22,36 Experimental studies have shown that energy restriction 
might reduce levels of circulating IGF-1 and insulin.1,22 As discussed in the previous 
paragraph, insulin and the IGF axis might play a role in pancreatic carcinogenesis. Fur-
thermore, energy restriction may also exert some if its anti-tumor effects by decreas-
ing free-radical oxygen species (ROS) production and enhancing antioxidant de-
fenses.36 
 
Epidemiological evidence 
As far as we know, we are the first epidemiological study that investigated the relation 
between energy restriction and pancreatic cancer risk. The NLCS is comprised of indi-
viduals who grew up during a period of severe short-term energy restriction, i.e., the 
Hunger winter (winter of 1944-1945). We also had information on two preceding  
periods of more moderate energy restriction: World War II (WW II; 1940-1944) and the 
Economic Depression (1932-1940). Although individual food intake data is not availa-
ble for these three time periods, a number of proxy measures have been collected 
from cohort members that reflect their exposure to energy restriction; that is, place of 
residence during the Hunger winter and WW II, and employment status of the father 
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during the Economic Depression. We observed a modestly decreased pancreatic can-
cer risk for individuals who resided in a city during the war years compared with those 
who did not. Regarding the exposure to a short period of severe energy restriction 
during the Hunger winter, results were not clear. Individuals living in western rural 
area had an increased pancreatic cancer risk compared with individuals living in non-
western area, whereas living in a western city was not associated. No association was 
observed for exposure to energy restriction during the Economic Depression. Previous 
work on the NLCS cohort has found an inverse association between severe energy 
restriction during the Hunger winter and colorectal cancer risk in men.39 
 
Conclusion 
No conclusions regarding the association between energy restriction and pancreatic 
cancer risk could be reached because too few studies, especially epidemiologically, 
have been conducted so far (Table 8.1). 
 
Glycemic index, glycemic load, and carbohydrates 
Mechanistic evidence 
As already described above, insulin might play a role in pancreatic carcinogenesis. 
Furthermore, type 2 diabetes seems to develop generally after prolonged periods of 
high insulin secretion rates with a gradual increase in insulin resistance of the liver and 
peripheral tissues.22 Because insulin is secreted into the blood in response to elevated 
blood glucose levels, dietary factors increasing these levels may be associated with 
pancreatic cancer risk. Glycemic index (GI) and glycemic load (GL) are such measures. 
 
Epidemiological evidence 
In this thesis, we did not observe an association between high GL, GI, and total carbo-
hydrate intake and pancreatic cancer risk. These null findings are consistent with 
four40-43 of five cohort studies40-44 conducted so far that examined either GL, GI and/or 
carbohydrate intake in relation to pancreatic cancer risk. Meinhold et al.44 observed a 
significantly increased risk with high GL and carbohydrates intake, but these associa-
tions were limited to the first 4 years of follow-up and no association was observed 
during later follow-up. Also, null findings have been reported in most case-control 
studies for carbohydrate intake; just few observed an increased risk (summarized in 
Ref. 1). 
 
Conclusion 
Most epidemiological studies did not observe an association between GL, GI, and car-
bohydrate intake and pancreatic cancer risk. Mechanistic evidence seems to support a 
role for insulin in pancreatic cancer etiology and therefore, investigating dietary factors 
that influence plasma insulin levels seems rational. The major rationale for using GI 
values is based on the assumption that postprandial blood glucose responses and insu-
lin responses are highly correlated; however, studies showed that this might not be the 
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case.45 In addition, the composition of a meal, the amount of rapidly available glucose 
and resistant starch, the degree of osmolality, the viscosity of the gut’s contents, are 
other important factors influencing the degree of postprandial insulin secretion.45 
Judging the evidence, we conclude that it is unlikely that GL, GI, and carbohydrates 
increase pancreatic cancer risk (Table 8.1). 
 
Alcohol intake 
Mechanistic evidence 
There is evidence that chronic alcohol consumption may alter pancreatic function,46 
which may predispose people to pancreatic cancer. Several mechanisms have been 
suggested. First, heavy alcohol consumption is a known risk factor for chronic pancrea-
titis,1 which has been linked to pancreatic cancer.8 In addition, studies have suggested 
that the metabolites generated during metabolism of alcohol (e.g., acetaldehyde) may 
be carcinogenic.1,47 Furthermore, the effects of alcohol may be mediated through the 
generation of ROS which can lead to the formation of DNA adducts and initiation of 
pancreatic carcinogenesis.47,48 In some animal studies, ethanol slightly enhanced pan-
creatic carcinogenesis, but in other studies did not demonstrate any effect on pancrea-
tic carcinogenicity.8,49,50 It is still not clear, though, at what stage of pancreatic carcino-
genesis ethanol plays a role because this has received limited attention among       
researchers in the field.48 However, given the findings described above, ethanol might 
play a role at both the initiation and promotion phase. 
 
Epidemiological evidence 
Both findings from cohort studies as from case-controls studies have been inconsis-
tent, observing no association between alcohol consumption and pancreatic cancer 
risk1,9,51-53 or observing an increased risk.1,54-57 In the NLCS, no association was         
observed between low-to-moderate alcohol intake and risk of pancreatic cancer. We 
did, however, find a significantly increased risk for consumers of a high level of ethanol 
(≥30 g/day) compared with abstention (hazard rate ratio [HR] = 1.57, 95% CI: 1.03-
2.39). A few other studies observed increased pancreatic cancer risks with heavy alco-
hol use as well, including a pooled analysis of 14 cohorts,54 a large US cohort,55 and two 
case-control studies.56,57 A recently published meta-analysis observed a 22% increase 
in pancreatic cancer risk (95% CI: 1.12-1.34; based on eight case-control studies and 
five cohort studies) for heavy alcohol drinking (≥3 drinks/day) compared with non- or 
occasional drinkers, this result was further strengthened by a dose-risk analysis which 
showed a significantly increase in cancer risk for an alcohol intake of ≥40 g/day.58 The 
observed increase in risk with heavy drinking appeared to be stronger in cohort studies 
versus case-control studies and stronger in studies that adjusted for smoking com-
pared with studies which did not adjust for smoking. Moderate alcohol consumption 
(<3 drinks/day) did not increase pancreatic cancer risk (risk ratio [RR] = 0.92, 95% CI: 
0.86-0.97; based on 17 case-control studies and seven cohort studies).  
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Many factors may contribute to the inconsistent results observed in the literature. Half 
of the observational studies investigating the role of alcohol on the etiology of pan-
creatic cancer had low case numbers. In addition, heavy alcohol drinkers may have 
lower participation rates than non-drinkers in both population-based case-control 
studies and cohort studies.59 Furthermore, alcohol intake is assessed by means of self-
report in most studies.58 If alcohol drinking is underreported, the RRs would be biased 
towards unity in case of non-differential underreporting of cases and non-cases. 
 We did not observe any relation between specific alcoholic beverages and pan-
creatic cancer risk apart from alcohol. This is in agreement with most epidemiological 
data, which suggest that it is ethanol itself and not the type of alcoholic beverage 
which plays a role in carcinogenesis.47 
 
Conclusion 
Based on the epidemiological and mechanistic evidence so far, we conclude that heavy 
alcohol consumption is a probable risk factor for pancreatic cancer (Table 8.1). Low-to-
moderate alcohol drinking is most probably not related to pancreatic cancer risk. 
 
Meat and fat intake 
Mechanistic evidence 
Meat contains numerous carcinogens, such as heterocyclic amines (HCAs), polycyclic 
aromatic hydrocarbons (PAHs), and N-nitroso compounds, which can be derived either 
from natural food or during the process of food preparation.60 These compounds are 
metabolically activated after which DNA adducts are formed.61,62 Anderson et al.63 
showed that the pancreas had the metabolic capacity to activate aromatic and hetero-
cyclic amines and found the presence of DNA adducts in human pancreatic tissue. In 
addition, some other studies have observed positive associations with meat-derived 
HCAs and benzo(a)pyrene, which is a marker of PAHs, and pancreatic cancer risk.64,65 
 Regarding dietary fat, studies in animals showed that diets high in fat increased 
the risk of pancreatic cancer compared with low-fat diets.66 In addition, they have 
shown that the development of tumors is generally enhanced by long-chain ω-6    
polyunsaturated fatty acids (PUFA), especially linoleic acid (LA), but inhibited by ω-3 
PUFA. LA can promote pancreatic carcinogenesis via an accelerated prostaglandin 
synthesis, caused by metabolism of LA-derived arachidonic acid,67 whereas ω-3 PUFAs 
can lead to a reduction in the availability of prostaglandins.66 Prostaglandins may be 
involved in the development of pancreatic carcinogenesis in animals.67 Saturated fat, 
on the other hand, seems not to be involved in the enhancement or promotion of 
pancreatic carcinogenesis in rats.38 
 
Epidemiological evidence 
Numerous epidemiological studies have investigated the relation between meat, eggs, 
and different types of fat and pancreatic cancer risk (summarized in Ref. 1). Findings 
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from these studies have been very diverse, observing both positive and negative asso-
ciations, as well as no association.1,8 
 A Finnish cohort of male smokers (ATBC Study) has observed no association with 
fried meat intake,68 whereas some case-control studies have observed positive associ-
ations with higher consumption of grilled and fried foods, such as meat.8 One large 
cohort study and one case-control study specifically assessed meat-cooking methods 
with respect to pancreatic cancer risk, finding positive associations with the intake of 
grilled/barbecued meat, high-temperature cooked meat, and broiled meat, but not 
with meat prepared differently.65,69 Most other observational studies including ours, 
were unable to investigate the association between meat-cooking methods and pan-
creatic cancer risk. 
 
Conclusion 
Epidemiological studies have failed to show an association between meat, processed 
meat, eggs, fat and different types of fat and pancreatic cancer, even though there 
seems to be support mechanistically. We conclude that it is unlikely that meat, 
processed meat, eggs, and different types of fat are associated with pancreatic cancer 
risk (Table 8.1). However, too few epidemiological studies have assessed whether 
meat-cooking methods are associated with pancreatic cancer risk. Therefore, future 
studies should carefully distinguish cooking methods to investigate the extent to which 
different cooking methods are associated with pancreatic carcinogenesis. 
 
Vegetables, fruits, carotenoids, vitamins C and E (both from diet and supplements) 
Mechanistic evidence 
Fruits and vegetables contain numerous substances with potential anti-carcinogenic 
activity (including vitamins, carotenoids, and Allium compounds)70 and could therefore 
play a role in the prevention of pancreatic cancer. Potential mechanisms of action 
include antioxidant protection against free-radical damage to DNA, enhancing immune 
function, and inhibiting IGF binding to IGF-receptors.1,70 In addition, short-term animal 
experiments suggest that beta-carotene and the vitamins C and E hinder the develop-
ment of preneoplastic lesions in both rat and hamster pancreas,71 but long-term stu-
dies demonstrated this inhibiting effect only for beta-carotene and vitamin C and only 
in rat pancreas.71,72  
 
Epidemiological evidence 
Epidemiological data have shown inconsistent results so far. Most case-control studies 
have observed an inverse association with total fruit and vegetable consumption 
(summarized in Ref. 1). On the other hand, results from most cohort studies including 
ours, have largely been null.1,9,68,73 Regarding the relation between antioxidant intake 
and pancreatic cancer risk, case-control studies observed inverse associations for beta-
carotene,74,75 lycopene (in men),76 vitamin C,74,75 and E;74 cohort studies reported only 
null findings on these carotenoids and vitamin intake.68,77 Other carotenoids, such as 
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alpha-carotene, lutein plus zeaxanthin and beta-cryptoxanthin, have only been investi-
gated in case-control studies so far, showing no associations with pancreatic cancer 
risk.76,78 Data on use of vitamin supplements has been very sparse;68,78 of these studies 
only one observed an inverse association with vitamin C supplement use.78 Also in the 
NLCS, no association was observed for the intake of carotenoids, vitamin C and E and 
pancreatic cancer risk. For fruit intake, the second World Cancer Research Fund/Amer-
ican Institute for Cancer Research expert report observed a pooled risk estimate of 
0.92 (95% CI: 0.81-1.04) for cohort studies and of 0.89 (95% CI: 0.82-0.98) for case-
control studies per 100 g/day of fruit intake.1 These estimates were, however, based 
on only three cohort studies and eight case-control studies. 
 Inconsistencies could have occurred because case-control studies used proxy 
interviews or are more prone to systematic biases compared with cohort studies. In 
addition, for several conducted studies no dietary information was available on indi-
vidual vegetables or fruits9,51 and some studies had small sample sizes (n for cases 
<150).74,77 
 
Conclusion 
We conclude that it is unlikely that fruit and vegetable intake may reduce pancreatic 
cancer risk (Table 8.1). For the intake of vitamins C and E and carotenoids – especially 
for carotenoids other than beta-carotene – the evidence is limited because just few 
studies have investigated this association or the quality of studies was too low to allow 
conclusions to be reached. 
 
 
METHODOLOGICAL ISSUES 
 
In this section we will discuss some important strengths and weaknesses of the study 
design of the NLCS and the analyses conducted in the current thesis. 
 
Selection bias 
Selection bias due to selection of the study population is not a major problem in cohort 
studies because at the start of cohort studies the population is disease-free. Selection 
bias due to a substantial numbers of subjects lost to follow-up could be a problem in 
cohort studies when losses to follow-up are correlated with both exposure and dis-
ease.79 This, however, is not a problem in the NLCS, as completeness of follow-up was 
estimated to be >96%.80 Additionally, in 13.3 years of follow-up only two male subco-
hort members were lost to follow-up and during later follow-up only one. So, it is  
unlikely that selection bias due to follow-up loss has distorted our analyses. 
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Information bias 
Information bias can be introduced into a study by errors in obtaining the information 
regarding the exposure and outcome of the study.79 In the sections below, we will first 
discuss misclassification of exposure and subsequently misclassification of disease. 
 
Misclassification of exposure  
In our study, non-random misclassification of exposure is unlikely because the self-
administered questionnaire was filled out before cancer was ascertained. But random 
misclassification of the exposures investigated in this thesis may have occurred      
because we had to rely on a self-administered questionnaire on dietary habits, lifestyle 
characteristics, and other potential risk factors for cancer, which might have led to 
under- or overreporting. 
 In the NLCS, the dietary section of the questionnaire was a 150-item semiquantit-
ative food frequency questionnaire (FFQ), which concentrated on the habitual con-
sumption of food and beverages during the year preceding the start of the study. The 
FFQ is often considered the method of choice for dietary assessment in large-scale 
epidemiologic studies.81 But it is also liable to error and this may have resulted in mis-
classification of dietary exposure. A validation study and reproducibility study have 
been performed within the cohort.82,83 
 So far, no gold standard for dietary intake to use in validation studies is available. 
Because the errors of diet records are assumed to be unrelated to the errors of the 
FFQ, this makes it the comparison intake method of choice in validation studies of 
FFQs.81 However, some studies showed that food records can have errors that are 
correlated with FFQ errors.84 Dietary biomarkers would seem better measures as gold 
standard (because of its uncorrelated measurement errors) or even as a useful meas-
ure of dietary intake and nutrient status itself. For several important nutrients, howev-
er, no feasible dietary biomarker is available at this moment.85 Also, several factors 
may affect the measurement and utility of a dietary biomarker which influences the 
validity, application and interpretation of these measures. These factors included the 
following: genetic variability (e.g., biological variation in nutrient absorption, metabol-
ism); lifestyle (e.g., smoking, alcohol consumption, exercise) or physiologic factors 
(e.g., stress, underlying disease); dietary factors (e.g., range/frequency of intake,   
nutrient bioavailability); biological sample (e.g., type, conditions of sample collection); 
and analytical methodology (e.g., precision, accuracy, detection limits).85 
 The validity of our semiquantitative FFQ was assessed by comparing the FFQ with 
a 9-day diet record.82 This study showed that for most nutrients and food groups mean 
intake according to the FFQ was lower than according to the record; on average, the 
questionnaire covered 91% of the record intake. Pearson correlation coefficients   
between nutrient intakes assessed by the record and the FFQ ranged from 0.40 for 
vitamin B1 to 0.86 for alcohol intake, with correlations for most nutrients between 
0.60 and 0.80. The Spearman correlation coefficients ranged from 0.38 for vegetables 
to 0.83 for alcoholic beverages. For some food groups, such as vegetables, the relative-
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ly low correlation was due to a lack of variation in consumption frequency. It was con-
cluded that the questionnaire could satisfactorily rank subjects according to the intake 
of nutrient intake and food(group) consumption.82 Also, because all these factors were 
measured before the diagnosis of pancreatic cancer, misclassification is likely to be 
non-differential with respect to the outcome, which will most likely bias risk estimates 
towards the null value.79 
 Information bias in our study could have occurred due to preclinical manifesta-
tions of disease. Due to these symptoms, subjects may have altered their dietary   
habits or other habits, such as smoking. Therefore, we have excluded the first 2 years 
of follow-up in additional analyses for all exposures investigated in the current thesis. 
These results were not different from the results using the total follow-up time. 
 Another possible source of misclassification of exposure in cohort studies is 
changing of habits during follow-up. The information on dietary intake and other life-
style factors was ascertained only once in the NLCS, and changes in diet and/or life-
style during follow-up may have weakened true relations between the exposures of 
interest that were investigated in the current thesis and pancreatic cancer risk. In the 
reproducibility study of our FFQ, it was shown that correlation coefficients with the 
baseline questionnaire declined just slightly with time; the average reduction for the 
nutrients examined was 0.07 over the 5-year period.83 This indicates that the single 
FFQ measurement can characterize dietary habits for a period of at least 5 years. It is, 
however, not known whether this applies to the total follow-up period used in this 
thesis. Data in the Netherlands indicated that people decreased their alcohol intake or 
even quitted drinking when they become older (≥60 years).86 Regarding smoking, it is 
known that few people aged ≥50 years will start smoking, but more people will quit 
while ageing.87 Therefore, a substantial proportion of the cohort members may have 
quitted smoking or decreased/quitted drinking alcohol during follow-up, although they 
still would be classified as current users in our analysis. This may have resulted in an 
underestimation of the effects observed for smoking and alcohol. 
 
Misclassification of disease 
Misclassification of disease could also have occurred in our study. This type of misclas-
sification is more likely to occur in studies on pancreatic cancer than for many other 
cancers because of the location of the pancreas, and the tendency for adenocarcino-
mas in sites such as the stomach, colon, prostate, and ovary to metastasize to the 
upper abdomen.88 However, we had the possibility to further restrict the analyses to 
microscopically verified cases, in which misclassification by disease status would be 
less likely than among non-microscopically confirmed pancreatic cancer cases.89    
Results based on these analyses were not materially different from the analyses in 
which all pancreatic cancer cases were included. Therefore, we believe that misclassifi-
cation of disease has not distorted our analyses. 
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Confounding  
It is very important to adequately control for confounders in epidemiological studies. It 
is, therefore, important that confounders are determined accurately. If not, this can 
cause bias in either direction, depending on the direction of the confounding.79 In the 
NLCS, detailed information on potential risk factors for pancreatic cancer was availa-
ble. We considered variables as possible confounders based on the literature. These 
potential confounding variables were added to the multivariable-adjusted model if 
they (i) were associated with the disease and with the exposure of interest and (ii) 
changed the age- and sex-adjusted regression coefficients by at least 10% (using a 
backwards stepwise procedure). 
 Many of the confounders we included in our multivariable models did not sub-
stantially alter the results in our analyses. Smoking, however, was an influential con-
founder in the analyses of alcohol. Effect estimates were reduced when adding con-
founders to the model which was mainly attributable to smoking (≥30 g of ethanol 
intake/day versus abstention: age-adjusted HR = 1.83, 95% CI: 1.24-2.71 and multivari-
able-adjusted HR = 1.57, 95% CI: 1.03-2.39; Chapter 3). We were unable to investigate 
in more depth whether residual confounding due to smoking had affected our results 
because only four cases who never smoked consumed ≥30 g of ethanol daily. However, 
other studies have confirmed our increased pancreatic cancer risk in heavy alcohol 
users,54-56 and a meta-analysis showed even a stronger effect estimate for studies that 
adjusted for smoking.58 Furthermore, self-reported smoking status (smoker or non-
smoker) is regarded as quite accurate.90 Self-report of number of cigarettes per day, 
however, may be biased towards round numbers,91 which could have resulted in some 
misclassification. Although we have checked many risk factors for their confounding 
effects, we cannot entirely exclude the possibility of residual confounding by unmea-
sured variables or misclassification of a confounder (especially smoking), which might 
have obscured our results. 
 
 
RECOMMENDATIONS FOR FUTURE RESEARCH 
 
Etiology of pancreatic cancer 
Gene-environment interactions 
So far, we still lack knowledge of the pancreatic cancer etiology with just few estab-
lished risk factors.92 These risk factors alone are most probably not sufficient to explain 
completely the incidence of pancreatic cancer and therefore novel approaches and 
strategies are needed to have a major impact on prevention of this rapidly fatal dis-
ease. Because both genetic and environmental factors may play a role in the etiology 
of pancreatic cancer, a possible approach could be to study the combined effect of 
environmental risk factors and genetic factors. Unfortunately, data on such interac-
tions in pancreatic cancer are scarce at the moment, possibly because of the difficul-
ties in recruiting sufficient numbers of patients and the inaccessibility of pancreatic 
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tissue.92 The studies conducted so far, have provided some clues to the etiology. KRAS 
mutations in pancreatic cancer have been associated with smoking, alcohol consump-
tion, organochlorines, and diet.92 Additionally, cytochrome P450 (CYP) 1A2 and           
N-acetyltransferase (NAT) 1 genotypes showed significant interactions with smoking in 
heavy smoking women, whereas a significant interaction of the NAT1 genotype with 
intake of dietary mutagens (e.g., dietary heterocyclic amines and polycyclic aromatic 
hydrocarbons) in modification of the risk of pancreatic cancer was observed among 
men.93 Also, a case-control study carried out among Japanese evaluated the effect of 
alcohol on pancreatic cancer in conjunction with polymorphisms in one-carbon meta-
bolism enzymes, including methylenetetrahydrofolate reductase (MTHFR), methionine 
synthase (MTR), and methionine synthase reductase (MTRR).56 Their results suggested 
that the effect of alcohol drinking on pancreatic cancer risk may be modified by the 
following polymorphisms: MTHFR 677 CC genotype, MTR 2756 AA genotype, and 
MTRR 66 G allele. Finally, a recently published case-control study showed that genetic 
variations in antioxidant defenses modify the risk of pancreatic cancer in diabetics or 
persons with a low dietary vitamin E intake.94 However, these findings need confirma-
tion in other populations, preferably with large case numbers, before effective strate-
gies for the prevention of this disease may be developed. 
 
Dietary biomarkers 
Because of the complexities and limitations of various dietary assessment methods, 
dietary biomarkers measured in biological specimens are being increasingly used.85 
Biomarkers can be defined as a biochemical indicator of dietary intake/nutritional 
status, or it may be an index of nutrient metabolism, or a marker of the biological con-
sequences of dietary intake. They can be used as (i) a means of validation of dietary 
instruments; (ii) surrogate indicators of dietary intake; or (iii) integrated measures of 
nutritional status for a nutrient.95 Examples of biomarkers that have a strong relation 
with dietary intake are doubly labeled water for dietary energy intake, and urinary 
nitrogen for protein intake. No such biomarkers have, however, been identified for 
total fat or carbohydrate intake.85 In some cases, a biomarker may even be a better 
indicator of dietary intake if direct measurement of dietary intake by using traditional 
methods is difficult or impossible. These include selenium, vitamin E and mutagenic 
compounds.95 
 As already indicated in the previous section on information bias, the validity,  
application and interpretation of dietary biomarkers are affected by many factors. 
More research is needed in this respect; especially the role of interactions between 
diet and genes needs to be elucidated because data on this is limited.85 Furthermore, 
there is need to identify and validate more and better dietary biomarkers, which 
should be possible using modern methods like the emerging fields of nutritional meta-
bonomics.85 Metabonomics can be an excellent tool to determine specific metabolic 
profiles, which may be utilized as dietary biomarkers that are specific to various dieta-
ry/nutrient intake patterns or dietary changes. In conclusion, dietary biomarkers re-
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quire much further research which can lead to better application and interpretation of 
these measures to gain further insights in the association of dietary exposures and 
pancreatic cancer risk. 
 
Diagnostic misclassification 
Some studies showed that diagnostic misclassification could seriously bias pancreatic 
cancer risk estimates.96,97 In a population based case-control study, this was investi-
gated in more depth. In this study, cases were classified as “likely” if at least one of the 
following criteria was satisfied: (i) a pancreatic mass was known by radiographic visua-
lization or surgery, with a compatible histological diagnosis; (ii) a pancreatic mass was 
known by surgery and, although a biopsy specimen was not obtained, it appeared to 
be malignant due to either visible hepatic metastasis or local extension; or (iii) a pan-
creatic mass was known by radiographic visualization, although a biopsy specimen was 
not obtained, and there were supporting clinical signs, symptoms, and course (e.g., 
rapid death).97 Cases were considered “unlikely” to have pancreatic cancer if they did 
not satisfy one of the above mentioned criteria. After adjustment for potential con-
founders, the observed odds ratio for ever smoker was 1.8 (95% CI: 1.4-2.4) for micro-
scopically confirmed cases considered “likely” to have had pancreatic cancer, 1.3 (95% 
CI: 0.6-2.8) for non-microscopically confirmed cases considered “likely” to have had 
pancreatic cancer, and 1.0 (95% CI: 0.4-2.4) for cases considered “unlikely” to have had 
pancreatic cancer. These findings suggest that restriction of the case series to “likely” 
cases with microscopic confirmation will generate the most precise estimates of risk.97 
Since then, just few studies have reported results restricted to microscopically con-
firmed cases.17,30,98,99 In a previous study within the NLCS on the association of anthro-
pometric factors and risk of pancreatic cancer, BMI was associated with pancreatic 
cancer only among microscopically verified cases, whereas this association was      
obscured when non-microscopically verified cases were included.100 Differences in 
characteristics of cases by degree of diagnostic certainty might explain the differences 
in results described above. American data from SEER registries indicated that the pro-
portion of microscopically verified cases decreases with age.97 Porta et al.101 observed 
differences in some case characteristics between a group of cases having a high proba-
bility of having pancreatic cancer and less certain cases. These differences included a 
higher proportion of cases with an interval ≤1 month from the first symptom to diag-
nosis and a slightly higher proportion of adenocarcinomas in the group with a high 
probability of having pancreatic cancer. Also, the proportion of smokers and drinkers 
seem to differ among cases with different diagnostic certainty. In the current thesis, no 
differences in results were observed between microscopically verified cases and all 
pancreatic cancer cases. Even though we did not observe obscured results in this thesis 
when we included non-microscopically verified cases in the analyses, future studies 
should assess whether heterogeneity exists in risk estimates by degree of diagnostic 
certainty.97,101 
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CONCLUSIONS AND IMPLICATIONS 
 
In summary, we observed significantly increased pancreatic cancer risks for heavy 
alcohol consumption and for active cigarette smoking, whereas quitting smoking   
reduced risk. No association was observed with exposure to passive smoking. Partici-
pating in sports in the past moderately decreased pancreatic cancer risk, whereas 
findings with respect to proxies for energy restriction did not support our hypothesis 
that energy restriction may reduce pancreatic cancer risk. We observed no association 
with the other dietary factors that were investigated, including GI, GL, intake of carbo-
hydrates, meat, fat, fruit, vegetables, carotenoids, and vitamins C and E. 
 From a public health perspective, a healthy lifestyle, including not smoking, main-
taining a healthy weight, being physically active and limiting alcohol use, might reduce 
the incidence and mortality of pancreatic cancer, which is important for this type of 
cancer with its extremely poor prognosis. 
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SUMMARY 
 
Pancreatic cancer is the 5th leading cause of cancer death in Europe and 4th in the Unit-
ed States. Survival rates for pancreatic cancer are amongst the worst of all cancers 
with a median survival of about 3 months and a 5-year survival rate of ≤6%. 
 Because the pancreas is intimately related to digestion and absorption, it is rea-
sonable to place diet high among the possible risk factors for pancreatic cancer. How-
ever, the specific dietary components and mechanisms that might be involved in the 
etiology of pancreatic cancer remain unclear, primarily because of limited and incon-
sistent study findings. One of the reasons that study findings have been inconsistent 
between case-control studies and cohort studies might be because case-control stu-
dies are prone to more biases, including recall bias, compared with cohort studies. 
Recall bias could lead to risk estimates that are either exaggerated or underestimated 
because dietary intake is assessed in cases after diagnosis. Furthermore, patients in 
case-control studies tend to report current rather than past diet which can introduce 
bias because current diet might be influenced by prediagnostic symptoms of disease. 
Differential misclassification of the exposure could also have occurred due to the need 
to use next-of-kin interviews in case-control studies because pancreatic cancer is rapid-
ly fatal. In addition, case-control studies of pancreatic cancer are highly susceptible to 
selection bias due to the high fatality rates among pancreatic cancer cases. Pancreatic 
cancer shows relatively low incidence rates, which has resulted in relatively low case 
numbers in most prospective studies. A large-scale cohort study with a substantial 
number of cases would be informative to overcome these biases and to make a sub-
stantial contribution to the epidemiological knowledge regarding the association   
between risk factors and pancreatic cancer risk. The prospective design avoids diffe-
rential misclassification and the need to use next-of-kin respondents. 
 The overall aim of this thesis was to investigate the associations between dietary 
and lifestyle factors and pancreatic cancer risk. These factors were investigated within 
the context of the Netherlands Cohort Study (NLCS) on diet and cancer. This prospec-
tive study was initiated in September 1986. At baseline, a total of 120,852 men and 
women aged 55 to 69 years returned a self-administered questionnaire on habitual 
dietary, lifestyle, and other risk factors for pancreatic cancer. For increased efficiency 
in the processing of the questionnaire and follow-up, the case-cohort approach was 
used. A randomly drawn subcohort consisting of 5,000 men and women was actively 
followed up for vital status to estimate the accumulating person time at risk, whereas 
the entire cohort was followed up annually for cancer occurrence by record linkage to 
the Netherlands Cancer Registry and the Netherlands Pathology Registry. Follow-up is 
still ongoing for the NLCS, which is why two different follow-up periods were used in 
this thesis. For the first part of the thesis, a total of 13.3 years of follow-up (baseline to 
December 1999) was used for the analysis, for which 408 incident exocrine pancreatic 
cancer cases were available. Sixty-six percent of these cases were microscopically con-
firmed pancreatic cancer (n = 269). When data became available in 2008 for a period 
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of 16.3 years, the follow-up period was extended. This extended follow-up period was 
used for the analyses described in the last chapters of this thesis, for which 520 inci-
dent exocrine pancreatic cancer cases (62% microscopically confirmed) were available. 
 Some studies have shown that diagnostic misclassification could seriously bias 
pancreatic cancer risk estimates. In a previous analysis of anthropometric measures 
and pancreatic cancer risk within the NLCS, a significantly positive association between 
body mass index and pancreatic cancer risk was observed only among microscopically 
verified cases, whereas this association was obscured when non-microscopically veri-
fied cases were included. Therefore, next to the overall analyses including all pancrea-
tic cancer cases, we restricted additional analyses in this thesis to microscopically veri-
fied cases to create a group with a higher degree of diagnostic certainty of pancreatic 
cancer. 
 
Previous studies showed that higher physical activity levels and energy restriction 
might decrease pancreatic cancer risk. In Chapter 2, we present the results for both 
non-occupational and occupational physical activity as well as energy restriction in 
relation to pancreatic cancer risk. The NLCS is comprised of individuals who grew up 
during the war years (1940-1944), the Hunger winter (winter of 1944-1945), and the 
Economic Depression (1932-1940). This gave us the opportunity to study the effect of 
energy restriction during adolescence on the risk of pancreatic cancer in later life. A 
number of proxy measures have been collected from cohort members that reflect the 
exposure to energy restriction during these three time periods. A modestly decreased 
pancreatic cancer risk was observed for individuals who resided in a city during the war 
years compared with those who did not. This was meant to indicate a period of more 
moderate energy restriction. Regarding the exposure to a short period of severe ener-
gy restriction during the Hunger winter, results were not clear. Individuals living in 
western rural area had an increased pancreatic cancer risk compared with individuals 
living in non-western area, whereas living in a western city was not associated. No 
association was observed for exposure to energy restriction during the Economic   
Depression. Regarding physical activity, a modestly decreased pancreatic cancer risk 
was observed for respondents who reported to have ever participated in sports in the 
past. Non-occupational physical activity at baseline and occupational physical activity 
were not associated with pancreatic cancer risk. 
 
So far, most cohort studies and case-control studies have provided little or no support 
for a positive association between low-to-moderate alcohol use and pancreatic cancer 
risk, but some studies suggested that heavy alcohol intake might increase risk. In  
Chapter 3, the association between alcohol consumption and pancreatic cancer risk 
was examined. Compared with abstention, consuming less than 3 glasses of alcohol 
was not associated with pancreatic cancer risk, whereas consuming 3 or more glasses 
of alcohol increased pancreatic cancer risk with 57%. In a subgroup of stable alcohol 
users (no change during the 5 years before baseline), a similarly increased pancreatic 
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cancer risk was found. No associations were observed between consumption of specif-
ic alcoholic beverages and risk of pancreatic cancer, which suggests that it is ethanol 
itself and not the type of alcoholic beverage which plays a role in pancreatic carcino-
genesis.  
 
Studies have shown that insulin might play a role in pancreatic carcinogenesis. Insulin 
is secreted into the blood in response to elevated blood glucose levels; therefore, 
dietary factors increasing blood glucose levels may be associated with pancreatic can-
cer risk. Glycemic index and glycemic load are such measures. In Chapter 4, it was 
examined whether these dietary measures were positively associated with pancreatic 
cancer risk, but no association was observed between dietary glycemic load and gly-
cemic index and pancreatic cancer risk in the NLCS. Also, no association was observed 
between the intake of carbohydrates and mono- and disaccharides and pancreatic 
cancer risk. 
 
Numerous carcinogens can be produced during the process of meat preparation, 
which may increase pancreatic cancer risk. Furthermore, animal studies showed that 
polyunsaturated fatty acids increase pancreatic cancer risk. So far, findings from the 
numerous epidemiological studies that investigated the association between the   
intake of meat and different types of fat and pancreatic cancer risk have been inconsis-
tent. In Chapter 5, the results are described on the associations between the consump-
tion of fresh meat, other types of meat, and the intake of different types of fat and risk 
of pancreatic cancer: no association was observed. Also, no association was observed 
between the consumption of fish and eggs and pancreatic cancer risk. 
 
Fruits and vegetables contain numerous substances with potential anticarcinogenic 
activity and could therefore play a role in prevention of pancreatic cancer. Most case-
control studies observed an inverse association with total fruit and vegetable con-
sumption, whereas results from most cohort studies have largely been null. In Chapter 
6, we described the results of the association between fruit and vegetable consump-
tion and pancreatic cancer risk in the NLCS. Total vegetable and total fruit consump-
tion were not associated with pancreatic cancer risk. Also, no association was observed 
for cooked vegetables, raw vegetables, and other specific subgroups of vegetables and 
fruits. Dietary carotenoids, vitamin C and E intake and use of supplements containing 
vitamin C or E were neither associated with pancreatic cancer risk. 
 
To date, cigarette smoking is the most consistent risk factor for pancreatic cancer. In 
Chapter 7, the results of the analyses on active and passive cigarette smoking in rela-
tion to pancreatic cancer risk were presented. Compared to the risk of never cigarette 
smokers, former and current cigarette smokers had a 37% and 88% increased pancrea-
tic cancer risk, respectively. We observed an increased pancreatic cancer risk of 51% 
for those smoking ≥20 cigarettes/day compared with never cigarette smoking, but no 
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dose-response relation was present. A dose-response effect was observed with dura-
tion of smoking. The hazard rate ratio for pancreatic cancer risk was 2.03 comparing 
smokers who smoked ≥40 years with never cigarette smokers. Pancreatic cancer risk 
was gradually reduced with increasing years of quitting among former smokers and 
approached the risk of never cigarette smokers after ≥20 years of quitting. No associa-
tion was observed for passive smoking exposure and pancreatic cancer risk in women. 
Exclusion of ever tobacco smokers when examining the association between passive 
smoking and cancer risk is important to estimate the independent effect of passive 
smoking. Therefore, this association was not investigated in men because >90% of the 
men in the NLCS were ever smokers. 
 
When for Chapter 2 till 7 additional analyses were restricted to microscopically verified 
pancreatic cancer cases, results were similar to the results including all pancreatic 
cancer cases. 
 
In Chapter 8, the main findings on the associations between pancreatic cancer risk and 
the lifestyle factors investigated in the current thesis were discussed in light of the 
existing literature – both epidemiological and mechanistic – and a final conclusion was 
made on the strength of the evidence so far. Additionally, some important strengths 
and weaknesses of the study design of the NLCS and the analyses performed in this 
thesis were discussed, including confounding and misclassification of exposure and 
disease. Some studies showed that diagnostic misclassification could seriously bias 
pancreatic cancer risk estimates. Differences in characteristics of cases, including age, 
proportion of smokers and drinkers, and tumor characteristics, by degree of diagnostic 
certainty might explain these biased results. However, as mentioned above, in the 
current thesis results restricted to microscopically verified cases were similar to the 
results including all pancreatic cancer cases. Furthermore, we have described that 
studying the combined effect of environmental risk factors and genetic factors and 
identifying more and better dietary biomarkers might gain further insights in the poss-
ible association of dietary exposures and pancreatic cancer risk. 
 In summary, we observed significantly increased pancreatic cancer risks for heavy 
alcohol consumption and for active cigarette smoking, whereas quitting smoking   
reduced risk. No association was observed with exposure to passive smoking. Partici-
pating in sports in the past moderately decreased pancreatic cancer risk, whereas 
findings with respect to proxies for energy restriction did not support our hypothesis 
that energy restriction may reduce pancreatic cancer risk. We observed no association 
with the other dietary factors that were investigated, including glycemic index, glycem-
ic load, intake of carbohydrates, meat, fat, fruit, vegetables, carotenoids, and vitamins 
C and E. 
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Alvleesklierkanker staat op de 5de plaats van de ranglijst van doodsoorzaken aan kan-
ker in Europa en op de 4de plaats in the Verenigde Staten. Overlevingskansen voor 
alvleesklierkanker behoren tot de slechtste van alle vormen van kanker met een medi-
ane overleving van ongeveer 3 maanden en een 5-jaars overlevingskans van 6% of 
minder. 
 Omdat de alvleesklier een belangrijke rol speelt in de spijsvertering en absorptie, 
zou voeding een mogelijk risicofactor voor alvleesklierkanker kunnen zijn. De specifie-
ke voedingscomponenten en -mechanismen die mogelijk betrokken zijn in de etiologie 
van alvleesklierkanker zijn echter tot op heden nog onduidelijk. Dit komt voornamelijk 
door het beperkt aantal onderzoeken, voornamelijk cohortonderzoeken, die dit heb-
ben onderzocht die tevens inconsistente bevindingen lieten zien. Een van de redenen 
dat er inconsistente bevindingen zijn gevonden tussen patiëntcontroleonderzoeken en 
cohortonderzoeken kan zijn dat patiëntcontroleonderzoeken gevoeliger zijn voor ver-
tekeningen van onderzoeksresultaten dan cohortonderzoeken. De voedingsinname 
van patiënten is nagevraagd na vaststelling van de diagnose en dit kan leiden tot sys-
tematische verschillen in de hoeveelheid informatie en de nauwkeurigheid van de 
informatie tussen patiënten en controlepersonen (recall bias). Dit kan leiden tot het 
over- of onderschatten van het risico. Verder hebben patiënten in patiëntcontrole-
onderzoeken de neiging hun huidige voedingsinname te rapporteren in plaats van hun 
vroegere voedingsinname. Vanwege klachten veroorzaakt door hun ziekte, kunnen 
patiënten echter hun huidige voedingsinname hebben aangepast voordat hun ziekte is 
gediagnosticeerd. In patiëntcontroleonderzoeken moet vaak de informatie over de 
risicofactoren van patiënten worden nagevraagd aan naaste familieleden. Dit komt 
omdat de meeste patiënten na het vaststellen van de diagnose alvleesklierkanker zeer 
snel overlijden, waardoor navraag bij de patiënt zelf vaak niet mogelijk is. Dit kan lei-
den tot differentiële missclassificatie van risicofactoren. Het zeer snel overlijden van 
patiënten na vaststelling van de diagnose zorgt er ook voor dat patiëntcontroleonder-
zoeken naar alvleesklierkanker zeer gevoelig zijn voor selectie bias. Het aantal nieuwe 
gevallen van alvleesklierkanker in de bevolking is relatief laag waardoor het aantal 
gevallen in de meeste prospectieve onderzoeken ook relatief laag is. Een grootschalig 
cohortonderzoek met een aanzienlijk aantal patiënten zou deze vertekeningen van 
onderzoeksresultaten kunnen overwinnen en zou een belangrijke bijdrage kunnen 
leveren aan de epidemiologische kennis over het verband tussen risicofactoren en 
alvleesklierkanker. De prospectieve opzet van de het cohortonderzoek vermijdt diffe-
rentiële misclassificatie en de noodzaak om gegevens van patiënten na te vragen aan 
naaste familie. 
 De doelstelling van dit proefschrift was het onderzoeken van de verbanden tussen 
voedings- en leefstijlfactoren en het risico op alvleesklierkanker. Hierbij werd gebruik 
gemaakt van de onderzoeksgegevens uit de Nederlandse Cohort Studie (NLCS) naar 
voeding en kanker. Dit prospectief onderzoek is gestart in september 1986. In totaal 
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hebben 120.852 mannen en vrouwen in de leeftijd van 55 tot 69 jaar in 1986 een vra-
genlijst retour gezonden over hun gebruikelijke eetgewoonten, leefstijl en andere 
risicofactoren voor alvleesklierkanker. Vanwege de efficiëntie in het verwerken van de 
vragenlijsten en het opvolgen van de deelnemers, is the case-cohortbenadering     
gebruikt. Een aselect getrokken steekproef uit het cohort, het subcohort bestaande uit 
5.000 mannen en vrouwen, werd opgevolgd voor informatie over overlijden. Zo kon 
voor elk subcohortlid het totaal aantal persoonsjaren die hij of zij had bijgedragen aan 
het onderzoek worden vastgesteld wat weer werd gebruikt voor een schatting van de 
opgebouwde persoonsjaren in het hele cohort. Voor het hele cohort werd jaarlijks het 
optreden van kanker vastgesteld door een koppeling tussen de gegevens van de NLCS 
en de Nederlandse Kanker Registratie en Pathologisch-Anatomisch Landelijk Geauto-
matiseerd Archief (PALGA). De deelnemers binnen de NLCS worden nog steeds opge-
volgd, waardoor in dit proefschrift twee verschillende follow-up periodes zijn gebruikt. 
Voor het eerste gedeelte van het proefschrift hebben we een follow-up tijd van 13.3 
jaar gebruikt (start van het onderzoek tot en met december 1999), waarbinnen 408 
alvleesklierkankerpatiënten zijn gediagnosticeerd. Hiervan hadden 66% patiënten (n = 
269) microscopische bevestiging. In 2008 werd de follow-up periode verlengd toen 
informatie beschikbaar kwam voor een periode van 16.3 jaar. Voor de laatste hoofd-
stukken van dit proefschrift is van deze verlengde follow-up periode gebruik gemaakt, 
waarbinnen 520 alvleesklierkankerpatiënten (62% microscopisch bevestigd) zijn gedia-
gnosticeerd. 
 Sommige onderzoeken hebben laten zien dat het verkeerd classificeren van pati-
nten (diagnostische misclassificatie) de risicoschattingen voor alvleesklierkanker ern-
stig kunnen vertekenen. In een vorig onderzoek binnen de NLCS naar het verband 
tussen antropometrie en alvleesklierkanker, werd al gezien dat er een significant posi-
tief verband bestaat tussen de body mass index en alvleesklierkanker binnen de groep 
patiënten met microscopisch bevestigde alvleesklierkanker. Dit verband werd niet 
meer aangetoond zodra ook de patiënten zonder microscopische bevestiging werden 
geïncludeerd in deze analyse. Daarom hebben we in dit proefschrift eerst alle analyses 
uitgevoerd met alle alvleesklierkankerpatiënten, waarna we vervolgens extra analyses 
uitgevoerd hebben waarin alleen patiënten met microscopisch bevestigde alvleesklier-
kanker zijn geïncludeerd. Dit om een groep met patiënten te krijgen waarvan met 
meer zekerheid gezegd kan worden dat ze alvleesklierkanker hebben. 
 
Voorgaande onderzoeken lieten zien dat hogere lichamelijke activiteitenniveaus en 
energierestrictie het risico op het krijgen van alvleesklierkanker zou kunnen verlagen. 
In Hoofdstuk 2 presenteren we de resultaten voor lichamelijke activiteit, zowel tijdens 
als buiten het werk, en energierestrictie in relatie tot het risico op alvleesklierkanker. 
De NLCS bestaat uit individuen die zijn opgegroeid gedurende de oorlogsjaren (1940-
1944), de Hongerwinter (winter van 1944-1945) en de crisisjaren (1932-1940). Dit gaf 
ons de gelegenheid het effect te bestuderen van energierestrictie gedurende de ado-
lescentie op het krijgen van alvleesklierkanker op latere leeftijd. Informatie over een 
ë
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aantal proxy-maten van de deelnemers zijn met dit doel verzameld om zo hun bloot-
stelling aan energierestrictie gedurende de drie bovenstaande periodes te meten. Er 
werd een verlaagd risico op alvleesklierkanker aangetoond voor individuen die gedu-
rende de oorlogsjaren in een stad woonden vergeleken met diegenen die niet in een 
stad woonden. Deze proxy-maat was een maat voor een meer gematigde energie-
restrictie. Wat betreft de blootstelling aan een korte periode van extreme energie-
restrictie gedurende de Hongerwinter waren resultaten niet eenduidig. Individuen die 
in het westen op het platteland woonden hadden een verhoogd risico op alvleesklier-
kanker vergeleken met individuen die niet in het westen woonden, terwijl het wonen 
in een stad in het westen niet was geassocieerd. Geen associatie werd waargenomen 
voor de blootstelling aan energierestrictie gedurende de Economische Depressie. Voor 
lichamelijke activiteit werd er een verlaagde kans op het krijgen van alvleesklierkanker 
gezien voor de deelnemers die in 1986 rapporteerden ooit aan sport gedaan te heb-
ben. Voor lichamelijke activiteit in 1986 buiten het werk en lichamelijke activiteit tij-
dens het werk bleek er geen verband te bestaan met het risico op alvleesklierkanker. 
 
Tot dusverre hebben de meeste cohort- en patiëntcontroleonderzoeken geen tot wei-
nig bewijs geleverd dat er een positief verband bestaat tussen laag-tot-matig alcohol-
gebruik en het risico op het krijgen van alvleesklierkanker. Maar er zijn onderzoeken 
die erop duiden dat overmatig alcoholgebruik het risico zou kunnen verhogen. In 
Hoofdstuk 3 is de relatie tussen alcoholconsumptie en alvleesklierkanker onderzocht. 
Het drinken van minder dan 3 glazen alcohol was niet geassocieerd met het risico op 
alvleesklierkanker ten opzichte van geheelonthouding. Echter verhoogde het drinken 
van 3 of meer alcoholische consumpties de kans op het krijgen van alvleesklierkanker 
met 57% ten opzichte van geheelonthouding. In een subgroep van stabiele alcohol 
gebruikers (geen verandering in gebruik gedurende de 5 jaar voor de start van het 
onderzoek) werd een vergelijkbaar verhoogde kans op het krijgen van alvleesklierkan-
ker aangetoond. Er bleek geen verband te bestaan tussen de inname van specifieke 
alcoholische dranken en het risico op alvleesklierkanker, wat suggereert dat het alco-
hol zelf is dat een rol speelt in het ontstaan en de groei (carcinogenese) van alvlees-
klierkanker en niet de soort alcoholische drank. 
 
Onderzoeken hebben laten zien dat insuline een rol speelt in de carcinogenese van 
alvleesklierkanker. Insuline wordt afgegeven in het bloed als reactie op verhoogde 
bloedglucose waarden. Daarom zouden voedingsfactoren die bloedglucosewaarden 
verhogen, geassocieerd kunnen zijn met het risico op alvleesklierkanker. Glykemische 
index en glykemische load zijn voorbeelden van dergelijke factoren. In Hoofdstuk 4 is 
onderzocht of deze voedingsfactoren positief geassocieerd waren met het risico op 
alvleesklierkanker, maar er bleek geen verband te bestaan tussen de glykemische  
index en glykemische load en het risico op alvleesklierkanker binnen de NLCS. Ook 
bleek er geen verband te bestaan tussen de inname van koolhydraten en mono- en 
disacchariden en het risico op alvleesklierkanker. 
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Bij de bereiding van vlees kunnen vele kankerverwekkende stoffen ontstaan welke het 
risico op alvleesklierkanker zouden kunnen verhogen. Verder liet dieronderzoek zien 
dat meervoudig onverzadigde vetzuren het risico op alvleesklierkanker verhogen.  
Bevindingen van de talrijke epidemiologische onderzoeken die tot dusverre gedaan zijn 
naar de relatie tussen de inname van vlees en verschillende soorten vet en het risico 
op alvleesklierkanker, zijn inconsistent. In Hoofdstuk 5 zijn de resultaten beschreven 
van het verband tussen verschillende soorten vlees en inname van verschillende vet-
soorten en het risico op alvleesklierkanker: er bleek geen verband te bestaan. Tevens 
bleek er geen verband te bestaan tussen de consumptie van vis en eieren en het risico 
op alvleesklierkanker.  
 
Fruit en groenten bevatten vele stoffen met potentiële antikankerverwekkende wer-
king en zou daarom een rol kunnen spelen in de preventie van alvleesklierkanker. De 
meeste patiëntcontroleonderzoeken hebben een beschermend effect aangetoond van 
totaal fruit en groente consumptie, terwijl voor de meest cohortonderzoeken geen 
verband bleek te bestaan. In Hoofdstuk 6 hebben we de resultaten beschreven over 
de relatie tussen fruit en groenteconsumptie en het risico op alvleesklierkanker binnen 
de NLCS. Voor totale groente en totale fruitconsumptie bleek geen verband te bestaan 
met het risico op alvleesklierkanker. Ook bleek er geen verband te bestaan voor     
gekookte groenten, rauwe groenten en andere subgroepen van groente en fruit. Ook 
voor carotenoïden, vitamine C en E inname en het gebruik van supplementen die vita-
mine C of E bevatten bleek geen verband te bestaan met het risico op alvleesklierkan-
ker. 
 
Tot op heden is het roken van sigaretten een van de meest consistente risicofactoren 
van alvleesklierkanker. In Hoofdstuk 7 zijn de resultaten van de analyses naar het  
actief en passief roken van sigaretten in relatie tot het risico op alvleesklierkanker 
gepresenteerd. Zowel ex- als huidige sigarettenrokers hadden een verhoogde kans van 
respectievelijk 37% en 88% op het krijgen van alvleesklierkanker ten opzichte van nooit 
sigarettenrokers. We zagen een verhoogd alvleesklierkanker risico van 51% voor die-
genen ≥20 sigaretten/dag rookten vergeleken met diegenen die nooit sigaretten rook-
ten, maar er werd geen dosisrespons relatie aangetoond. Er werd een dosisrespons 
relatie gezien met het aantal jaren roken. De hazard ratio voor het risico op alvlees-
klierkanker was 2.03 wanneer rokers die ≥40 jaar hadden gerookt vergeleken werden 
met mensen die nooit hadden gerookt. Het risico op alvleesklierkanker werd geleidelijk 
verlaagd met het toenemend aantal jaren dat ex-rokers gestopt waren met roken en 
naderde na ≥20 jaar het risico van nooit sigarettenrokers. Er bleek geen verband te 
bestaan tussen de blootstelling aan passief roken en alvleesklierkanker bij vrouwen. 
Het is belangrijk om mensen die ooit gerookt hebben uit te sluiten bij onderzoek naar 
de relatie tussen passief roken en het risico op kanker om het onafhankelijke effect 
van passief roken te kunnen schatten. Daarom hebben we deze relatie niet onderzocht 
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bij mannen aangezien meer dan 90% van de mannen binnen de NLCS ooit hadden 
gerookt. 
 
Toen voor de Hoofdstukken 2 tot en met 7 aanvullende analyses uitgevoerd werden 
waarin we ons beperkten tot de patiënten met microscopisch bevestigde alvleesklier-
kanker, waren de resultaten van deze analyses vergelijkbaar met de resultaten van de 
analyses waarin alle alvleesklierkanker patiënten waren geïncludeerd. 
 
In Hoofdstuk 8 zijn de belangrijkste bevindingen van de in dit proefschrift onderzochte 
verbanden tussen alvleesklierkanker en de leefstijlfactoren, bediscussieerd in het licht 
van de bestaande literatuur, zowel epidemiologisch en mechanistisch, en is er een 
eindconclusie getrokken over de sterkte van het bewijs tot dusverre. Vervolgens zijn er 
een aantal belangrijke sterke en zwakke punten van de opzet van de NLCS en de analy-
ses uitgevoerd in dit proefschrift bediscussieerd, waaronder confounding en misclassi-
ficatie van de risicofactoren en ziekte. Sommige onderzoeken lieten zien dat diagnosti-
sche misclassificatie de risicoschattingen voor alvleesklierkanker ernstig kunnen verte-
kenen. Verschillen in de karakteristieken van patiënten, waaronder leeftijd, proportie 
van rokers en drinkers, en tumor karakteristieken, binnen de mate van diagnostische 
misclassificatie zou deze vertekende resultaten kunnen verklaren. Zoals hierboven al 
beschreven is, lieten de onderzoeken beschreven in dit proefschrift echter geen ver-
schil zien tussen de resultaten van de analyses beperkt tot patiënten met microsco-
pisch bevestigde alvleesklierkanker en de resultaten van de analyses met alle alvlees-
klierkankerpatiënten. Verder hebben we beschreven dat het onderzoeken van het 
gecombineerde effect van omgevingsrisicofactoren en genetische factoren en het 
identificeren van meer en betere biomarkers meer inzicht zou kunnen geven in het 
mogelijke verband tussen voedingsrisicofactoren en het risico op alvleesklierkanker. 
 Samenvattend zagen we significant verhoogde risico’s op het krijgen van alvlees-
klierkanker voor overmatig alcoholgebruik en voor het roken van sigaretten, terwijl het 
stoppen met roken het risico verlaagde. Er bleek geen verband te bestaan met bloot-
stelling aan passief roken. Het ooit aan gesport gedaan te hebben verlaagde het risico 
op het krijgen van alvleesklierkanker. Bevingendingen met betrekking tot de proxy-
maten voor energierestrictie ondersteunde onze hypothese niet dat energierestrictie 
het risico op het krijgen van alvleesklierkanker zou verlagen. Er bleek geen verband te 
bestaan met de andere onderzochte voedingsfactoren, waaronder glykemische index, 
glykemische load, de inname van koolhydraten, vlees, vet, fruit, groente, carotenoïden 
en vitamine C en E. 
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DANKWOORD 
 
Een proefschrift schrijf je nooit alleen, dus bij deze wil ik alle mensen die direct danwel 
indirect hebben bijgedragen aan de totstandkoming van dit proefschrift. 
 
Als eerste wil ik mijn compromotor en mijn promotor bedanken. Bas, ik heb heel veel 
van je geleerd in de afgelopen 4 jaar en ik wil je dan bedanken voor de geweldige ma-
nier waarop je me hebt begeleidt. Ik vond onze discussies altijd erg leerzaam en ook 
heel leuk. Vooral jouw vermogen om alles in een breder perspectief te plaatsen wan-
neer ik weer eens dreigde te verzuipen in al die kleine details… Je kon alles ook zo goed 
uitleggen en het werd je ook nooit teveel om dit te doen. Maar ja, je bent ook niet 
voor niks docent van het jaar geworden! Ik zat in ieder geval altijd weer barstenvol 
energie na onze besprekingen om er weer vol tegenaan te kunnen gaan. Ook onze 
discussies en gesprekken over niet onderzoeksgerelateerde zaken waren heel interes-
sant en leuk. De tijd vloog altijd voorbij tijdens een overleg. Natuurlijk wil ik je ook heel 
erg bedanken voor de mooie kaft die je voor mij hebt gemaakt; niet alleen jij bent daar 
heel erg trots op, maar ik ook!! Ik had me geen beter en mooier ontwerp kunnen voor-
stellen. Ik ben heel blij dat ik nog een 2-jarige postdoctraject onder jouw begeleiding 
mag doen en dat we dus ook nog geen afscheid hoeven te nemen! 
Piet, jou wil ik graag bedanken voor het goed in de gaten houden van de tijdsplanning 
en de hoofdlijnen van het project. Tevens heb je me geleerd efficiënter te werken. Ook 
wil ik je bedanken voor je kritische commentaar op de artikelen (die je ook altijd stipt 
op tijd klaar had!). Ook waardeer ik je humor die je soms op hele onverwachte mo-
menten (en hoeken) liet zien. 
 
Graag wil ik tevens mijn coauteurs bedanken die altijd de moeite hebben genomen om 
mijn manuscripten te becommentariëren. Sandra, ik heb je kritische blik op de artike-
len altijd heel erg gewaardeerd. Je kennis met betrekking tot de voedingskant (zowel 
praktisch als methodologisch) is echt enorm en ik heb dan onze discussies (via de mail 
danwel via de telefoon) altijd erg gewaardeerd en ook heel veel van geleerd. Dit alles 
zorgde er altijd weer voor dat het artikel een stuk beter werd! Dr. Lumey, ik heb het 
altijd erg gewaardeerd dat u mijn artikelen heeft willen becommentariëren. Dr. Am-
bergen, uw hulp bij de spline analyses die ik plotseling moest uitvoeren omdat revie-
wers hierom gevraagd hadden, heb ik zeer gewaardeerd. Zeker omdat dit ook in zeer 
korte tijd moest gebeuren en ik op dat moment nog amper wist wat deze analyse 
techniek inhield. Henny, je bent maar op een artikel in dit boekje coauteur maar ik wil 
je niet alleen bedanken voor je bijdrage aan dat artikel. Je vond namelijk ook altijd 
(snel) tijd om mijn andere vraagjes over de voedselfrequentievragenlijst en andere 
voedingsgerelateerde vragen die ik maar had, te beantwoorden. 
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Mireille, als mijn kamergenote gedurende de afgelopen 4 jaren wil ik jou graag bedan-
ken voor de fijne tijd. De leuke gesprekken, vaak over alles behalve werk ;-), waren een 
welkome afwisseling van het werk. Ik vind het dan ook heel leuk dat ik nog steeds bij je 
op de kamer zit nu ik als postdoc ben begonnen! 
Ook wil ik alle NLCS leden bedanken uit Maastricht en van TNO. Jullie bijdrage aan de 
opzet dan wel uitvoer van de NLCS hebben ervoor gezorgd dat ik dit proefschrift heb 
kunnen schrijven. Bedankt! 
Mijn (oud-)collega’s wil ik graag bedanken voor de fijne tijd die ik mede dankzij jullie 
heb gehad (en nog steeds heb!) op de afdeling Epidemiologie. Altijd was er tijd voor 
een gezellig praatje bij de koffiehoek of op de gang. Bedankt voor jullie collegialiteit en 
gezelligheid! 
Pieter E., ook al heb je geen directe bijdrage geleverd aan dit boekje, toch wil ik je 
graag bedanken voor je werk aan de analyses over medische aandoeningen en alvlees-
klierkanker. Onze samenwerking is altijd heel prettig verlopen en ik ben blij dat jij de 
eerste stagiair was die ik mocht begeleiden. Nou nog het artikel in een mooi blad ge-
publiceerd krijgen! 
Dan nog mijn mede-promovendi van Epidemiologie: Janneke, Jessie, Laura, Colinda, 
Brenda, Stefan, Esther, Caroline, José, Monique L., Karolina, Sander, Anne, Nadine, 
Milan en Ivette. Jullie wil ik graag bedanken voor de gezellige lunches/lunchwandelin-
gen en de plezierige AIO-uitjes. Ik kon altijd bij jullie terecht als ik het even had gehad 
met mijn promotietraject, maar ook hebben we de leuke momenten kunnen delen. Of 
we hadden het gewoon even over zaken die helemaal niets met het werk van doen 
hadden. Voor diegenen die nog niet gepromoveerd zijn: succes met jullie promotieon-
derzoek! 
 
Graag wil ik ook nog Yvonne en Nathalie bedanken: ik kon altijd bij jullie terecht als er 
weer eens een afspraak met Piet moest worden ingepland of als ik weer eens een 
vraagje had over wat dan ook... 
Harry en Jos, bedankt voor al die keren dat jullie voor me klaarstonden als ik weer eens 
technische vragen had of als ik weer eens ruzie met mijn pc had (ik heb nu eenmaal 
twee linkerhanden wat betreft een computer…). 
 
Dan mijn paranimfen, Audrey en Mirjam. Ik ben heel blij en trots dat jullie op deze 
belangrijke dag naast me willen staan. Mirjam, als mijn allerbeste vriendin heb ik jouw 
vriendschap altijd heel erg gewaardeerd en ook je geduld als ik weer eens niet kon 
afspreken omdat mijn werk voorging… Ik zal vanaf nu mijn leven proberen te beteren. 
Audrey, aangezien je nu net zelf gepromoveerd bent, ben ik erg blij dat jij me met raad 
en daad terzijde staat in het laatste gedeelte van mijn promotietraject. Maar ook om-
dat je gewoon een hele leuke en vooral ook fijne collega bent! 
Dankwoord 
 
 
186 
Dankzij mijn vrienden kon ik af en toe het werk het werk laten en lekker genieten van 
het leven buiten werk! 
Erik, Nuria, Rita, Luis, Ester, Ruben, Hilde, Bea, Stephanie, Siu Hing, Alissa, and Baerbel: 
when I started with my PhD project in 2006 I hardly knew anyone but that soon 
changed thanks to you guys. You made my life in Maastricht really enjoyable with all 
the coffee-breaks, dinners, going outs etc. Some of you already left (or will leave soon) 
Maastricht, but I hope we’ll all keep contact! Also the last holiday in Portugal with 
Nuria, Esther, Mike, Lars and Alejandro for the wedding of Rita and Luis: that was the 
best break before handing in my thesis to the reading committee. I really needed that, 
thanks guys! 
Ook wil ik mijn oud-ProVUM maatjes niet vergeten: Floris, Cynthia, Jennifer, Janine, en 
Conrad. Jullie zijn echte vrienden geworden gedurende de tijd dat we ons hard maak-
ten voor de Maastrichtse promovendi! En ik hoop jullie nu ook weer wat vaker te kun-
nen zien nu ik bijna klaar ben met mijn promotietraject. 
De JCM, de Journal Club Maastricht, wil ik hier ook graag noemen. Janaica, Martine, 
Joris, Sil, Petra, Mandy, Viola, Luc, Merijn, Francien, Eline, Sander en Baerbel, bedankt 
voor alle leuke en zeer interessante discussies over de artikelen die door een van ons 
werden ingebracht. Maar ook bedankt voor het leuke en gezellige samenzijn, het sa-
men eten en de leuke uitjes die werden georganiseerd. En ik ben heel blij dat ik bij de 
JCM mag blijven ook nu dat ik bijna ga promoveren!! 
Lisette, Tamara, Sandra, Janneke en Céline, oud-studiegenootjes van Voeding en Diëte-
tiek. Helaas zie ik jullie minder vaak als ik zou willen en hopelijk komt daar vanaf nu 
verandering in, maar ik wil jullie graag bedanken voor de gezellige tijd die ik elke keer 
met jullie had op het moment dat we elkaar weer eens zagen! Ook wil ik jullie bedan-
ken voor de interesse in mijn onderzoek. Janneke, je bent nu zelf ook aan een promo-
tietraject begonnen: heel veel succes daarmee en je kunt altijd bij mij terecht met 
vragen en andere zaken over je promotietraject! 
 
Mijn lieve familieleden, jullie wil ik graag bedanken voor al jullie blijvende interesse in 
mijn onderzoek. Ook al heb ik vaak moeten uitleggen dat promoveren en afstuderen 
twee heel verschillende dingen zijn, ik vond het altijd heel fijn dat jullie elke keer vroe-
gen hoe het stond met mijn onderzoek en mijn ‘scriptie’. Jullie dachten waarschijnlijk 
lang dat ik een soort ‘eeuwige student’ zou blijven, maar het is nu toch echt bijna 
klaar: mijn proefschrift is een feit! 
 
En dan, last but not least, pap, mam en Arnoud, bedankt voor al die tijd dat jullie er 
voor me zijn geweest, voor jullie onvoorwaardelijke steun en jullie begrip als ik weer 
eens geen tijd had om naar jullie toe te komen. Zonder jullie steun zou het een stuk 
moeilijker zijn geweest. Bedankt voor alles!! 
 
Mirjam
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